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CHAPTER 1. INTRODUCTION 
1.1.  Motives of the research 
1.1.1. Medicinal chemistry lacks diversity in compound collections 
Drug discovery is a highly complex and multidisciplinary process. The medicinal 
chemistry community has driven tremendous advances in drug discovery programs in last 
two decades. The need of screening millions of compounds to develop one lead in the 
drug development process led to the development of high throughput screening (HTS). 
HTS can efficiently generate millions of data just by screening large libraries in short 
periods of time.1 Both the academic and the industrial communities benefit enormously 
from HTS in terms of time and cost of identifying preclinical drug candidates (lead 
compounds). As a result, HTS originated small molecules dominate the collections of the 
US FDA approved  new drug candidates implying that HTS is an essential and necessary 
frontline tool in drug discovery today.2  
As HTS and its latest variant, the fragment-based approach, are in full-swing and 
are key methods in drug discovery programs, the compositions of compound libraries will 
have a significant impact on the outcomes in pharmaceutical discoveries.1,3 To assure 
the quality of the outcomes that can be tractable in clinical phases,  medicinal chemists 
today follow principles of drug-like or lead-like molecules while generating compound 
libraries. These principles use several molecular descriptors in order to filter the 
compounds. One of the widely used practices in HTS compound collections is Lipinski’s 
rule of five (RO5).4 Alternatively, the fragment based approach follows the Astex rule of 
three (RO3).5 Several properties like molecular weight, topological polar surface area, 





while filtering.4,5 Another approach in identifying drug-like chemical space is exclusion of 
undesirable molecular moieties from compound collections.6 Moieties which are known 
to generate false positives in screening and are associated with toxicities are 
undesirable.6 For example, molecules with heteroatom-heteroatom bonds are excluded 
from current compound collections based upon their perceived reactivity and toxicity.6 
Although HTS is a successful approach in addressing multiple biological targets, 
failures in clinical phases as well as in hitting challenging complex biological targets such 
as protein-protein interactions are also common.3 These failures are warnings to 
medicinal chemists about the lack of the diversity in their current compound libraries and 
are unavoidable. Also, the descriptors used in the commonly applied principles of drug-
like molecules do not address molecular complexity directly.7 As a result, current HTS 
libraries are highly populated by low molecular weight and relatively planar compounds 
with high sp2 character and little stereochemical complexity.3,7 Unfortunately, such planar 
compounds cover only a very small corner of the chemical space. Furthermore, the 
binding sites in biological targets are rarely planar, which undoubtfully can be viewed as 
one of the primary reasons of failure in HTS campaigns. In order to overcome the 
limitations of planarity, the so-called flatland, and to fulfil the need for complexity, the 
strategy of increasing the fraction of saturated carbons (Fsp3) within compounds should 
be considered. In 2009, Lovering et al. conducted a survey7 on the collection of 
compounds in different phases of drug discovery and development processes and found 
that the fractions of sp3 hybridized atoms and the number of stereogenic centers are 
higher in those compounds. Therefore, the survey suggested considering the Fsp3 of the 





Recognizing the need for complexity and diversity, several creative strategies have 
been designed to date in order to generate more diverse libraries. Diversity oriented 
synthesis (DOS)8-11 is one of the approaches that generates architecturally diverse 
molecules in few steps starting from simple starting materials. These compounds 
resemble more natural product or drug-like molecules with high Fsp3 and stereochemical 
complexity. Other strategies are centered on the use of natural products as the starting 
point to generate the natural product-like molecules.12 Even though these creative ideas 
have introduced natural product-like moieties with complexity in terms of Fsp3 and the 
presence of stereogenic centers, several problems are still left unaddressed such as the 
creation of new complex scaffolds from unexplored parts of chemical space. Furthermore, 
the synthesis of compounds with the natural product-like scaffolds is still considered as a 
challenging and time-consuming area of the research. 
 To overcome these shortcomings, the medicinal chemistry community needs a 
novel strategy that can open up the new chemical space with new scaffolds. Also, these 
scaffolds should have the potential of generating large libraries of compounds with 
reduced synthetic difficulty but high structural complexity. 
1.1.2.  Hydroxylamines and hydrazines as surrogates of sp3 carbons  
The Crich lab has identified the hydroxylamine and the hydrazine functionalities as 
new scaffolds that have the potential to enrich compound collections by increasing Fsp3 
in compounds and to address the necessity of diversity from the new chemical space 






With low basicity (pKa = 5.9 in water)13,14 and a low inversion barrier (~15 kcal.mol-
1),15-19 hydroxylamines are little protonated under normal physiological conditions and 
have the potential of changing configuration by rapid inversion at the nitrogen center. 
Therefore, tri-substituted hydroxylamines, in particular, can serve to mimic both 
enantiomers of simple stereogenic ethers and alkanes while reducing synthetic and 
structural complexity (Figure 1). 
 
Figure 1. Hydroxylamines as convertible mimics of stereogenic centers. a) N-
Alkoxypiperidines as mimics of axial and equatorial glycosides.18,19 b) Hydroxylamines 
as mimics of chirally substituted alkanes and ethers. 
Hydrazines share similar properties to hydroxylamines including their low inversion 
barriers (~8 kcal.mol-1)20 and weak basicity (pKa = 6.4 in water).21 These properties 
establish hydrazines as another interesting functional group in which the two nitrogen 
atoms can substitute for two stereogenic centers and reduce synthetic and structural 
complexity (Figure 2). 
 
Figure 2. Hydrazines as convertible mimics of two stereogenic centers. 
Taking advantage of these unique properties of hydroxylamines and hydrazines, 
the Crich lab initiated a program to design molecules in which the nitrogen atoms of 





medicinally important molecules, with the goal of reducing synthetic complexity and 
developing new compositions of matter. As a proof of concept, the Crich lab has recently 
prepared and evaluated a series of mono-, di-, and tri-meric N-alkoxyimino sugars as β-
(1→3)-glucan mimetics in which the hydroxylamine nitrogen replaces the anomeric 
carbon and eliminates the need for diastereoselective glycosidic bond formation (Figure 
3).18,19 
 
Figure 3. Hydroxylamine based β-(1→3)-glucan mimetics as hydroxalogs of β-(1→3)-
glucans. 
1.1.3.  Aims of the research 
Recognizing the inherent potentials of hydrazines and hydroxylamines in medicinal 
chemistry, the research presented in this thesis aims to apply the concept of hydrazine 
and hydroxylamine analogs beyond the carbohydrates studied initially. However, before 
the broader application of hydroxylamines and hydrazines can be investigated, improved 
methods for their synthesis are required. Therefore, the work will also focus on developing 
an effective methodology that can give easy access to diverse sets of tri-substituted 
hydroxylamines and so potentially be applied in generating libraries of compounds.  
Characteristic features of the hydroxylamines and hydrazines including their 








1.2.  Hydroxylamines 
1.2.1.  Introduction 
Hydroxylamines or alkoxyamines represent the class of compounds that are 
derived from the parent hydroxylamine (H2N-OH). Depending upon the substitution 
patterns on the nitrogen and oxygen atoms, they can be classified as mono-substituted, 
di-substituted, or tri-substituted (Figure 1).  
 
Figure 4. Structures of substituted hydroxylamines. 
The N-O bond is also present in oximes and hydroxamic acids (Figure 5), which 
are considered as derivatives of the parent hydroxylamine (NH2OH). However, oximes 
have C=N double bonds and hydroxamic acids have N-acyl groups giving properties that 
differentiate them from hydroxylamines particularly in the context of their planar sp2 
nitrogens.22  
 
Figure 5. Structures of hydroxylamines, oximes, and hydroxamic acids. 
A common confusion in the literature revolves around the use of the word 
hydroxylamine. Some literature uses it to represent all the derivatives of the parent 





represent only aryl and alkyl-substituted hydroxylamines. In this thesis, the later 
representation will be followed. 
1.2.2.  Conformational properties of hydroxylamines 
The presence of an oxygen atom adjacent to nitrogen atom has a substantial effect 
on the conformation of hydroxylamines. The repulsive interaction between the lone pairs 
of electrons on these atoms should be minimized in the preferred conformation. In 
molecular orbital calculations, two energy minima were observed for hydroxylamines 
representing two stable conformations 1a and 1b (Figure 6).22,23 The energy differences 
between these conformers range from 0.67 kcal.mol-1 to 10.79 kcal.mol-1 depending upon 
the substitution patterns.23 Interestingly, conformer 1a is more stable with eclipsing of lone 
pairs with bonds, whereas conformer 1b is less stable with staggered lone pairs and 
bonds. This property of hydroxylamines can be viewed as an effect of maximization of 
separation of the lone pairs on adjacent atoms.23 
 
Figure 6. Conformations of hydroxylamine. 
Another interesting phenomenon in hydroxylamines is the fast conformational 
inter-conversion. This stereomutation is attributable to either an individual or a 
combination of two unique processes; nitrogen inversion (Ninv) and N-O bond rotation (N-
Orot).17 The energy barriers for nitrogen inversion in hydroxylamines were determined15-18 





they are low enough to permit rapid inversion at the nitrogen center at ambient 
temperature. Due to their fast inversion at room temperature, the pyramidal nitrogen 
atoms in hydroxylamines are not configurationally stable. 
 The stereomutation of hydroxylamines can be best illustrated as in Scheme 1.17 
Owing to the low barrier to inversion, the more stable conformer 1a converts to the less 
stable conformer 1b, which in turn converts to the enantiomer of the more stable 
conformer 1a* by rotation of the N-O bond and minimization of the lone pair-lone pair 
repulsions. The barrier to rotation in the above conversion (1b → 1a*) is usually small (< 
5 kcal.mol-1).17 Similarly, another enantiomeric less stable conformer 1b* is the result of 
N-O bond rotation of 1a or nitrogen inversion of 1a* . The barrier to rotation for the 
conversion of 1a to 1b* is unusually high (12 - 15 kcal.mol-1), since the former is more 
stable than the latter and the high torsional barriers are associated with the process.17 
The more stable conformers 1a and 1a* are epimers of each other as are the less stable 
conformers 1b and 1b*. As the population of the more stable conformer 1a and 1a* are 
identical and interconvertible at room temperature, a single molecule of a hydroxylamine 
can represent both epimers of a compound. This is the principle behind the hydroxylamine 






Scheme 1. Stereomutation in hydroxylamines. 
1.2.3.  Hydroxylamines in medicinal chemistry 
The hydroxylamine moiety is an underrepresented functional group in medicinal 
chemistry, though it has potential to enrich compound collections without synthetic 
complication from the presence of an additional stereogenic center. Although not 
common, the hydroxylamine moiety does exist in a small number of bioactive natural 
products. The antitumor antibiotics esperamicin A125,26 and calicheamicins,27,28 and the 
selective inhibitor of bacterial tyrosyl tRNA synthase SB-21938329 are some 






Figure 7. Natural compounds with hydroxylamine moieties. 
On the other hand, there are a few examples of the use of hydroxylamines in medicinal 
chemistry that aim to exploit its rich potential. Two examples are the hydroxylamine-based β-
(1→3)-glucan mimetics19 from Crich lab, and a selective inhibitor of human neuraminidase 
isoenzymes NEU330 from the Cairo lab (Figure 8).  
 
Figure 8. Synthetic compounds with hydroxylamine moieties for use in medicinal chemistry. 
Though hydroxylamines have the potential to enrich compound libraries, they have 





with the N-O bond, particularly, its supposed weakness and electrophilicity. However, 
both DFT6 and experimentally32 determined bond dissociation energies for the N-O bond 
range from 55 to 65 kcal.mol-1 depending upon the substitution patterns. Therefore, they 
are stable entities and are not thermodynamically liable as perceived. On the other hand, 
hydroxylamines, particularly N-arylhydroxylamines, with free -NH or -OH groups, are 
intermediates on the metabolic pathway of amines, and are converted to electrophilic 
metabolites by acylation or sulfation as exemplified in Scheme 2. 33,34 These metabolites 
further bind covalently to DNA and induce mutation. In contrast, with no free -NH and -
OH groups, tri-substituted hydroxylamines cannot activated to electrophiles in this 
manner. Therefore, they are not prone to form adducts with DNA to cause genotoxicity 
and also do not bind covalently with proteins to result in the false positives in screening.6 
Moreover, heteroatom-heteroatom bonds such as N-O and N-N bonds and other 
electrophilic scaffolds are rather common in marketed drugs.31 Therefore, discarding 
hydroxylamines from screening collections based upon the perceived false positives and 






Scheme 2. A representative pathway of metabolic activation of aromatic amines.  
1.2.4.  Synthesis of tri-substituted hydroxylamines 
Depending upon the strategic disconnection approach and the available synthetic 
methods in the literature, three possible ways for tri-substituted hydroxylamines synthesis 
can be devised (Scheme 3). An ideal route to the substituted hydroxylamines should 
involve N-O bond formation (Scheme 3 route a). This ideal route has a huge potential of 
generating large libraries of compounds starting from commercially available amines and 
alcohols as starting materials. However, very few examples of tri-substituted 
hydroxylamine synthesis were reported to date following this route, which involves the 
displacement of a leaving group from a nitrogen atom by an alcohol or from an oxygen 
atom by an amine or an amide.36-39 Progress in this line of work has not been promising 
due to the combination of low yields and harsh reaction conditions. This approah remains 






Scheme 3. Possible ways for the synthesis of tri-substituted hydroxylamines. 
N-Alkylation (Scheme 3 route b) of N,O-disubstituted hydroxylamines or O-
alkylation (Scheme 3 route c) of N,N-disubstituted hydroxylamines  are viewed as  
plausible alternative routes. Several synthetic methods for hydroxylamine derivatives 
have been developed using direct N-alkylation and O-alkylation routes,40,41 however 
methods for the synthesis of tri-substituted hydroxylamines, in particular, are relatively 
sparse.  
One of the traditional and common approaches for the tri-substituted 
hydroxylamines is N-alkylation of N,O-disubstituted hydroxylamines via reductive 
amination (Scheme 4a) or SN2 substitution reactions (Scheme 4b).41 Several N-
alkoxyiminosugar derivatives have been prepared from O-substituted hydroxylamines as 
starting materials by using either double reductive amination (Scheme 4c) or combination 
of reductive amination and SN2 substitution reactions (Scheme 4d).18,19,42,43 Various tri-
substituted hydroxylamines have also been synthesized from N-methoxyamides in a one 
pot reaction that involved partial reduction with DIBAL, followed by Lewis acid catalyzed 
in situ generation of N-oxy iminium ions and the nucleophilic addition of carbon 
nucleophiles (Scheme 4e).44 Moreover, bicyclic N-oxy amides have also been reduced 





these methods give access to tri-substituted hydroxylamines with diversity on the nitrogen 
only. 
 
Scheme 4. Synthesis of tri-substituted hydroxylamines. 
Alternatively, the approach of O-alkylation of N,N-disubstituted hydroxylamine has 
the potential to introduce diversity on the O-substituent. However, only alkylation with 
simple and activated electrophiles such as allyl and aryl halides was reported by this route 
(Scheme 5).41 
 
Scheme 5. O-Alkylation of N,N-disubstituted hydroxylamines. 
In conclusion, an efficient method is lacking for the synthesis of tri-substituted 
hydroxylamines, which particularly, should have the potential of not only the diversification 
of O-substituents but also easy access to these class of compounds, so that the library 





community. Recognizing this need, an efficient method will be developed to  address the 
existing problem in the synthesis of tri-substituted hydroxylamines.  
1.3.  Hydrazine 
1.3.1.  Introduction 
Hydrazines represent the class of compounds that are the derivatives of parent 
hydrazine (H2N-NH2). Depending upon the substitution patterns on both nitrogen atoms, 
they can be classified as mono-substituted, di-substituted, tri-substituted, and tetra-
substituted hydrazines (Figure 9). 
 
Figure 9. Structures of substituted hydrazines. 
If one of the substituents is an acyl group, the compounds are classified as 
hydrazides, and if one of the nitrogen forms a double bond with sp2 hybridized carbon 
atom, the compounds are classified as hydrazones (Figure 10). Since N-N bonds are 
present in both the hydrazones and the hydrazides, they are also considered as hydrazine 
derivatives, however, they differ significantly from hydrazines in terms of properties. In 
this thesis, the use of the term hydrazine does not incorporate hydrazones or hydrazides. 
 





1.3.2.  Conformational properties of hydrazines 
Alkyl hydrazines are considered bipyramidal, and two diastereomeric staggered 
conformations, gauche (2) and trans (3) (referring to the lone pairs), are possible (Figure 
11).46  
 
Figure 11. Possible conformations of hydrazine. 
The lone pair-lone pair repulsive interaction is a dominant factor in determining the 
conformation and should be minimized in the most stable one. The low energy lone pair-
bond pair and bond pair-bond pair interactions are neglected accordingly. The trans 
conformation (3) at first seems to be the more stable one since it offers minimal interaction 
between the lone pairs. However, the quasi-gauche conformation (5) (Figure 11) with 90o 
of interorbital angle (Ø) is the most stable conformation according to the spectroscopic 
studies and molecular orbital calculations.46 The calculated potential energy function of 
hydrazine has two energy maxima and one energy minimum (Figure 12).47,48 One 
maximum corresponds to the cis (Ø = 0o) conformation (4) and the other to the trans (Ø 







Figure 12. The torsional potential function of H2N-NH2. 
Several interpretations have been proposed to explain why the trans conformation 
with the least lone pair-lone pair interaction is not adopted by the system.46-54 The most 
conceptual and qualitative interpretation46 is the interaction between the lobes of non-
bonding orbitals of two nitrogen atoms is minimal at 90o, while it is maximum at 180o 
(Figure 13). Therefore, two maxima and one minimum are observed in the torsional 
potential function of hydrazine.  
 
Figure 13. Interactions of non-bonding orbitals of nitrogen atoms at Ø = 90o and 180o. 
The interconversion of conformations about the N-N bond is a common 
phenomenon in hydrazines and is a result of the interplay of internal N-N bond rotations 
and/or pyramidal nitrogen inversions. The inversion barrier for the parent hydrazine (H2N-
NH2) is about 7.5 kcal.mol-1.55 The experimentally calculated barriers for either rotations 





upon the nature of alkyl substituents.20 Though the quasi-gauche (Ø = 90o) conformation 
is the stable conformation, the staggered gauche (Ø = 60o) conformation will be used to 
describe the inversion and rotation processes here after for convenience. 
The conformational changes of hydrazine by inversion processes are described in 
Scheme 6.20 In hydrazines, two distinct types of N-inversion are recognized,46 which are 
named as non-eclipsing inversion (non-passing) and eclipsing inversion (passing 
inversion). The non-eclipsing inversion is a fast and low energy process without eclipsing 
of substituents. A gauche conformation (6) leads to another gauche conformation (7) via 
a non-eclipsing inversion and the barrier to inversion is around 7.5 kcal.mol-1.  The 
eclipsing inversion, on the other hand, is a high energy process with eclipsing of 
substituents. A gauche conformation (6) leads to a trans conformation (8) via eclipsing 
inversion process and the barrier to inversion is 10.5 kcal.mol-1 (7.5 kcal.mol-1 for inversion 
and 3 kcal.mol-1 for eclipsing interactions of alkyl groups). However, the barrier to 
inversion for the reverse process (trans to gauche) is 3 kcal.mol-1 smaller than the forward 






Scheme 6. Diagram showing two different types of N-inversions. 
The conformational changes of hydrazine by rotation are described in Scheme 7.20 
In an acyclic hydrazine two distinct rotational processes are recognized.46 The first one is 
the low energy rotational process that involves eclipsing of one pair of substituents. The 
conversion of gauche (9) to trans (10) conformation is a result of 120o torsional rotation 
and is a low energy rotational process with an energy barrier of 6-7 kcal.mol-1. However, 
the barrier to the rotation for reverse transformation (trans to gauche) is lower by 3 
kcal.mol-1 than for the forward transformation (gauche to trans). The second one is the 
high energy rotational process that involves eclipsing of two pairs of substituents and two 
lone pairs. This process occurs in only the gauche conformation and leads to another 
gauche conformation. The energy barrier for this type of transformation is around 16 
kcal.mol-1 (10 kcal.mol-1 for eclipsing lone pairs, and 6 kcal.mol-1 for two eclipsed 






Scheme 7. Diagram showing two types of N-N bond rotations. 
1.3.3.  Hydrazines in medicinal chemistry 
N-N bond motifs are relatively scarce in natural products.56-58 Nevertheless, a 
survey from Sperry and Blair in 201357 showed that over 200 natural products containing 
the N-N bond motif are known including hydrazines, hydrazones, hydrazides, and many 
other related functionalities. However, only four of them have the simple hydrazine 
functionality namely N-amino-D-proline, munroniamide, braznitidumine, and ostrerine A 
(Figure 14). Ostrerine A, which was isolated from a mollusk, is the only compound 
belonging to the tetra-substituted hydrazine class and biological activity of the molecule 






Figure 14. Natural products with the hydrazine moiety. 
Recently, Zhang and Hertweck have independently isolated dixiamycins A and B 
(Figure 15), the atropisomeric indoloterpenoid natural products.59,60 These compounds 
are the N-N linked dimers of an antibacterial natural product xiamycin A and were found 
to be more potent than xiamycin A itself (Figure 15).59,60 
 
Figure 15. Structures of xiamycin A and dixiamycins A and B. 
Hydrazine derivatives are an important class of compounds in medicinal chemistry 
as they are present in several clinical therapeutics. Some of the representative examples 
are listed in Figure 16. Anti-depressant phenelzine61 and anti-hypertensive agent 





procarbazine is used to treat Hodgkin’s disease, melanoma, and bronchogenic carcinoma 
as a part of a chemotherapeutic cocktail.61 Anti-depressant isocarboxazid and anti-
tuberculosis antibiotic isoniazid belong to hydrazide class of compounds.61 Anti-cancer 
compound PAC-1 is a hydrazone that selectively induces apoptosis in cancerous cells.63 
However, no therapeutic agents with a tetra-substituted hydrazine moiety have been 
reported to date.  
 
Figure 16. Structures of therapeutic hydrazines and hydrazides. 
Although the hydrazine moiety is common in therapeutic agents and has several 
pharmacological applications in treating pathological diseases, their clinical use is limited 
due to their toxicity.34,61 Several hydrazine containing drugs were discontinued in the last 
decades based on their toxic side effects like hepatotoxicity, induction of systemic lupus 
erythematosus, and cancinogenesis.61 Octamoxin, pheniprazine, phenoxypropazine, and 
safrazine are some of the antidepressants which were withdrawn from the market owing 
to hepatotoxicity concerns (Figure 17).64 In addition to pharmaceutical agents, toxicity 






Figure 17. Structures of discontinued therapeutic hydrazines. 
The toxicity of the hydrazine derivatives is attributable to the alkylation of DNA by 
the reactive intermediates like carbocations, carbon-centered radicals, and reactive 
oxygen species that are generated during the enzyme catalyzed metabolism 
process.34,61,66 The metabolisms of mono-substituted and di-substituted derivatives are 
catalyzed by several enzyme systems like cytochrome P450, horseradish peroxidase 
(HRP), hepatocytes, microsomes, oxyhemoglobin (HbO2), myeloperoxidase, and 
neutrophils (PMNs). Scheme 8 describes the common mechanism for the formation of 
the reactive species from N,N-disubstituted hydrazines. The carbocations and the alkyl 
radicals are formed from two distinct pathways (path a and b respectively) after oxidation 
of hydrazine-derived azo compounds. The so-formed reactive intermediates induce 






Scheme 8. Metabolic transformation of di-substituted hydrazines. 
In case of mono-arylhydrazines, several possible metabolic pathways have been 
reported.66 The arenediazonium ion is the reactive intermediate that is supposed to react 
directly with DNA bases, such as adenine, to generate aryl triazenes (Scheme 9).67 This 
ion can also react with the DNA backbone to cleave the strand.66 Alternatively, the 
diazonium ion can reduce to an alkyl radical which in turn may react with purines (Scheme 






Scheme 9. Metabolic transformation in mono-aryl hydrazines. 
Because of these observed toxicities together with the observance of false 
positives from hydrazine derivatives in the screening process, medicinal chemists have 
classified hydrazines as undesirable moieties, and they are currently excluded from 
compound collections.6,31 However, the exclusion of the whole hydrazine class of 
compounds based upon the negative results of some compounds is arbitrary. In fact, 
several therapeutic agents in the market still contain hydrazine moieties and are non-
toxic. More importantly, the toxicities are reported only for the mono-substituted, and the 
di-substituted hydrazines and the key intermediates for the formation of the reactive 
species are azo-compounds or diazonium ions. However, the formation of these key 
intermediates is not possible from tetra-substituted hydrazines, which might be one of the 
reasons why toxicity reports for the tetra-substituted hydrazines are not available. In 
addition, the false positives in the screening process result from the attack of proteins on 
electrophilic hydrazine derivatives like hydrazides and N-sulfonamides. In contrast, tetra-
substituted hydrazines are not electrophilic like their lower congeners. Therefore, 





from compound collection based on the few toxicity and false positive reports, is reducing 
the chance of finding quality hits in the drug discovery process. Tetra-substituted 
hydrazines, in particular, have the potential to enrich compound collections without 
additional synthetic and stereogenic complexity because of their low basicity and low 
inversion barriers. 
1.3.4.  Synthesis of tetra-substituted hydrazines 
The development of synthetic routes for substituted hydrazines is an attractive 
area in synthetic organic chemistry due to their importance in pharmaceutical, 
agrochemical, polymer, and dye industries and as precursors for organic synthesis.74 An 
ideal route for the synthesis of all kinds of substituted hydrazines is the reaction between 
two amines forming an N-N bond (Scheme 10). Since thousands of amines are available 
commercially, this route would have a huge potential for generating a large library of 
compounds with diversity. In the flip side, success by this route is considered challenging 
since forming a heteroatom-heteroatom bond itself remains a challenging goal in the 
synthetic organic chemistry. Despite the challenge of forming an N-N bond, a few 
aminations of amines with aminating reagents like chloroamines and sulfonate derivatives 
of hydroxylamines are documented and are used in laboratory and industrial 
preparations.75,76 However, the scope of those methods is narrow due to the limited 
substrate scope and poor yields. An alternative route is the alkylation or reductive 
amination of parent hydrazines. However, multiple steps are required to access tri and 
tetra-substituted hydrazines by this route. Since the synthesis of mono, di, and tri-





hydrazines, the available methods for all classes of substituted hydrazines will be 
discussed briefly including aminations of amines. 
 
Scheme 10. Ideal route for the synthesis of hydrazines. 
1.3.4.1.  From hydrazines and their derivaties 
Several synthetic methods have been reported aiming at mono-substituted 
hydrazines.77 The direct mono-alkylation approach of a free hydrazine, although seems 
practical, is difficult to control and delivers a mixture of mono-substituted product, over-
alkylation, and starting material.76,77 Therefore, alkylation of N-protected hydrazines, 
followed by deprotection, became the method of choice to access mono-subsituted 
hydrazines (Scheme 11a).75 Alternatively, reduction of hydrazones and hydrazides with 
suitable reducing agents like NaBH4, NaCNBH3, and LiAlH4 was also found to be practical 
and efficient methods (Scheme 11b and 11c).75-78 
 
Scheme 11. Synthesis of mono-substituted hydrazines. 
The di-substituted hydrazines can be classified into two distinct types namely N,N-





hydrazines) and N,N’-disubstituted hydrazines (also known as 1,2-disubstituted or sym-
disubstituted hydrazines).76,77 Direct alkylation of mono-substituted hydrazines was 
generally used to afford N,N-disubstituted hydrazines (Scheme 12a), whereas strategic 
protection of the mono-substituted precursor before alkylation and deprotection after 
alkylation are necessary to generate the N,N’-disubstituted hydrazines (Scheme 
12b).75,77 Furthermore, the N,N’-disubstituted hydrazines were also accessed from 
reduction of hydrazones (Scheme 12c) and N,N’-diacylhydrazines (hydrazides) (Scheme 
12c) under similar reduction conditions to those used in reduction approaches for the 
mono-substituted hydrazines.75,77,78 
 
Scheme 12. Synthesis of di-substituted hydrazines. 
Similarly, tri and tetra-substituted hydrazines were also prepared from the direct 
alkylation of di-substituted hydrazines, mostly with activated alkyl halides and alkenes 
(Michael addition).77 A recent approach of controlled alkylations of di-anions of N,N’-
disubstituted hydrazines to generate tri and tetra-substituted hydrazines is a noteworthy 
example of this kind (Scheme 13a and 13b).74,79,80 The tri-substituted hydrazines also 
result from the transformation of N,N-disubstituted hydrazines to hydrazone or hydrazide 





alkylhydrazines were also prepared by the sequence of hydrazone formation from N,N-
disubstituted hydrazines and reduction by NaCNBH3 in the presence of formaldehyde 
(Scheme 13c).75,77 Reduction of tetra-substituted hydrazides with powerful reducing 
agents like diborane or LiAlH4 is a common method used in the preparation of simple to 
complex tetra-substituted hydrazines.75-77,81  
 
Scheme 13. Synthesis of tri and tetra-substituted hydrazines. 
1.3.4.2.  From direct amination of amines 
Several N-N linked dimers of carbazole derivatives have been generated by 
electrochemical oxidation via nitrogen centered radical intermediates (Scheme 14a).82 
However, this method is limited to symmetric hydrazines only. The reactions of primary 
and secondary amines with chloroamine83-85 or hydroxylamine-O-sulfonic acid76,86,87 are 





(Scheme 14b). For example, the reaction of dimethylamine with chloroamine is an 
industrial preparation of N,N-dimethylhydrazine (rocket fuel).75 The N,N’-disubstituted 
hydrazines were prepared from the reaction of N-chloro derivatives of primary amines 
with azomethines followed by the hydrolysis (Scheme 14c).75,77 Moreover, a series of 
aminating agents based on N-protected oxaziridines with various substituents on their 
carbons has been developed for electrophilic amination of amines (Scheme 14d).75,88 
This method was found to be efficient for the synthesis of N,N-disubstituted hydrazines 
only. Several other aminating agents based on hydroxylamine sulfonates can be 
accessed commercially or synthetically89 and have the potential to form hydrazines 
directly from amines. 
 
Scheme 14. Synthesis of substituted hydrazines by direct aminations. 
In conclusion, N-alkylations of protected hydrazines, reductions of hydrazones and 





and widely used methods in the synthesis of substituted hydrazines.77 Several other 
methods including transition metal catalyzed reactions are also reported,90-93 however, 
short and efficient entries to substituted hydrazines are always in demand. 
1.4.  Designing hydroxylamine and hydrazine analogs of kalkitoxin 
1.4.1.  Discovery of kalkitoxin and its biological activitites 
Kalkitoxin (13) is a natural stretch-peptide that was discovered by Gerwick, Shioiri, 
and co-workers as a secondary metabolite of Lyngbya majuscule, a marine 
cyanobacterium.94,95 It was isolated from an extract of L. majuscule by the brine shrimp 
and gold fish toxicity assay guided fractionation process and was disclosed as 
ichthyotoxic against common gold fish (Carassius auratus, LC50 700 nM) and potently 
toxic against brine shrimp (Artemia salina, LC50 170 nm).95 The potencies of kalkitoxin 
were also observed in the inhibition of the cell division process in a fertilized sea urchin 
embryo assay (IC50 ~50 nM), in suppression of inflammation as measured in an 
inflammatory disease model that measures IL-1β-induced sPLA2 secretion from HepG2 
cells (IC50 27 nM), and in blockage of voltage sensitive Na+ channel in mouse neuro-2a 
cells (EC50 1 nM).95-98 In addition, an exceptional concentration-dependent neurotoxicity 
(LC50 3.86 nM) was observed with kalkitoxin when tested in a primary cell culture of rat 
cerebral granule neurons whose the effects were prevented with non-competitive N-
methyl-D-aspartate (NMDA) receptor antagonists.94 Furthermore, The potent anti-cancer 
property of kalkitoxin was revealed by its excellent cytotoxicity (IC50 1 nM) measured 
against the human colorectal cancer cell line (HCT-116).99 In a recent mechanistic study 
by Nagle, Zhou, and co-workers,100 kalkitoxin was found to inhibit hypoxia-induced 





mitochondrial oxygen consumption at electron transport chain (ETC) complex I (NADH-
ubiquinone oxidoreductase). Further, kalkitoxin was also found to inhibit angiogenesis by 
blocking the induction of angiogenic factors like vascular endothelial growth factors 
(VEGF) in tumor cells. 
 
Figure 18. Structure of kalkitoxin. 
The structure of kalkitoxin is as interesting as its biology. Gerwick, Shioiri and co-
workers carried out the total synthesis of natural kalkitoxin and its possible stereoisomers 
in order to determine the configuration.95,101 After comparing their NMR spectra and on 
the basis of the asymmetric synthesis, the absolute configuration of natural (+)-kalkitoxin 
was assigned as (3R,7R,8S,10S,2’R). The structure of kalkitoxin includes a 2,4-
disubstituted thiazoline with one substituent being an unsaturated side chain and the 
other a stretch-peptide side chain. The arrangement of the three methyl substituents in 
the 1,2,4-anti,anti fashion is the most significant and structurally attractive feature of the 
stretch-peptide side chain. 
1.4.2.  Total syntheses of kalkitoxin 
With its exceptional biological activities and three methyl substituents in 1,2,4-
anti,anti fashion in its stretch-peptide side chain, kalkitoxin became an attractive target 
for the synthetic chemists. As a result, five total syntheses have been published to date. 
Gerwick, Shioiri, and co-workers reported a first total synthesis of kalkitoxin in 2000 
(Scheme 15), while determining its absolute configuration.95 The synthesis commenced 





subjected to hydroboration, followed by azide 15 formation. The azide 15 was then 
reduced to an amine, coupled with (R)-methylbutyric acid (16), and methylated to provide 
amide 17. The subsequent O-desilylation and oxidation resulted in an aldehyde, which 
was further subjected to the Horner-Emmons reaction with 18 in order to afford the 
precursor to asymmetric conjugate addition. Hruby’s method103 of conjugate addition 
resulted in the adduct 19 with the required 1,2,4-anti,anti methyl sequence as a single 
isomer. Conversion of the chiral auxiliary to the acid functionality and coupling with (R)-
amino alcohol 20 delivered di-amide 21. Finally, Wipf’s oxazoline-thiazoline 
interconversion reaction sequence104 was utilized in order to get kalkitoxin (13). In this 
process the amide 21 was first cyclized to a 2-oxazoline in the presence of DAST, then 
treatment with hydrogen sulfide afforded the thioamide. DAST was again used for the 
second cyclization to deliver the targeted kalkitoxin (13). In conclusion, the synthesis of 
kalkitoxin was accomplished in 17 linear steps, starting from a known compound 14 in 
9% of overall yield. The 1,2,4-anti,anti sequence was achieved by 1,4-conjugate addition 
with the aid of a chiral auxiliary and the thiazoline ring was introduced by Wipf’s oxazoline-






Scheme 15. Total synthesis of kalkitoxin by Gerwick, Shioiri, and co-workers. a) n-BuLi, 
pTsCl. b) LiAlH4. c) 9-BBN, ultrasound; NaOH, H2O2. d) MsCl, Et3N, DMAP. e) NaN3, 55 
oC. f) H2 (1 atm) 5% Pd-C. g) 16, DEPC, Et3N. h) n-BuLi, MeI. i) TBAF. j) Py.SO3, Et3N, 
DMSO. k) 18, NaHMDS. l) MeMgBr, CuBr.DMS, -30 oC. m) LiOH, H2O2. n) 20, EDCI, 
DIPEA, DMAP. o) DAST, -20 oC. p) H2S, Et3N. q) DAST, -20 oC. 
The second total synthesis was executed by the White group in 2003 (Scheme 
16).99,105 A one pot entry to the 1,2,4-anti,anti methyl sequence via asymmetric conjugate 
addition, followed by in situ enolate alkylation, and a TiCl4 induced thiazoline ring 
formation were the two key steps of the synthesis. The synthesis started with a three-step 
reaction sequence involving asymmetric alkylation, reduction, and Appel reaction to 
generate alkyl bromide 23 from literature molecule 22106 as a starting material. After 
transformation of 23 to an organocopper species, it was treated with (S)-N-(trans-
crotonyl)-4-phenyloxazolidin-2-one (24) and the so-obtained anti-1,3-dimethyl enolate 





anti,anti configuration) and 26 favoring 25 (3.6:1). After hydrogenation of 25, the resulting 
alcohol side chain was extended to amide 27 by Swern oxidation, reductive amination, 
and coupling with (R)-methylbutyric acid (16). The chiral auxiliary was removed by 
reduction and the resulting alcohol was subjected to Swern oxidation, followed by 
homologation, to give a mixture of alkenes (E/Z) 28 via the Wittig reaction. The mixture 
28 was then hydrolyzed to an aldehyde and oxidized to an acid 29. Next, amine 32, the 
coupling partner of the acid 29, was synthesized from L-cysteine (30) in 5 steps. First, the 
free thiol and amine groups of 30 were protected as a benzyl thioether and a carbamate, 
respectively, and the remaining free acid function was transformed to Weinreb amide 31. 
Then reduction, Wittig reaction, and selective amine deprotection delivered amine 32. 
The resulting amine 32 was coupled with acid 29 and the so-formed thioamide 33 was 
subjected to Birch reduction conditions to get thioamide 34 with a free thiol group. Finally, 
the TiCl4-mediated cyclization of 34 delivered the targeted kalkitoxin. In summary, 







Scheme 16. Total synthesis of kalkitoxin by White et al. a) LDA, LiCl, 2-iodoethyl benzyl 
ether, 0 oC, 98%. b) LDA, BH3.NH3, 0 oC, 90%. c) Ph3P, NBS, 74%. d) Mg; CuBr.SMe2; 
24; MeI, 64%. e) H2 (1 atm), 15% Pd-C, 100%. f) (COCl)2, DMSO, Et3N, 85%. g) 
MeNH2.HCl, NaCNBH3, 81%. h) 16, EDCI, HOAt, 84%. i) LiBH4, 80%. j) (COCl)2, DMSO, 
Et3N. k) Ph3PCH2OMeCl, n-BuLi, 52% (2 steps) l) HCl, MeCN. m) NaClO2, NaH2PO4, 2-
methyl-2-butene, 96% (2 steps). n) BnBr, NaOH, EtOH, 94%. o) Boc2O, Et3N, 99%. p) 
MeNHOMe.HCl, EDCI, HOBt, 84%. q) LiAlH4, 91%. r) Ph3PCH3Br, n-BuLi, 55%. s) TFA, 





The next total synthesis was reported by the Shioiri group in 2004,101 and was 
similar to their first total synthesis except for the installation sequence of some of the 
building blocks in the developing stretch-peptide chain. In 2012, Matsuda and co-workers 
also reported a total synthesis,107 in which the stretch-peptide chain was synthesized 
following the route of the Gerwick and Shioiri synthesis, and the thiazoline ring was 
installed following White’s protocol.  
More recently, Aggarwal and co-workers have reported the shortest route to date 
for kalkitoxin using an iterative synthesis approach (Scheme 17).108 The most attractive 
feature of this synthesis was the stereoselective achievement of amide 41 from boronic 
ester 35 in a few steps with a single purification process. First, the boronic ester 35 was 
converted to a core aliphatic chain 38 by a reaction sequence of two consecutive 
homologations with (S)-36, a methylene insertion with 37, another homologation with (R)-
36, and two methylene insertions. The-so obtained boronic ester 38 was treated with 
lithiated methoxyamide (39) and the resulting amine 40 was coupled with (R)-
methylbutyric acid (16) to furnish amide 41. After methylation of amide 41, the resulting 
amide intermediate was converted to acid 29 in the presence of RuCl3 and NaIO4. Unlike 
the White synthesis, the coupling partner of acid 29 (i.e., 32) was prepared from butadiene 
monoepoxide (43) as a starting material. An allylic imide 45 was prepared from the 
reaction of phthalimide and butadiene monoepoxide under Trost’s dynamic kinetic 
asymmetric transformation conditions. The free hydroxyl group was next converted to a 
thioether via mesylation and subsequent displacement by benzylmercaptan and the 





amine 32 in hand, the synthesis of kalkitoxin was completed following White’s protocol. 
The total steps for kalkitoxin synthesis were cut down to thirteen in 12% overall yield. 
 
Scheme 17. Total synthesis of kalkitoxin by Aggarwal and co-workers. 
1.4.3.  SAR studies of kalkitoxin 
Several kalkitoxin analogs have been synthesized and screened for their 
bioactivities in order to understand the role of structural and configurational motifs of 
kalkitoxin in its observed bioactivity. The structures of these kalkitoxin analogs and their 
activities against brine shrimp bioassay (LC50 data) or against human colon cancer cell 








Table 1. Biological activities of kalkitoxin and its analogs. 
 Kalkitoxin and its isomers Brine shrimp 






170-180 1 95,99,101,107 
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15000 - 107 
3 
 
3600 - 107 
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1700 - 107 
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620 - 107 
6 
 
550 - 101 
7 
 
1800 - 107 
8 
 
Inactive - 107 
9 
 







Inactive - 101 
11 
 
Inactive - 101 
12 
 
1700 - 101 
13 
 
1100 - 101 
14 
 
- 400 99 
15 
 
- 190 99 
 
From these results it is clear that the configuration of the stereogenic center C-3 
of kalkitoxin is very important for the activity since the 3S-isomer (46) of kalkitoxin was 
found to be ~80 fold less active than kalkitoxin (Table 1, entry 2). The activities of 7S-
isomer (47) and 8R-isomer (48) (Table 2, entries 3 and 4) were found to be 20 and 10 
fold less than that of kalkitoxin suggesting that the configurations of stereogenic centers 
C-7 and C-8 in kalkitoxin are also important for the activity. However, the configurations 
of stereogenic centers C-10 and C-2’ in kalkitoxin are comparatively less important for the 
activity as both the10R isomer (49) and 2’S-isomer (50) (Table 1, entries 5 and 6) were 





entry 10 and 11) were found to be almost inactive and the enantiomer (53) of kalkitoxin 
(Table 1, entry 9) was found to be 50 fold less active than kalkitoxin. Moreover, isomers 
56 and 57 (Table 1, entry 12 and 13) were also found to be less potent than kalkitoxin. 
The LC50 values for 10-nor-kalkitoxin (51) and 16-nor-kalkitoxin (52) suggest that the 
methyl groups CH3-15 and CH3-16 are very important for the activity. White et al. have 
screened the synthetic precursors of kalkitoxin (33 and 34) against human colon cancer 
cell line (HCT-116) in addition to kalkitoxin (Table 1, entries 1, 14, and 15). The precursors 
33 and 34 were found to be 400 and 190 fold less potent, respectively than kalkitoxin. 
Therefore, the thiozoline ring is a very important part of the molecule for the activity. In 
conclusion, the configurations of all stereogenic centers, methyl groups CH3-15 and CH3-
16, and thiazoline ring are important for the potency of the kalkitoxin. 
 1.4.4.  Design of hydroxylamine and hydrazine analogs 
In order to test the concepts of hydroxylamine and hydrazine analogs, kalkitoxin 
was chosen as a potential candidate for three reasons. First, kalkitoxin has potent 
bioactivity as described in section 1.5.1. Second, the configurations of stereogenic 
centers in kalkitoxin are important for the activity as discussed in section 1.5.3. And third, 
kalkitoxin has the potential to serve as a common candidate to test both the 







Figure 19. Kalkitoxin and its hydroxalogs and hydrazine analog. 
Two hydroxalogs of kalkitoxin were designed, namely, 6-oxa-7-azakalkitoxin (58) 
and 9-oxa-10-azakalkitoxin (59). The former was designed by substituting the C-6 with 
an oxygen atom and the stereogenic center C-7 with a nitrogen atom and the latter was 
designed by substituting the C-9 with an oxygen atom and the stereogenic center C-10 
with a nitrogen atom. The hydrazine analog of kalkitoxin, 7,8-diazakalkitoxin (60), was 
designed by substituting the stereogenic centers C-7 and C-8 with two nitrogen atoms 
thereby introducing the hydrazine moiety. These modifications are intended to reduce the 
synthetic as well as the stereogenic complexities due to the rapid inversions at the 
nitrogen centers. The synthesis of all three analogs will be executed and the compounds 
will be screened against several cancer cell lines in the Valeriote lab at the Henry Ford 








CHAPTER 2. SYNTHESIS OF N,N,O-TRISUBSTITUTED HYDROXYLAMINES 
2.1.  Design and development of the method 
As is described in section 1.2.4 of Chapter 1 (Scheme 3), an ideal route for the 
synthesis of tri-substituted hydroxylamies is the N-O bond formation in which commercial 
amines and alcohols can be utilized to generate a library of compounds. However, owing 
to the challenges associated with this line of work, chemists have shifted their interest to 
alternative routes such as N-derivatization of N,O-disubstituted hydroxylamines and O-
derivatization of N,N-disubstituted hydroxylamines. Several methods for N-alkylation 
have been devised for tri-substituted hydroxylamine synthesis.18,19,41-43 However, 
methods for O-alkylation of N,N-disubstituted hydroxylamine are limited with the 
exception of O-alkylation with simple and activated electrophiles like allyl and aryl 
halides.41 In addition to the observed limitation of the substrate scope, the available 
method for O-alkylation also lacks the potential to introduce diversity on the O-substituent. 
To introduce diversity on O-substituent, an efficient method for O-alkylation of N,N-
disubstituted hydroxylamines is needed to provide easy access to libraries of tri-
substituted hydroxylamines with great diversity. 
To solve the existing problem in O-alkylation, indirect O-alkylation of N,N-
disubstituted hydroxylamine was designed. Since acylation is much easier than alkylation, 
O-alkylation of N,N-disubstituted hydroxylamines was considered analogous to the 
synthesis of ethers from alcohols by reductive etherification, for which a number of 
attractive ideas were formulated recently.109,110 Therefore, by adapting Rychnovsky 
reductive etherification,109  acylation of N,N-disubstituted hydroxylamines to N-





substituted hydroxylamines based upon the stepwise reduction of N-acyloxyamines 
(Scheme 18). The N-acyloxyamines was first reduced with diisobutylaluminum hydride 
(DIBAL)  at lower temperature and then was treated with acetic anhydride in the presence 
of pyridine and 4-(dimethylamino)pyridine (DMAP). The resulting O-(α-
acetoxyalkyl)hydroxylamine was further reduced with triethylsilane in the presence of 
Lewis acid such as BF3.OEt2 to provide tri-substituted hydroxylamine. 
 
Scheme 18. a) Rychnovsky reductive etherification. b) Synthesis of tri-substituted 
hydroxylamines from N-acyloxyamines. 
A possible mechanism for this two-step method is proposed in Scheme 19. 
Scheme 19a is the mechanism for the first reduction step, and Scheme 19b is the 
mechanism for the second reduction step. Partial reduction of the N-acyloxyamine with 
DIBAL generates a chelation-stablized tetrahedral intermediate similar to Colby’s 
aluminium complex of hydroxylamine111 at −78 oC. This tetrahedral intermediate is 
trapped in situ with acetic anhydride in the presence of DMAP generating a more stable 
O-(α-acetoxyalkyl)hydroxylamine. In the second reduction step, an acetoxy anion is 
released from the O-(α-acetoxyalkyl)hydroxylamine with an aid of a Lewis acid and forms 
an aminoxocarbenium ion intermediate in situ. Donation of hydride from triethylsilane to 






Scheme 19. Proposed mechanism for 2-step reaction in Scheme 18. 
2.1.1. Synthesis of N,N-disubstituted hydroxylamines 
A simple protocol to prepare N,N-disubstituted hydroxylamines from N-
(benzoyloxy)amines derived from the reaction of amines with dibenzoyl peroxide was 
executed (Table 2). N-(Benzoyloxy)amines (62a-62e) were prepared from benzoyl 
peroxide and commercial secondary amines by adaptation of the Ganem protocol112 in 
good yields. On exposure to 2.5 equivalents of DIBAL in ice cold conditions, these N-










Table 2. Synthesis of N,N-disubstituted hydroxylamines. 
 




1 61a, R1 = R2 = Bn 62a, 81% 63a, 90% 
2 61b, R1 =Me, R2 = Bn 62b, 82% 63b, 93% 
3 61c, piperidine 62c, 86% 63c, 63% 
4 61d, 4-methylpiperidine 62d, 82% 63d, 84% 
5 61e, 4-chloropiperidine 62e, 81% 63e, 85% 
[a] Stirring with (BzO)2 (1.1 equiv) and K2HPO4 (1.5 equiv) in DMF, at rt for 1-22 h. [b] 
Stirring with DIBAL (2.5 equiv) in CH2Cl2 at 0 oC for 15 min. 
 
 
 Scheme 20. An alternative synthesis of N-acyloxy amines exemplified for N-(4-
phenylbutyroyl)pyrrolidine. 
Alternatively, N,N-disubstituted hydroxylamine 63f was effectively generated from 
aza-Michael addition of a secondary amine to acrylonitrile, followed by N-oxide formation 





phenylbutyric acid in the presence of dicyclohexylcarbodiimide (DCC) and DMAP 
afforded N-acyloxyamine 62f. 
2.1.2. Synthesis of N-acyloxyamines 
N-acyloxyamines (62g-62o) were prepared from N,N-disubstituted 
hydroxylamines (63a-63f) and the corresponding carboxylic acids with DCC and DMAP 
as activating reagents (Table 3).114 
Table 3. Synthesis of N-acyloxyamines. 
 
Entry R1 R2 R3 N-Acylhydroxylamine, 62, 
%yield 
1 Bn Bn Ph(CH2)3 62g, 98% 
2 Bn Bn C10H15 62h, 72% 
3 Bn Bn tBuCH2 62i, 63% 
4 Bn Me Ph(CH2)4 62j, 93% 
5 -(CH2)5- Ph(CH2)3 62k, 93% 
6 -(CH2)2CHMe(CH2)2- Ph(CH2)3 62l, 91% 
7 -(CH2)2CHCl (CH2)2- Ph(CH2)3 62m, 80% 
8 Bn Bn 2-C10H7OCH2 62n, 89% 
9 Bn Bn 3-C5H4N 62o, 97% 
[a]  R3CO2H (1.25-2.5 equiv), DCC (1.25-2.5 equiv), DMAP (0.2 equiv), CH2Cl2, 





2.1.3. Synthesis of N,N,O-trisubstituted hydroxylamines 
With a series of N-acyloxyamines in hand, the efficiency of the two-step by method 
for the synthesis of tri-substituted hydroxylamines (Table 4) was investigated adapting 
Rychnovsky’s protocol109 for the synthesis of ethers from esters. The N-acyloxyamines 
were reduced with DIBAL at −78 °C, and the tetrahedral intermediates were trapped in 
situ as O-(α-acetoxyalkyl)hydroxylamines with acetic anhydride in the presence of 
pyridine and DMAP, followed by warming to 0 °C. A diverse range of O-(α-
acetoxyalkyl)hydroxylamines 65 were obtained in good to excellent yields. The reaction 
is quite general, as exemplified through a diverse set of substrates with alkyl and aryl 
groups in both nitrogen and oxygen substituents. In addition, substrates with branching 

















Table 4. Synthesis of trisubstituted hydroxylamines. 
 
 
[a] i) DIBAL (1.25-2 equiv), CH2Cl2, -78 oC, time; ii) Ac2O (6 equiv), Py (3 equiv), DMAP 
(2 equiv), CH2Cl2, -78 o to 0 oC. [b] Et3SiH (2.5-5 equiv), BF3OEt2 (2.5-6.25 equiv), 
CH2Cl2, -78 o to RT.  [c] Not isolated. [d] Yield over two steps. 
 
The so-obtained O-(α-acetoxyalkyl)hydroxylamines were then treated with 
triethylsilane in the presence of boron trifluoride etherate at −78 °C, and the reaction was 
warmed to 0 °C to give the desired N,N,O-trisubstituted hydroxylamines in good yields 
(Table 4). As some O-(α-acetoxyalkyl)-N,N-dialkyl hydroxylamines intermediates (65a, 
65b, and 65o) were found to be quite unstable and decomposed during the purification 





(66a, 66b, and 66o) directly without further purification in overall good yield for the two-
step process. 
On careful monitoring of the reactions, the actual temperature of the Lewis acid-
mediated reduction of the O-(α-acetoxyalkyl)hydroxylamines by triethylsilane was 
observed to be substrate dependent, reflecting the stability of the presumed intermediate 
aminoxocarbenium ions. The β-(2-naphthyloxy)-ethyl system 65n is an extreme example 
of the effect of substituent on reduction as it required multiple equivalents of triethylsilane 
and BF3.OEt2 at room temperature,  and took 7 days in order to afford a 38% isolated 
yield of hydroxylamine 66n. The relative slowness of this particular reduction reflects the 
destabilizing influence of alkoxy groups on oxocarbenium ion like intermediates such as 
is widely appreciated in carbohydrate chemistry.115-117 
To understand the effect of electron withdrawing groups in the reduction further 
and to support the existence of assumed aminoxocarbenium ion intermediate, reductions 
of a series of three O-(β,γ, and δ-azido-1-acetoxyalkyl) hydroxylamines were executed 
(Scheme 21). 
 
Scheme 21.  Synthesis of azidoalkylhydroxylamines. 
The synthesis of three O-(β,γ, and δ-azido-1-acetoxyalkyl) hydroxylamines were 
achieved by a similar protocol to the one described previously.  As anticipated, the 





(azidoalkyl)hydroxylamines was strongly affected by the proximity of the azido group to 
the center of reaction.  Thus, while the 1-acetoxy-4-azidobutyl system 65r was reduced 
to the hydroxylamine 66r in 54% yield under the standard conditions of treatment with 
BF3.OEt2 and triethylsilane at −78 oC in dichloromethane followed by warming to 0 oC and 
workup, a more modest 48% yield of the lower homolog 66q was obtained from the 1-
acetoxy-3-azidopropyl precursor 65q only when the reaction was warmed to room 
temperature and stirred for 24 h.  Reduction of next lower homolog 65p was significantly 
slower, such that 66p was obtained only in 17% yield after stirring for four days at room 
temperature.  The presence of an electron-withdrawing group vicinal to the reaction 
center therefore, very strongly retards reduction of the O-(1-acetoxyalkyl)hydroxylamines, 
but the effect falls off rapidly with the insertion of successive methylene groups. The 
strongly retarding effect of the electron-withdrawing group thus observed in the reduction 
of both 65n and 65p supports the intermediacy of an aminoxocarbenium ion intermediate 
(Scheme 22) in these reactions. 
 
Scheme 22. Intermediate aminoxocarbenium ion destabilized by the electron-
withdrawing group X. 
2.1.4. Synthesis of tri-substituted hydroxylamines with C-C bond formation 
The isolation of the O-(α-acetoxyalkyl)hydroxylamines also provided an 
opportunity to introduce nucleophiles adjacent to the oxygen and increase the molecular 
complexity of the product hydroxylamines. Therefore, adapting literature methods for the 
reductive allylation of α-acetoxy ethers,118,119 various carbon nucleophiles such as 





promoted substitution to afford a number of novel hydroxylamines (Table 5) in modest to 
excellent yields. 
Table 5. Synthesis of trisubstituted hydroxylamines with concomitant C-C bond formation. 
 
Entry Ester O-(α-Acyloxy)hydroxyl 
-amine, 65[a] 
Reagent, conditions Hydroxylamine, 
70, %yield 
1 62a 65a, -[b] Bu3SnCH2CH=CH2 (2.5 equiv), 
BF3OEt2 (2.5 equiv), CH2Cl2, -78 to 0 oC 
70a, 82%[c] 
2 62b 65b, -[b] Bu3SnCH2CH=CH2 (2.5 equiv), 
BF3OEt2 (2.5 equiv), CH2Cl2, -78 to 0 oC 
70b, 54%[c] 
3 - 65h Bu3SnCH2CH=CH2 (2.5 equiv), 
BF3OEt2 (2.5 equiv), CH2Cl2, -78 to 0 oC 
70c, 79% 
4 62a 65a, -[b] CH2=C(OTMS)CMe3, (2.5 equiv), 
BF3OEt2 (2.5 equiv), CH2Cl2, -78 to 0 oC 
70d, 66%[c] 
5 62a 65a, -[b] 2-methylfuran (2.5 equiv), 
BF3OEt2 (2.5 equiv), CH2Cl2, -78 oC 
70e, 51%[c] 
6 - 65g 2-methylfuran (2.5 equiv), 
BF3OEt2 (2.5 equiv), CH2Cl2, -78 to 0 oC 
70f, 20% 
[a] i) DIBAL (2 equiv), CH2Cl2, -78 oC; ii) Py (3 equiv), DMAP (2 equiv), Ac2O (6 equiv),  CH2Cl2, -78 to 0 oC. 






2.1.5. Study of stereoselectivity of addition of nucleophiles 
As the carbon nucleophile addition on aminoxocarbenium ion intermediate in Lewis 
acid-mediated reaction creats a new stereogenic center in the molecule, the 
stereoselectivity of the reaction was investigated by applying the standard conditions in 
the substrates with pre-existing stereocenters (Scheme 23). Intermediate 73 was 
prepared from Evan’s alkylated product 71.120 Reaction of hydrogen peroxide and lithium 
hydroxide with 71 afforded the corresponding acid. The resulting acid was then used for 
acylation of N,N-dibenzylhydroxylamine in the presence of N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide (EDCI) and Hunig’s base, and O-acyl hydroxylamine 72 was 
generated. Upon reduction with DIBAL at −78 oC followed by treatment with acetic 
anhydride and warming to 0 oC, 72 was converted to O-(α-acetoxyalkyl)-N,N-dialkyl 
hydroxylamine 73.  
 





With the intermediate 73 in hand, the stereoselectivity of the nucleophilic addition 
was studied. In a reaction of 73 with allyltributylstannane as a nucleophile in the presence 
of BF3.OEt2, a mixture of two inseparable diastereomers (74a and 74b) was isolated in 
87% yield with poor selectivity (1:1.2). The product 74b (conformation D) and product 74a 
(conformation A) were identified as the major and minor products, respectively  from the 
NOE experiments and 3JH1,H2 values (Figure 20). Under similar reaction conditions, an 
unassigned mixture of inseparable diastereomers (75a and 75b) was obtained in a ratio 
of 1:1 when using dimethylzinc as a nucleophile. Owing to the observed poor selectivity 
of these reactions, further investigation towards diastereoselective reaction was aborted. 
 
Figure 20. NOE correlation of 74a and 74b. 
2.1.6. Considering an analogy between tetra-substituted hydrazines and tri-
substituted hydroxylamines 
The synthesis of tetra-substituted hydrazines was considered analogously to the 
synthesis of tri-substituted hydroxylamines. Therefore, a two-step reaction method was 





hydrazide, which itself can be accessed from N-acylation of a tri-substituted hydrazine 
(Scheme 24.).  
 
Scheme 24. Synthesis of tetra-substituted hydrazines. 
To test the idea, hydrazide 79 was prepared from 1-Boc-1-methylhydrazine 76121  
(Scheme 25). Benzylation of 76 with excess benzyl bromide afforded 1-Boc-1-methyl-
2,2-dibenzylhydrazine (77), which was then deprotected to 1,1-dibenzyl-2-
mehylhydrazine (78) by treatment with trifluoroacetic acid. Treatment of 78 with 4-
phenylbutyric acid in the presence of DCC and DMAP afforded the hydrazide 79 in 
excellent yield. 
 
Scheme 25. Synthesis of hydrazide 79. 
Reduction of hydrazide 79 to N-(α-acetoxyalkyl)hydrazine 80 was tested by 
treating with 1.5 equivalents of DIBAL at −78 oC, followed by addition of acetic anhydride, 
pyridine, and DMAP, and warming to 0 oC. Surprisingly, the anticipated N-(α-
acetoxyalkyl)hydrazine 80 was not observed, but the tetra-substituted hydrazine 81 and 
hydrazide 82 were isolated in 33% and 30% yields, respectively. When 79 was treated 
only with 3 equivalents of DIBAL at lower temperature, the tetra-substituted hydrazine 81 
was isolated in 65% yield, and 14% of starting material was recovered. When the reaction 
was exposed to allyltributylstannane after treatment with 1.25 equivalent of DIBAL at −78 






Scheme 26. Results from the reductions of hydrazide 79. 
Consistent with the reduction of 79, hydrazide 84, which was prepared from tri-
substituted hydrazine 78 and benzoic acid, also resulted in the formation of tetra-
substituted hydrazine 85 in 61% yield when reduced with 3 equivalents of DIBAL at −78 
oC. Similarly, precursor 86, which was prepared from sym-dimethylhydrazine and an 
excess of 4-phenylbutyric acid, also afforded tetra-substituted hydrazine 87 in 46% yield 
with 6 equivalents of DIBAL.  
 
Scheme 27. Synthesis of tetra-substituted hydrazines 85 and 87. 
The failure to observe N-(α-acetoxyalkyl)hydrazine 80 from hydrazide 79 in the 
presence of DIBAL and acetic anhydride, and complete reduction of hydrazides 79, 84, 





proceeds via azaiminium ion intermediate (Figure 21). As azaiminium ion is more stable 
than aminoxocarbenium ion, at low temperature, the formation of azaiminium ion 
intermediate was facile and unavoidable in the DIBAL reduction of hydrazide, whereas 
the formation of aminoxocarbenium ion in the reduction of O-acylhydroxylamine was not 
observed . 
 
Figure 21. Structures of azaiminium ion and aminoxocarbenium ion intermediates. 
2.2.  Conclusion 
A straightforward two-step synthesis of N,N,O-trisubstituted hydroxylamines has 
been developed based upon the stepwise reduction of O-acylhydroxylamines. The O-
acylhydroxylamines were easily accessed from acylation of N,N-disubstituted 
hydroxylamines, which themselves were achieved from the benzoylation of commercial 
amines followed by deacylation. The reductive deacetoxylation of an intermediate O-(α-
acetoxyalkyl)hydroxylamine is proposed to proceed via intermediacy of an 
aminoxocarbenium ion. This hypothesis is supported by the diminished reactivity of O-(α-
acetoxyalkyl)hydroxylamine with electron withdrawing substituents in an alkyl side chain. 
The replacement of triethylsilane with various carbon nucleophiles in the reductive 
deacetoxylation step enabled the introduction of substitutions on the α-position of the O-
substituents. Poor stereoselectivities were observed when the reductive deacetoxylation 
was conducted on substrates with the pre-existing stereocenters adjacent to the acetoxy 





extended the availability of a range of fully substituted hydroxylamines permitting wider 
application of this under-utilized functionality in medicinal chemistry. 
2.3.  Future directions 
The scope of the hydroxylamine-forming process can be further expanded by 
manipulating final reduction steps in several ways. Some of the possible manipulations 
are presented in Scheme 28. A well-designed intramolecular cyclization in reductive 
deacetoxylation of O-(α-acetoxyalkyl)hydroxylamine has a potential to form a series of 
compounds with carbocycles on O-substituents (Scheme 28a). Also, aminoxysugar 
derivatives are possible if the intramolecular nucleophile is an oxygen atom (Scheme 
28b). Alternatively, endocyclic hydroxylamines can be achieved if the intramolecular 
nucleophile is appended to the N-substituent (Scheme 28c). Overall, the method has the 
potential to generate diverse sets of tri-substituted hydroxylamines to enrich compound 
libraries for medicinal chemistry. 
 





CHAPTER 3. CONFORMATIONAL DYNAMICS OF N-ALKOXYPIPERIDINES AND 
PYRROLIDINES 
To minimize repulsive interactions between the lone pairs of electrons on nitrogen 
and oxygen atoms, hydroxylamines adopt two stable conformers (Figure 22) with lone 
pairs of one atom eclipsing bonds of the next atom. The inter-conversion of these 
conformers at ambient temperature is a rapid process that is attributable to the low 
inversion barrier at the nitrogen and the low rotation barrier around the N-O bond. 
Understanding the degree of contributions and the relative energetics of these two 
processes in the stereomutation of hydroxylamines has been an area of interest for 
chemists. As a result, extensive studies, both computational and spectroscopic, have 
been conducted and described in a series of reviews.17,122-124  
 
Figure 22. Stereomutation of acyclic hydroxylamine. 
The situation is more complex for cyclic hydroxylamines in which the N-O bond is 
a part of the ring system, and understanding the conformational changes of such systems 
is rather more complicated due to ring inversion. This complication in stereomutation can 
be attributable to the individual processes of nitrogen inversion, N-O bond rotation, and 
ring flip or the interplay of a combination of all three processes. Several studies discussing 
about this problem have been reported for the endocyclic systems like oxazines in which 
the N-O bond is a part of the ring system.17,122-124 However, the studies for the exocyclic 
hydroxylamines such as N-alkoxypiperidines are rare. To shed light on conformational 
preferences in the N-alkoxypiperidine system, variable temperature NMR (VT-NMR) 





alkoxypyrrolidines (Figure 23) were conducted, and the data were analyzed together with 
the literature data of analogous comparators. 
 
Figure 23. N-hydroxypiperidines, N-alkoxypiperidines, and N-alkoxypyrrolidine studied 
by variable temperature NMR. 
 
Figure 24. Cyclic hydroxylamines with exocylic N-O bond. a) Six-membered and b) five-
membered. 
According to the existing literature on saturated six membered hydroxylamines 
with an exocyclic N-O bond, the nitrogen atoms are predominantly pyramidal as revealed 
by their X-ray crystal structures,17,122-124 and the rings adopt chair conformations with the 
nitrogen substituents in equatorial positions (Figure 24a).45,125-128 The nitrogen atom is 
also pyramidal in similarly substituted five-membered nitrogen heterocycles as observed 
in their X-ray crystal structures (Figure 24b).129-133  Consistent with the acyclic and 





conformations in which the lone pair on nitrogen eclipses with the substituent on oxygen, 
whether it is a simple alkyl group,45,125,128,133 a vinyl group,131 a trifluoromethyl group,127 
an acyl group,132 or a 1-hydroxyalkyl group.126 Therefore, N-alkoxypiperidines and 
pyrrolidines are expected to exist in solution as a mixture of two equivalent conformers, 
and nitrogen inversion, ring inversion, and rotation about the N-O bond is involved in the 
interconversion of these conformers (Figure 25).   
 
Figure 25.  Stereomutation of the N-alkoxypiperidines (n = 2) and pyrrolidines (n = 1). 
In 1985, Jenkins et al. conducted VT-NMR studies in a series of 2-alkoxy-1,1,3,3-
tetramethylisoindolines 95 (Figure 26) and measured the energy barriers to 
stereomutation. Based upon the increasing barriers with increasing steric bulk of alkoxy 
group and decreasing barriers with increasing solvent polarity, the authors inferred that 
the two processes, the nitrogen inversion and the N-O bond rotation, on these molecules 
take place at the same time.134 Later in a VT-NMR study  of a series of 1-alkoxy-2,2,6,6-
tetramethylpiperidines 96 (Figure 26), Anderson et al. also  observed similar changes in 
energy barriers with the steric bulk of the alkoxy groups, although not in a linear fashion.125   
Anderson and coworkers further considered that, as each of the three individual 
processes of N-O bond rotation, ring inversion, and nitrogen inversion have substantial 
individual barriers, stepwise processes are more likely than composite ones.  Finally, they 
concluded that the main component of the observed barrier in 96 is the barrier to N-O 
bond rotation.125  Although VT-NMR studies were performed in a series of N-hydroxy and 





determine the energy barriers,135 no such studies are reported for 4-substituted N-
alkoxypiperidines. 
 
Figure 26. General structures of literature comparators. 
To understand the stereomutation process in 4-substituted N-alkoxypiperidines 
and N-hydroxylpiperidines in the absence of extreme steric buttressing like in 95 and 96, 
VT-NMR studies were performed in N-hydroxypiperidines 88-90, N-alkoxypiperidines 91-
93, and N-alkoxypyrrolidine 94. These exocyclic hydroxylamines were previously 
synthesized during the methodology development program for trisubstituted 
hydroxylamine (Chapter 2) and are re-numbered in this section for the sake of 
convenience.  
After comparing the 1H NMR spectra of N-hydroxypiperidines 88-90 at ambient 
temperature in CDCl3, the effect of substituent at the 4-position on the conformational and 
configurational equilibria of these systems was clearly noted (Figure 27).  The 
unsubstituted N-hydroxypiperidine system 88 predominantly adopts a chair-like 
conformation with a distinct axial and equatorial protons at the 2- and 6-postions, since 
two sets of two non-equivalent hydrogens germinal to the ring nitrogen are observed in 
the 1H NMR spectrum. However, the spectrum of 4-chloro-N-hydroxypiperidine 89 reveals 
two isomers, 89a and 89b, in a 1:1 ratio. The spectrum of 89a is similar to that of 88 with 
the chloride group in an equatorial position of the chair conformation. In contrast, the 





protons at the 2- and 6-positions which are merged into a single resonance, and a third 
one for the combined protons at 3- and 5-postions mixed together.  
As in 89, the spectrum of 4-methyl-N-hydroxypiperidine 90 also represents two 
species 90a and 90b, but in a nearly 8.5:1 ratio. The major isomer 90a adopts a chair-
like conformation in which the methyl group is in an equatorial positions. Otherwise, the 
spectrum is consistent with the unsubstituted system 88 and the isomer 89a of the 4-
chloro system. The spectrum of the minor isomer 90b, however, is similar to that of the 
isomer 89b of the 4-chloro system as all methylene protons at the 2- and 6-positions are 
aggregated as a single resonance as are other protons at the 3- and 5-positions.  
 





When the unsubstituted system 88 was heated above 90 oC (coalescence 
temperature), the signals for the geminal protons at the 2- and 6-positions merged 
together as they became equivalent. This phenomenon clearly signifies that out of three 
processes, N-O bond rotation, ring inversion, and nitrogen inversion, at least one of them 
is slow at room temperature on the NMR time scale. When the system is substituted at 
the 4-position as in 89 and 90, the nitrogen inversion process is slow on the NMR 
timescale and two diastereomers, namely cis and trans, are observed. However, the ratio 
of these diastereomers depends upon the size of the substituents present. When the 
substituent is smaller like a chlorine atom (steric A value = 0.53 – 0.64 kcal.mol-1),136 the 
ratio is about 1:1 and when the substituent is larger like a methyl group (steric A value = 
1.74 kcal.mol-1),136 the trans isomer is favored.  In general, Figure 28 represents the 
overall conformational equilibria of a series of N-hydroxypiperidines.  
 
Figure 28.  Conformational dynamics of the N-hydroxypiperidines (R = H) and N-
alkoxypiperidines (R = alkyl). 
Therefore, unsubstituted N-hydroxypiperidine 88, isomer 89a of 4-chloro-N-
hydroxypiperidine, and major isomer 90a of 4-methyl-N-hydroxypiperidine adopt 
predominantly chair conformations in which both the substituents are in equatorial 





hydroxypiperidine and minor isomer 90b of 4-methyl-N-hydroxypiperidine, a mixture of 
several rapidly interconverting conformers including twist boats (Figure 28, cis-manifold)  
is possible, which results in the aggregation of the four protons geminal to nitrogen atom 
into a single resonance. Likewise, the four vicinal protons to nitrogen coalesce into a 
single peak in the minor cis isomers. A similar conclusion can be drawn from the 1H NMR 
spectra of a series of N-alkoxypiperidines 91-93 recorded at room temperature in CDCl3 
(Figure 29).   
  
Figure 29.  Partial 1H-NMR spectra of the N-alkoxypiperidines 91 (a), 92 (b), and 93 (c), 
and the N-alkoxypyrrolidine 94 (d). 
After inspection of 1H-NMR spectra of these N-alkoxy systems, three crucial pieces 
of information are instantly discerned. First, all alkoxy groups are fully conformationally 





observed for all the 4-phenylbutyl protons in each molecule.  Second, the cis and trans 
isomers are still present in the N-alkoxy systems 92 and 93, with broader line shapes for 
the piperidine moiety than in the corresponding N-hydroxy systems. Similar broadening 
was also observed for the unsubstituted system 91. These broader resonances of the 
piperidine moiety imply that the N-alkoxy series is closer to the coalescence temperature 
for interconversion between the cis and trans configurations than the N-hydroxy series, 
and the nitrogen inversion barrier is lower for the former than for the latter.  This result is 
in line with the inversion process occurring through a low energy planar transition state 
due to relief from steric interactions in the case of N-alkoxy series. Third, the entire set of 
NMR signals for the protons in N-alkoxypyrrolidine 94 at room temperature were sharp 
suggesting complete conformational equilibration on the NMR time scale.  In order to 
scrutinize further, VT-NMR studies were conducted in N-hydroxypiperidine 88 and N-
alkoxy systems 91-94 in toluene and DMF as NMR solvents, and the energy barriers to 
stereomutation were determined. These energy barriers are listed in Table 6 in increasing 













Table 6.  Barriers to stereomutation in 91-94, 88, and literature18,137,138 comparators as 
determined by VT 1H-NMR. 


























15.3 (DMF-d7) 18 
7 
 
14.6 (DMF-d7) 18 
8 
 
14.5 (DMF-d7) 18 
9 
 







17.0 (CCl4) 137 
11 
 
12.0 (DMF-d7) 138 
[a]: this work. [b]: no coalescence below 120 oC. 
The inversion barriers for the series of N-alkoxypiperidines 91-93 and 97-99 (Table 
6, entries 2-4 and 6-8) are significantly higher than for the N-alkoxypyrrolidine 94 (Table 
6, entry 1).  This result is consistent with the fact that i) the six-membered ring inversion 
is a more difficult process than the pseudorotation of the five-membered ring, and ii) the 
accommodation of an sp2-hybridized atom is much easier for a five-membered than for 
six-membered ring. Failure to achieve a coalescence temperature for 4-methyl-N-
alkoxypiperidine 93 (Table 6, entry 4) below 120 oC led to a conclusion that the inversion 
barrier is significantly higher for the 4-methyl system than for the unsubstituted system 
91, 4-chloro system 92, and other literature comparators (Table 6, entries 6-8). Based on 
the observations of increasing barrier with increasing steric at 4-postision in the piperidine 
system and the lower barrier for the pyrrolidine system over the piperidine system, the 
barrier in the piperidine system can be primarily attributed to the ring flip. The 
comparatively higher barrier to stereomutation of the literature molecule N-methoxy-
2,2,6,6-tetramethylpiperidine 101 (Table 6, entry 10) than the barriers of the N-
alkoxypiperidines 91 and 92 (Table 6, entries 2 and 3) and the other literature 
comparators (Table 6, entries 6-8) indicates that the main component of the barrier has 
switched to N-O bond rotation from ring flip due to steric buttressing in 101 as described 





N-hydroxypiperidine series. The barrier to stereomutation of N-alkoxypiperidine 91 (Table 
6, entry 3) is slightly smaller than that of the corresponding N-hydroxy system 88 (Table 
6, entry 5), implying that the oxygen substituent has minimal effect on stereomutation 
process. However, the barrier of N-methoxy-2,2,6,6-tetramethylpiperidine (Table 6, entry 
10) is considerably higher than that of its N-hydroxy analog (Table 6, entry 9), which can 
be attributed to steric buttressing on N-O bond rotation. The observed lower barrier to 
stereomutation in the tetra-alkyl system 100 (Table 6, entry 9) in comparison to its 
sterically less hindered N-hydroxy and alkoxy analogs 88 and 91 (Table 6, entries 3 and 
5) is, however, not surprising, since a similar pattern is observed in N-alkyl piperidine 
systems139-141 and N-diazenyl piperidine systems142,143 (Figure 30). The barrier is lower 
for 2,2,6,6-tetramethyl system 104 than for its unsubstituted congener 103. A similar trend 
is also observed for 2,2,6,6-tetramethyl system 106 and its unsubstituted analog 105. 
These phenomena reflect the situation in cyclohexane and 1,1,3,3-tetramethyl 
cyclohexane systems wherein the chair/twist boat energy gap is reduced on tetra-
substituted systems in comparison to unsubstituted systems, as in the former case the 
chair conformation is destabilized by the repulsive syn 1,3-diaxial interaction between the 
alkyl groups.144 
 
Figure 30. Unsubstituted and 2,2,6,6-tetramethyl substituted systems of N-alkyl 







In order to explore the remained uncertainty in the N-alkoxypiperidine system, 
variable temperature NMR studies of a series of 4-substituted N-hydroxypiperidines, N-
alkoxypiperidines, and N-alkoxypyrrolidines were conducted. The observed strong 
dependence of VT NMR phenomena on the substituent at the 4-position together with 
other evidence from literature comparators led to the conclusion that the rate-determining 
step in the stereomutation of such piperidines is the ring flip and not the nitrogen inversion 
or the N-O bond rotation. When the system is sterically crowded like in N-alkoxy-2,2,6,6-
tetramethylpiperidines, the barrier to N-O bond rotation becomes the major component of 


















CHAPTER 4. SYNTHESES OF HYDROXYLAMINE AND HYDRAZINE ANALOGS OF 
KALKITOXIN 
As described in Chapter 1, hydrazines and hydroxylamines have the potential to 
enrich compound collections in medicinal chemistry as they can be used to increase the 
sp3 fraction of molecule as well as molecular complexity and diversity. As weak bases, 
hydroxylamines and hydrazines are little protonated under normal physiological 
conditions. Their low inversion barriers allow them to invert rapidly at nitrogen at ambient 
temperature, thereby reducing the stereogenic complexity of the molecule. Owing to 
these unique properties, hydroxylamine and hydrazine moieties can be considered as the 
surrogates of sp3 carbons in the carbon frameworks (Figure 31), offering new 
compositions of matter to new libraries representing unexplored areas of chemical space. 
Taking advantage of these unique properties of the hydroxylamine and hydrazine 
functionalities, a broad program was initiated where hydroxylamine and hydrazine serve 
as convertible mimics for stereogenic centers in the carbon framework . 
 
Figure 31. Hydroxylamine and hydrazine as surrogates of sp3 carbons. 
To test the concept of hydrazine and hydroxylamine analogs, kalkitoxin, a natural 
anticancer compound, was chosen as an initial substrate, because of the combination of 
its potent bioactivity and the presence of stereogenic centers that are crucial for activity. 
Two hydroxalogs  and a hydrazine analog of kalkitoxin were designed, as shown in Figure 





atom for C-6 and replacing the stereocenter C-7 with a nitrogen atom. The second 
hydroxalog, 9-oxa-10-azakalkitoxin (109), was designed by replacing C-9 with an oxygen 
atom and the stereogenic center C-10 with a nitrogen atom. The hydrazine analog 7,8-
diazakalkitoxin (110) was designed by substituting the stereogenic centers C-7 and C-8 
with two nitrogen atoms. These hydrazine and hydroxylamine analogs are intended to 
reduce the synthetic and stereogenic complexity of the target owing to the rapid 
inversions at nitrogen centers, and to test their influence on biological activity. 
 
Figure 32. Kalkitoxin and the proposed hydroxylamine and hydrazine analogs. 
The program commenced with the synthesis of these analogs. The parent 
compound, kalkitoxin, was also synthesized for the comparative study. The syntheses of 










4.1.  Synthesis of kalkitoxin (107) 
 
Scheme 29. Retrosynthesis of kalkitoxin. 
Kalkitoxin was synthesized by partially adapting previous methods as shown in the 
retrosynthetic analysis (Scheme 29).95,105 Wipf’s oxazoline-thiazoline ring conversion 
sequence104 (Scheme 30), utilized by Gerwick’s synthesis,95 was selected to construct 
thiazoline ring. The stretched-peptide chain 111 was, however, was prepared from alkyl 
bromide 113 by following the reaction conditions from White’s kalkitoxin synthesis,105 
relying on their short and efficient pathway to assemble the 1,2,4-anti,anti-methyl 
sequence. γ-Butyrolactone (114) was chosen as a starting substrate to synthesize alkyl 
bromide 113. 
 
Scheme 30. Wipf’s oxazoline-thiazoline conversion strategy. 
The synthesis of kalkitoxin (107) commenced with hydrolysis of γ-butyrolactone 
(114), followed by benzylation of the resulting alcohol (Scheme 31).145 Acylation of 
Lithiated (R)-4-benzyl-2-oxazolidinone (120) with acid 119 delivered N-acyloxazolidinone 





122 stereoselectively. Lithium borohydride-mediated reduction afforded next alcohol 123, 
which was transformed to bromide 113 upon subjection to Appel’s reaction conditions. 
 
Scheme 31. Synthesis of alkyl bromide 113. 
Alkyl bromide 113 was then used to synthesize the stretch-peptide 111 by White’s 
procedure (Schemes 32 and 33). After transformation of alkyl bromide 113 to an 
organocopper species 124, it was treated with (S)-N-(trans-crotonyl)-4-phenyloxazolidin-
2-one (125). The so-obtained product (126) with the 1,3-anti dimethyl configuration (79% 
yield) was enolized and further alkylated to deliver 127 (with the desired 1,2,4-anti,anti 
configuration) and 128 (with 1,2,4-syn,anti configuration) in 62% and 20% yields, 
respectively. The stereochemistry of  compounds 126, 127, and 128 were confirmed by 
comparing their NMR spectra and specific rotation data with the literature data of these 






Scheme 32. Construction of the 1,2,4-anti,anti methyl sequence. 
After hydrogenation of the major diastereomer 127, Swern oxidation of the 
resulting alcohol 129 generated corresponding aldehyde 130 (Scheme 33). This 
aldehyde was then extended to amide 133 by reductive amination followed by coupling 
with (R)-methylbutyric acid (132). The chiral auxiliary was removed by lithium 
borohydride-mediated reduction to obtain alcohol (134). Subjection of this alcohol to 
Swern oxidation, followed by homologation by a Wittig reaction, gave a mixture of alkenes 
(E/Z) 135. The mixture 135 was converted to acid 111 by hydrolyzing to the aldehyde, 






Scheme 33. Synthesis of acid 111. 
Further development of acid 111 to kalkitoxin was achieved by Gerwick’s protocol 
(Scheme 34).95 Acid 111 was coupled with amine 112 to access amido alcohol 136, the 
precursor for Wipf’s oxazoline-thiazoline reaction sequence.  A DAST-mediated 
cyclization of 136 to 2-oxazoline derivative 137 and subsequent treatment with hydrogen 
sulfide resulted in thioamide 138. DAST was again used for the second cyclization to 
deliver the targeted kalkitoxin (107) as a colorless oil. As expected, a mixture of rotamers 






Scheme 34. Synthesis of kalkitoxin from acid 111. 
In summary, kalkitoxin, a stretch-peptide, was synthesized in 21 linear steps from 
γ-butyrolactone to provide 94 mg of the natural product. The unique 1,2,4-anti,anti 
configuration in the alkyl chain was obtained by the protocol used in White’s kalkitoxin 
synthesis. However, the thiazoline ring was constructed efficiently adapting the procedure 
from the Gerwick’s kalkitoxin synthesis. The so-obtained kalkitoxin (107) and its oxazoline 
congener (137) were then submitted for biological assessment in the Valeriote lab at the 









4.2.  Synthesis of 6-oxa-7-azakalkitoxin (108) 
 
Figure 33. Structure of kalkitoxin and its proposed hydroxalog 6-oxa-7-azakalkitoxin. 
The intended modification of kalkitoxin 107 to hydroxalog 108 introduces a novel 
and unexplored functional moiety, the 2-aminoxy thiazoline, in the molecule. Hence, 
before undertaking the total synthesis of 108, it was necessary to find a route to introduce 
such moiety with the aid of a simple model. Therefore, the model compound 141 was 
targeted for synthesis (Scheme 35). Treatment of ethyl (R)-2-oxothiazolidine-4-
carboxylate (139),146 an L-cysteine-derived thiazolidinone, with triflic anhydride in the 
presence of Hunig’s base afforded triflate 140. Owing to its unstable nature, triflate 140 
was subsequently treated with the sodium alkoxide of N,N-dibenzylhydroxylamine without 
purification. The targeted compound 141 was observed in the crude reaction mixture by 
mass spectrometry but decomposed during the workup, leading to the conclusion that the 
targeted functionality is unstable and difficult to handle. Based on the observed instability 
of the model compound 141, the plan to synthesize 108 was halted.  
 






4.3.  Synthesis of 9-oxa-10-azakalkitoxin (109) 
 
Figure 34. Structure of kalkitoxin and its hydroxalog 9-oxa-10-azakalkitoxin. 
The retrosynthetic analysis for hydroxalog 109 was performed relying partially on 
Gerwick’s kalkitoxin synthesis95 (Scheme 36). The synthesis of the target was proposed 
from three fragments, 112, 142, and 132. As in Gerwick’s kalkitoxin synthesis,95 thiazoline 
ring was envisaged by adaptation of Wipf’s oxazoline-thiazoline conversion strategy104 
(Scheme 30). Fragment 112 is a known compound, which was derived from L-serine in 
literature,147 whereas fragment 132 is a commercial species. Fragment 142, with a 1,2-
trans dimethyl moiety, was proposed to access from acid 143 and hydroxylamine 144 
using an indirect alkylation approach of N,N-dialkylhydroxylamine (Chapter 2), developed 
previously for tri-substituted hydroxylamines (Scheme 37). The pre-existing methyl 
substituent in the substrate was predicted to direct the reaction to achieve the required 
diastereoselectivity. Acid 143 is an accessible species from a stereoselective reaction 
involving a chiral auxiliary system, and sym-dimethylethylenediamine 145 was intended 






Scheme 36. Retrosynthetic analysis of 9-oxa-10-azakalkitoxin. 
 
Scheme 37. Indirect alkylation of N,N-disubstituted hydroxylamine. 
Before approaching the synthesis of hydroxalog 109, suitable protecting groups 
for one of the secondary amines in sym-dimethylethylenediamine 145 and for the alcohol 
in fragment 143 were required, and their compatibility under the standard reaction 
conditions for tri-substituted hydroxylamine synthesis was examined. For the secondary 
amine, the triazene moiety was considered as a possible protecting group whereas a tert-
butyldimethylsilyl ether was chosen for the alcohol protection. First, the compatibility was 





model (Scheme 38). To begin the synthesis, one amino group of sym-
dimethylethylenediamine 145 was protected as a triazene, after which the other was 
oxidized with benzoyl peroxide to deliver 146. Upon reduction with DIBAL, compound 146 
was converted to a N,N-diakylhydroxylamine, which was further acylated in situ to give 
N-acyloxyamine 147. Adapting the protocol for the tri-substituted hydroxylamine 
synthesis, 147 was then reduced with DIBAL at -78 oC, and the resulting tetrahedral 
intermediate was trapped with acetic anhydride as O-(α-acyloxyalkyl)hydroxylamine 148 
in good yield. However, the Lewis acid-mediated conversion of 148 to the tri-substituted 
hydroxylamine 149 was unsuccessful in the presence of dimethylzinc, as deprotection of 
the triazene functionality was observed after addition of BF3.OEt2, suggesting that the 
triazene protecting group is incompatible with the reaction conditions for the tri-substituted 
hydroxylamine synthesis. 
 
Scheme 38. Compatibility test for triazene group. 
Next, the carboxybenzyl (Cbz) protecting group was chosen for the secondary 
amine functionality (Scheme 39), considering its tolerance to a wide range of reaction 





one amino group was protected as the benzyl carbamate and the other was 
benzoyloxylated. Debenzoylation of 150 with DIBAL, however, afforded N,N-dialkyl 
hydroxylamine 151 in only 52% yield, as partial deprotection of the carbamate group was 
observed. Alternatively, debenzoylation was best achieved by a transesterification 
reaction in an excellent yield.  
 





Following a known protocol,148 acid 153 was prepared from the hydrolysis of 
compound 152.148 After purification, the acid 153 was isolated as a colorless oil with [α]20D 
–13.21 (c 8.25, EtOH). However, the specific rotation of the acid 153 was recorded with 
opposite sign in literature [lit148 [α]20D +13.51 (c 1.8, EtOH)]. The so-obtained acid 153 
was then used for the acylation of di-substituted hydroxylamine 151 in the presence of 
EDCI and hydroxylbenzotriazole (HOBt). The resulting N-acyloxyamine 154 was reduced 
with DIBAL at -78 oC followed by treatment with acetic anhydride, DMAP, and pyridine 
and warmed to 0 oC in order to provide  O-(α-acyloxyalkyl)hydroxylamine 155. When 155 
was subjected to Lewis acid-mediated deacetoxylation followed by the reaction with 
dimethylzinc, two products, 156 and 157, were isolated in 27% and 50% yields, 
respectively. From the NMR spectra, 156 was analyzed as a mixture of two diastereomers 
of the desired product in a ratio of 5:3, and 157 was characterized as a mixture of two 
anomers of a cyclic derivative in a 4:1 ratio. The individual isomers in both of the mixtures 
were not characterized due to the presence of rotamers in the NMR spectra. The aminoxy 
sugar derivatives in 157 are the cyclized products resulting from nucleophilic attack of the 
silyl ether oxygen on the two faces of aminoxocarbenium ion intermediate. After observing 
the cyclized products as the major outcome, the need for an alternative alcohol protecting 
group was recognized. However, the carbamate protection for the secondary amine was 
compatible with the reaction conditions. 
To overcome the problem of cyclization, acid 153 was replaced with acid 160,149 
which carries an olefinic bond, instead of the silyl ether, and which can be converted to 
the desired alcohol functionality whenever needed (Scheme 40). Acid 160 was prepared 





(158)150 with cinnamyl bromide, followed by lithium peroxide-mediated hydrolysis. The so-
obtained acid 160 was then used for acylation of N,N-dialkylhydroxylamine 151 to isolate 
N-acyloxyamine 161. Upon reduction with DIBAL at a low temperature, followed by the 
treatment with acetic anhydride, pyridine, and DMAP, 161 was transformed to O-(α-
acyloxyalkyl) hydroxylamine 162. The subsequent subjection of 162 to a Lewis acid 
promoted deacetoxylation, followed by the treatment with dimethylzinc, gave only the 
desired product 163 in 62% yield as a 4:3 diastereomeric ratio, proving the compatibility 
of the olefinic double bond to the reaction conditions. However, the poor selectivity, 
coupled with difficulties in separation and characterization for each diastereomer, 
necessitated an alternative route for the hydroxalog 109.  
 





In a view of the difficulty in installing the hydroxylamine moiety stereoselectively, 
an alternative retrosynthesis (Scheme 41) was proposed for hydroxalog 109. The 
strategy for the thiazoline ring construction remained the same as depicted in the previous 
synthetic plan. Nevertheless, disconnection of acid 164 was proposed such that it could 
be obtained from N,O-disubstituted hydroxylamine 165 and aldehyde 166, exploiting a 
classical reductive amination-like reaction.  The enantiomerically pure acid 132 was 
chosen as a precursor to aldehyde 166. The synthesis of hydroxylamine 165 was planned 
to begin from a literature compound 167,151 wherein the two methyl groups in 1,2-anti-
fashion will be incorporated directly from 167, and the hydroxylamine moiety will be 
introduced by amination of terminal benzylated hydroxyl group after hydrogenolysis.  
 





To start the synthesis, literature compound 167 was synthesized on a gram scale 
in 8 steps following the literature protocol151 from (+)-L-arabinose in 33% overall yield 
(Scheme 42). Conversion of 167 to imidazolyl thioether 169 was achieved in excellent 
yield by stirring with thiocarbonyldiimidazole (TCDI) at 50 oC. Upon subjection to Barton’s 
radical deoxygenation, followed by hydrogenolysis, thioether 169 was converted to 
alcohol 170.  
 
Scheme 42. Synthesis of alcohol 170. 
In order to introduce the hydroxylamine moiety to alcohol 170, direct amination of 
the hydroxyl functionality was conceived. However, methods for hydroxylamine synthesis 
via the construction of the N-O bond are extremely rare in the current toolbox due to 
several unsolved challenges as described in Chapter 1. Although not common, the Boger 
lab was successful in forming an N-O bond during the syntheses of the prodrugs of 
duocarmycin via amination of aryl alcohol with carbamate tosylates and N-






Scheme 43. Examples of amination of aryl alcohols from the Boger lab.   
Before attempting amination on 170, the feasibility of the reaction was studied on 
1-phenyl-2-propanol as a model (Scheme 44). A series of aminating reagents, NH2Cl, 
H2N-OTs, CbzHN-OTs, and PhthN-OTs, were synthesized153-155 and were tested for the 
substitution reactions with 1-phenyl-2-propanol in basic media. Unfortunately, all attempts 
at amination of this alcohol were unsuccessful. 
 
Scheme 44. Test reactions for the amination of alcohol. 
As the direct N-O bond formation was unsuccessful in a model substrate, the 
hydroxylamine functionality was installed by utilizing the Mitsunobu reaction, a classical 
approach for hydroxylamine synthesis (Scheme 45). First, the configuration of the alcohol 
was inverted by a Mitsunobu reaction with nitrobenzoic acid, followed by 
transesterification to access alcohol 172. A second Mitsunobu reaction with N-
hydroxyphthalimide resulted in hydroxylamine 173 with overall retention of the 






Scheme 45. Installation of the N-O bond by Mitsunobu reaction. 
Before moving forward with the hydroxylamine intermediate 173, aldehyde 166 
was synthesized from acid 132 in two steps (Scheme 46). Acid 132 was first coupled with 
N-allylmethylamine in the presence of HOBt and EDCI and the resulting amide 174  was 
then subjected to reductive ozonolysis to access crude aldehyde 166. 
 
Scheme 46. Synthesis of aldehyde 166. 
After the synthesis of aldehyde 166, the hydroxylamine intermediate 173 was 
extended to hydroxalog 109 (Scheme 47). Deprotection of the hydrazine functionality in 
173 with hydrazine hydrate, followed by the treatment with paraformaldehyde, delivered 
oxime 175 in an excellent overall yield over 2 steps.  Further reduction of this oxime was 
carried out by using sodium cyanoborohydride as a reductant in an acidic medium, and 
the resulting N,O-disubstituted hydroxylamine intermediate was subjected to reductive 





hydroxylamine 176. Compound 176 was then converted to acid 164 via a three-step 
reaction sequence of tetrabutylammonium fluoride (TBAF)-mediated deprotection of 1,2-
diol, oxidative cleavage to aldehyde, and Pinnick oxidation. Transformation of the so-
obtained acid 164 to amide 177 was accomplished by amidation with amino alcohol 112 
with the aid of EDCI and DMAP. The conversion of amide 177  to 2-oxazoline 178 was 
best achieved by diethylaminosulfur trifluoride (DAST)-mediated cyclization at -78 oC. 
Finally, Wipf’s oxazoline-thiazoline conversion sequence was utilized to convert oxazoline 
derivate 178 to hydroxalog 109, wherein the oxazoline ring was first opened to the 
thioamide by stirring with hydrogen sulfide-saturated methanolic triethylamine and then 
cyclized to the thiazoline ring in the presence of DAST at -78 oC.  The hydroxalog 109 
was isolated as a colorless oil and as a single stereoisomer. Like in kalkitoxin, a mixture 






Scheme 47. Synthesis of the hydroxalog 109 from the hydroxylamine intermediate 173. 
In summary, a total synthesis of the novel hydroxalog 109 of natural kalkitoxin was 
accomplished in 25 linear steps, starting from a commercially available (+)-L-arabinose in 
3% overall yield. The hydroxylamine moiety in the molecule was installed by utilizing the 
Mitsunobu reaction, and reductive amination was applied to generate the tri-substituted 
hydroxylamine intermediate 176 from its N,O-disubstituted precursor. The thiazoline ring 





strategy from oxazoline derivative 178, which itself was synthesized via DAST-mediated 
cyclization of amido alcohol intermediate 177. 
4.4.  Synthesis of 7,8-diazakalkitoxin (110) 
 
Figure 35. Structure of kalkitoxin and its hydrazine analog. 
The retrosynthetic analysis for the hydrazine analog 110 is presented in Scheme 
48. The synthesis of analog 110 was proposed from fragments 180, 181, and 132. A 
Lewis acid-mediated cyclization was chosen to construct the thiazoline ring, by adapting 
protocol from White’s kalkitoxin synthesis.105 Compound 180, with a suitable protecting 
group for the thiol functionality, was designed to synthesized from L-cysteine. Reductive 
amination was planned to deliver tetra-substituted hydrazine core 181 from tri-substituted 
hydrazine 183 and known aldehyde 184,156 whereas 183 itself was proposed to generate 
from sym-dimethylhydrazine 185, and cinnamyl bromide 186 was chosen as an initial 






Scheme 48. Retrosynthetic analysis of 7,8-diazakalkitoxin (110). 
The synthesis of hydrazine analog 110 commenced with the synthesis of 
enantiomeric aldehyde 184156 as described in  Scheme 49. Alcohol 187157 was obtained 
from reduction of 159, a cinnamyl bromide-derived oxazoline derivative (Scheme 40), 
with LiBH4 as a reductant. Dess-Martin periodinane (DMP)-mediated oxidation of the 
resulting alcohol 187 gave the desired aldehyde 184.  
 
Scheme 49. Synthesis of an aldehyde 184. 
 The tri-substituted hydrazine 183, a product resulting from the controlled mono-
alkylation of sym-dimethylhydrazine 185 with benzyl bromoacetate,158 was subjected to  





Upjohn dihydroxylation159 of the resulting tetra-substituted hydrazine backbone 188, 
followed by the NaIO4-mediated oxidative cleavage, gave aldehyde 189 in 52% overall 
yield over two steps. Conversion of this aldehyde 189 to amine 190 was best achieved 
via a reductive amination reaction. After acylation of the secondary amine 190 with 
commercial acid 132 in the presence of HOBt and EDCI, amide 191 was furnished in 67% 
yield. 
 
Scheme 50. Synthesis of tetra-substituted hydrazine core 191. 
Before advancing to the next stage, synthesis of vicinal amino thiol 180 (Scheme 
48) with a suitable protecting group on the thiol functionality was necessary. Earlier, White 
and co-workers synthesized the benzyl thioether derivative of amino thiol 180 for the 





benzyl thioether deprotection were predicted to be impractical in the presence of the 
hydrazine moiety. Therefore, a protecting group with a comparatively milder deprotection 
conditions was required. The replacement of the benzyl thioether with the 
trimethoxybenzyl (Tmob) thioether protecting group was considered, as milder reaction 
conditions (e.g., stirring with a mixture of trifluoroacetic acid and triethylsilane) can be 
applied for deprotection of such functionality.160 Therefore, amino trimethoxybenzyl 
thioether 196 was synthesized (Scheme 51) starting from L-cysteine by slight 
modifications of the protocol of benzyl analog synthesis reported by White and co-
workers.105  
 
Scheme 51. Synthesis of amino trimethoxybenzyl thioether 196. 
The thiol group of L-cysteine was masked as the trimethoxybenzyl thioether and 
was isolated as its trifluoroacetate salt 192.160 The amino group was protected as the tert-
butylcarbamate, and the acid functionality was converted to a Weinreb amide. The 





195 via a Wittig reaction. Subsequent deprotection of the amine functionality with 
trifluoroacetic acid offered amine 196. 
After unmasking the acid functionality of amide 191 by hydrogenolysis (Scheme 
52), it was coupled with amine 196 in the presence of hexafluorophosphate 
azabenzotriazole tetramethyl uranium (HATU) to afford intermediate 197. Unmasking of 
the thiol functionality was best achieved by stirring with trifluoroacetic acid in the presence 
of triethylsilane as a cation scavenger. The resulting amido thiol 198 was exposed to 
titanium tetrachloride to induce cyclization to obtain targeted analog 110, by adapting the 
protocol from White’s kalkitoxin synthesis.105 Unfortunately, no cyclization was detected 
and only precipitation was observed in the reaction mixture, leading to the conclusion that 
the hydrazine moiety of  the precursor complexed with the titanium salts. Several other 
reaction conditions (e.g., using TMSOTf as Lewis acid or adding Tf2O in basic condition) 
were tested, however, no thiazoline ring formation was observed under these conditions. 
 





The failure of the Lewis acid-mediated cyclization to thiazoline ring necessitated 
an alternative route. Wipf's oxazoline-thiazoline conversion reaction sequence,104 which 
was previously applied in the synthesis of the hydroxalog and a kalkitoxin itself, was 
chosen as a promising path to deliver the target. However, before using this approach in 
the target molecule, it was considered prudent to test it in a model substrate with similar 
functionalities. Therefore, compound 201 (Scheme 53) was synthesized as a model from 
the tri-substituted hydrazine 78 (Chapter 2, Scheme 25) in a three-step reaction 
sequence; i) substitution reaction of 78 with benzyl bromoacetate to provide tetra-
substituted hydrazine 199, ii) saponification of ester 199 to afford acid 200, and iii) 
amidation of acid 200 to obtain amino alcohol 201.   
 





With substrate 201 in hand, Wipf’s oxazoline-thiazoline conversion reaction 
sequence was tested. On treatment of amide 201 with DAST at -78 oC, cyclization was 
completed within 5 minutes, but, the cyclized product 202 was isolated in only 32% yield, 
together with the recovery of 40% of starting material 201 after purification. After careful 
observation, derivative 202 was found to be unstable due to facile reversion to its 
precursor alcohol 201. When product 202 was stirred with hydrogen sulfide saturated 
methanolic triethylamine without purification, thioamide 203 was isolated in 66% overall 
yield in two steps, together with traces of alcohol 201. Upon subsequent DAST-mediated 
cyclization reaction, thiazoline derivative 204 was isolated in 77% yield. The thiazoline 
moiety in 204 was found to be more stable than that of the oxazoline moiety in 202, since 
ring-opening was not observed during the synthesis. The observed facile ring opening 
process of the oxazoline derivative can be viewed as the manifestation of the electron 
withdrawing effect of the hydrazine moiety, which is responsible for high electrophilicity 
of the sp2 carbon of oxazoline ring. The stability of the thiazoline derivative compared to 
the oxazoline derivative is attributable to the difference in electronegativity of sulfur and 
oxygen atom in the ring. 
After a successful cyclization sequence on the model substrate, the reaction 
conditions were employed for the synthesis of hydrazine analog 110 (Scheme 54). Amido 
alcohol 206 was obtained in 70% yield from the intermediate 191 by hydrogenolysis, 
followed by coupling the intermediate acid with amine 112. In DAST-mediated cyclization, 
oxazoline derivative 207 was isolated in 30% yield, together with the recovery of 35% 
yield of starting material 206, since the ring opening phenomenon similar to 202 was 





52% isolated overall yield over 2 steps. Eventually, the targeted hydrazine analog 110 
was isolated in 89% yield from the thioamide 208 upon treatment with DAST. Here the 
thiazoline derivative 110 was also more stable than of its oxazoline counterpart 207. The 
hydrazine analog 110 was isolated as a colorless oil and as a single stereoisomer. Like 
in kalkitoxin, a mixture of rotamers was observed in the NMR spectra of 110 due to the 
amide functionality. 
 
Scheme 54. Synthesis of hydrazine analog 110 of kalkitoxin. 
To summarize, the hydrazine analog 110 was synthesized in 11 linear steps 
starting from commercially available sym-dimethylhydrazine in 4% overall yield. As 





simplified the synthesis by reducing the number of steps from 21 to 11. A classical SN2 
substitution reaction was utilized to convert a di-substituted hydrazine to a tri-substituted 
hydrazine (185 to 183), and reductive amination delivered a tetra-substituted hydrazine 
backbone 188. Wipf’s oxazoline-thiazoline ring conversion strategy was used to construct 
thiazoline ring. The oxazoline ring was found to be labile to ring opening due to the 
perceived electron withdrawing effect of the hydrazine moiety, whereas, the thiazoline 
ring was found to be relatively stable. 
4.5.  Biological assessments 
After completing the syntheses of kalkitoxin (107) and its hydroxylamine and 
hydrazine analogs (109 and 110), they were submitted for cytotoxicity assays against 
various cell lines in the Valeriote laboratory at Henry Ford Hospital in Detroit. The 
oxazoline analogs (137, 178, 207) were also submitted to study the importance of the 
thiazoline ring on the biological activity. All compounds were subjected to in vitro disk 
diffusion assay to quantify differential cell killing against the eleven human cell lines; one 
leukemia (CCRF-CEM), one normal (CFU-GM), and nine solid tumors. The human solid 
tumor cell lines were Lung (H125), Ovarian-(OVCAR-5), pancreatic (PANC-1), Liver 
(HepG2), Brain (U251N), prostate (LNCaP), colon (H-116), and breast (MCF-7 and MDA).  
The in vitro disk diffusion assay was designed to identify the solid tumor selective 
compounds by collaborative effort of the Valeriote laboratory at Henry Ford Hospital in 
Detroit and the Crews laboratory at the University of California in Santa Cruz.161 Human 
lymphocytic leukemia cells, CCRF-CEM, were used as a reference tumor for the assay. 
The second reference cell line chosen was a normal cell (CFU-GM). However, before 





murine colon cancer cell (Colon38) in relation to murine leukemia (L1210) and murine 
normal cell (CFU-GM) were conducted. These murine cell lines were selected as they 
closely resemble human cell lines. There are four positive results from these assays; i) a 
compound is selective to the murine solid tumor over leukemia, ii) a compound is selective 
to the murine solid tumor over normal cells, iii) a compound is selective to the human solid 
tumor over leukemia, and iv) a compound is selective to the human solid tumor over 
normal cells. This unique and effective zone assay guides the discovery of novel 
molecular structures with solid tumor selective anticancer properties. 
In in vitro disk diffusion assay, samples were solubilized in 0.5 mL DMSO; 15 L of 
each sample was applied to a 6.5 mm filter disk, which was allowed to dry overnight and 
then placed close to the edge of the petri dish. Depending upon the cell type, the plates 
were incubated for 7-10 days and the zones of inhibition were examined by measuring 
from the edge of the filter disk to the beginning of normal-sized colony formation. The 
diameter of the filter disk was arbitrarily taken as 200 units. A sample is selective if the 
zone difference between solid tumor cells and either normal or leukemia cell is greater 
than 250 units and is expressed as, for example, H-125CEM = 400, which indicates that 
there is a 400 unit zone differential between human colon H-125 and leukemia CCRF-
CEM. If the compound is excessively toxic at the first dosage, the sample solution was 
diluted (at 1:4 decrements) and retested against the same tumors. At some dilution, 
quantifiable cytotoxicity was invariably obtained. 
As the assay is under progress in the Valeriote lab, complete data are not available 
currently. Table 7 presents the available data from in vitro disk diffusion assay. Since the 





cells (normal cells and leukemia) are not available currently, the quantifications of 
selectivity of these compounds are not possible. However, kalkitoxin was found to be 
highly cytotoxic against most of the cancer cell lines as expected. The toxicity of the 
kalkitoxin decreased slightly when the thiazoline ring was changed to oxazoline. 
Interestingly, the 9-oxa-10-azakalkitoxin (109) was found equally cytotoxic as parent 
kalkitoxin. The potency of its oxazoline analog (178) was reduced against most of the cell 
line except against hepato carcinoma cell (HepG2). 
In contrast, cytotoxicity of hydrazine analogs 110 and 207 were found to be 
comparatively poor against all cancer cell lines except murine colon tumor cell line (colon 
38), against which the potencies were average. The observed weak cytotoxicity of these 
analogs could be attributable to their less stable thiazoline or oxazoline rings. As the zone 
inhibition data for hydrazine analogs 110 and 207 against reference cells except human 
normal cells are available, quantifications of their selectivity are possible. Both the 
hydrazine analogs 110 and 207 show differential cytotoxicity for murine colon 38 versus 
normal cell (38CFU = 550 for 110 and 350 for 207). In addition to murine colon 38, 
hydrazine analog 110 also shows differential cytotoxicity for murine colon 38 versus 
leukemia (38L1210 = 450) and for human brain tumor cell (U251N) versus leukemia 
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IC50 values were determined for kalkitoxin 107, hydroxylamine analog 109, and 
oxazoline analogs 137 and 178 against liver cancer cell line (HepG2) and the results are 
presented in Table 8. Comparison of data indicates that 9-oxa-10-azakalkitoxin 109 and 
kalkitoxin are equally potent, which proves the concept of hydroxylamines as convertible 
mimics of stereogenic centers. Analog 137 is 50 fold less potent than kalkitoxin and 
analog 178 is 500 fold less potent than  9-oxa-10-azakalkitoxin 109. These data together 
with the zone inhibition data demonstrate that the thiazoline moiety of the kalkitoxin and 
9-oxa-10-azakalkitoxin are needed for the potency of the compounds.  
Table 8. IC50 values for kalkitoxin and its analogs against human liver cancer cell line 
(HepG2). 
Compound HepG2 (IC50, ng.mL-1) 
107 3.2 
137 1.6 x 102 
109 2.4 
178 1.5 x 103 
 
4.6.  Conclusion  
Kalkitoxin was chosen as a candidate to test the idea of hydroxylamine and 
hydrazine analogs. Analogs 108 and 109 were designed as hydroxylamine analogs and 
analog 110 was designed as a hydrazine analog. As a model 2-aminoxy thiazoline with 
similar functionality like in hydroxalog 108 was found unstable, further work on this analog 
was discontinued. Hydroxalog 109 was synthesized from (+)-L-arabinose, in which the 
hydroxylamine moiety was introduced by Mitsunobu reaction, and tri-substituted 





condition in di-substituted hydroxylamine. Hydrazine analog 110 was synthesized from 
sym-dimethylhydrazine, and here too reductive amination condition was best applied to 
construct tetra-substituted backbone. Wipf’s oxazoline-thiazoline interconversion strategy 
was found to be efficient for the thiazoline ring formation for both the analogs, 109 and 
110. For the comparative study of the biological activities, kalkitoxin was synthesized by 
partially following previously reported syntheses. The stretched-peptide chain of 
kalkitoxin was best achieved by following White’s synthesis whereas, the thiazoline ring 
was constructed adapting Gerwick’s synthesis.  
Currently, anti-cancer assays of kalkitoxin and its analogs including oxazoline 
derivatives are under progress in the Valeriote laboratory at Henry Ford Hospital in 
Detroit. The hydroxalog 9-oxa-10-azakalkitoxin (IC50 = 2.4 nm) was found to be as active 
as kalktoxin (IC50 = 3.2 nm) against the liver cancer cell line, providing the evidence for 
the hydroxylamine analog concept. However, when the thiazoline ring of both kalkitoxin 
and hydroxalog were replaced with the oxazoline ring, a remarkable decrease in activity 













CHAPTER 5. CONCLUSION 
An efficient method for the synthesis of tri-substituted hydroxylamines was 
developed, adapting Rychnovsky’s reductive etherification protocol. In this method N,N-
dialkylhydroxylamines were first acylated to O-acylhydroxylamines, which were then 
reduced with DIBAL and the intermediate hemiacetals were trapped in situ with acetic 
anhydride as O-(α-acyloxyalkyl)hydroxylamines. In a subsequent Lewis acid-mediated 
deacetoxylation reaction, the O-(α-acyloxyalkyl)hydroxylamine was converted to several 
novel tri-substituted hydroxylamines by conducting the reaction in the presence of 
triethylsilane as a nucleophile. Various highly substituted tri-substituted hydroxylamine 
derivatives, with branching to the oxygen substituent, were also isolated when the 
triethylsilane was replaced with carbon nucleophiles. 
In order to understand the relative energetics and contributions of N-inversion, N-
O bond rotation, and ring inversion on the stereomutation process, variable temperature 
(VT) NMR studies were conducted on several 4-substituted N-hydroxypiperidines, N-
alkoxypiperidines, and N-alkoxypyrrolidines. As the VT-NMR phenomena were found to 
be strongly dependent on the substituents at the 4-position, the ring flip process was 
concluded to be the rate determining step in the stereomutation process of such N-
alkoxypiperidine systems. 
Kalkitoxin, an anti-cancer agent, was chosen to test the concept of hydrazine and 
hydroxylamine analogs. Hydroxylamine analog 9-oxa-10-azakalkitoxin and hydrazine 
analog 7,8-diazakalkitoxin were designed by replacing one stereogenic center (C10) and 
two stereogenic centers (C7 and C8) of kalkitoxin, respectively with nitrogen. Syntheses 





milligrams. Currently, the anti-cancer assays of all these compounds are under progress 
in the Valeriote laboratory at the Henry Ford Hospital in Detroit. From the available IC50 
values against hepato-carcinoma cells (HepG2), hydroxalog 9-oxa-10-azakalkitoxin 
retains bioactivity comparable to kalkitoxin, supporting the concept of hydroxylamines as 























CHAPTER 6. EXPERIMENTAL SECTION 
All reactions were conducted in oven dried glasswares under an argon 
atmosphere. All commercial solvents and reagents were used as purchased without 
further purification unless otherwise specified. All purifications were performed in flash 
column chromatography on silica gel (230-400 mesh) or neutral alumina (32-63 μm) as 
stationary phase unless otherwise noted. Reactions were analyzed by thin layer 
chromatography technique using pre-coated glass backed plates (w/UV 254), whcih were 
visualized by UV irradiation (254 nm) or by charring in cerium-ammonium-molybdate 
(CAM) or ninhydrin solution. 400 MHz, 500 MHz, or 600 MHz instruments were used to 
record 1H and 13C NMR spectra of all compounds. High-resolution mass spectra were 
recorded under electrospray conditions with a time of flight (TOF) mass analyzer. Melting 
points of compounds were determined by using electrothermal melting point apparatus 
whenever needed.  
Experimental section for chapter 2 
General procedure (A) for O-benzoyl hydroxylamines synthesis. 
O-Benzoyl hydroxylamines were synthesized by adapting Ganem protocol.112 To 
a stirred suspension of K2HPO4 (1.5 mmol), benzoyl peroxide (50% w/w blended with 
dicyclohexyl phthalate, 1.1 mmol), and dry DMF (2.5 mL) was added secondary amine (1 
mmol) at room temperature. The stirring was continued until the completion of the 
reaction, and water (10 mL) was added followed by stirring vigorously for 1 h. The reaction 
mixture was extracted with EtOAc, and the resulting EtOAc extract was washed with 





concentration. The so-obtained crude was purified by flash column chromatography on 
silica gel to give the desired O- benzoyl hydroxylamine.  
O-Benzoyl-N,N-dibenzylhydroxylamine (62a). 
Following the general procedure A, N,N-dibenzylamine (0.5 mL, 2.60 mmol) was 
converted to compound 62a162 (0.67 g, 81%) after stirring for 10 h, which was isolated as 
a white solid (eluent: 0 – 5%  of acetone in hexane). M.p. 97 – 98 oC; lit162 m.p. 96 – 98 
oC; 1H NMR (400 MHz, CDCl3) δ 7.86 – 7.80 (m, 2H), 7.50 (t, J = 7.3 Hz, 1H), 7.46 – 7.44 
(m, 4H), 7.39 – 7.22 (m, 8H), 4.21 (s, 4H); 13C NMR (100 MHz, CDCl3) δ 164.9, 135.9, 
132.8, 129.4, 129.3, 128.3, 128.3, 127.6, 62.1. 
O-Benzoyl-N-benzyl-N-methylhydroxylamine (62b). 
Following the general procedure A, N-benzyl-N-methylamine (0.5 mL, 3.88 mmol) 
was converted to compound 62b (0.77 g, 82%) after stirring for 10 h, which was isolated 
as a colorless oil (eluent: 0 – 5%  of EtOAc in toluene). 1H NMR (400 MHz, CDCl3) δ 7.93 
– 7.88 (m, 2H), 7.52 (t, J = 7.3 Hz, 1H), 7.45 – 7.36 (m, 4H), 7.34 – 7.22 (m, 3H), 4.16 (s, 
2H), 2.93 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 164.9, 135.6, 132.9, 129.4, 129.3, 128.4, 
128.3, 127.7, 65.1, 46.1; ESIHRMS calculated for C15H15NO2Na [M+Na]+, 264.1000; 
found, 264.1006. 
1-Piperidinyloxy benzoate (62c). 
Following the general procedure A, piperidine (1.0 mL, 10.12 mmol) was converted 
to compound 62c162 (1.80 g, 86%) after stirring for 1.5 h, which was isolated as a white 
solid (eluent: 0 – 5%  of EtOAc in toluene). M.p. 58 – 60 oC; lit162 m.p. 55 – 59 oC; 1H NMR 





3.48 (br s, 2H), 2.76 (d, J = 5.9 Hz, 2H), 1.86 – 1.76 (m, 4H), 1.64 (br s, 1H), 1.36 – 1.18 
(m, 1H); 13C NMR (100 MHz, CDCl3) δ 164.7, 132.9, 129.6, 129.4, 128.3, 57.5, 25.0, 23.3. 
4-Methylpiperidin-1-yl benzoate (62d). 
Following the general procedure A, 4-methylpiperidine (2.5 mL, 20.57 mmol) was 
converted to compound 62d163 (3.71 g, 82%) after stirring for 1 h. It was isolate as a white 
solid (eluent: 0 – 10%  of EtOAc in toluene). M.p. 91 –  92 oC; 1H NMR (400 MHz, CDCl3) 
δ 7.99 (d, J = 7.3 Hz, 2H), 7.53 (t, J = 7.3 Hz, 1H), 7.41 (t, J = 7.6 Hz, 2H), 3.51 (d, J = 
8.8 Hz, 2H), 2.72 (t, J = 10.5 Hz, 2H), 1.75 (d, J = 13.2 Hz, 2H), 1.65 – 1.52 (m, 2H), 1.52 
– 1.40 (m, 1H), 0.93 (d, J = 5.9 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 164.8, 132.9, 
129.6, 129.4, 128.3, 57.2, 33.5, 30.1, 21.2. 
4-Chloropiperidin-1-oxyl Benzoate (62e). 
Following the general procedure A, 4-chloropiperidine (1.79 g, 15.0 mmol) was 
converted to compound 62e (2.92 g, 81%) after stirring for 1.5 h. It was isolated as a white 
solid (eluent: 0 – 10% of EtOAc in toluene). M.p. 63 – 65 oC; IR (neat, cm-1) √ 1738; 1H 
NMR (400 MHz, CDCl3) δ 8.00 (d, J = 6.6 Hz, 2H), 7.55 (t, J = 7.4 Hz, 1H), 7.43 (t, J = 
7.7 Hz, 2H), 4.35 (br s, 0.6H), 4.07 (br s, 0.4H), 3.58 (br s, 0.8H), 3.34 (s, 2.4H), 2.97 (br 
s, 0.8H), 2.37 – 2.24 (m, 2H), 2.20 – 2.02 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 164.6, 
133.1, 129.4, 129.2, 128.4, 55.1, 54.4, 52.8, 51.7, 33.0; ESIHRMS calculated for 
C12H14NO2ClNa [M+Na]+, 262.0611; found, 262.0613. 
General procedure (B) for the synthesis of N,N-disubstituted hydroxylamines  
To an ice-cold (<5 oC) solution of O-benzoyl hydroxylamine (1 mmol) in dry 
dichloromethane (6 mL) was added DIBAL (1 M solution in hexane, 2.5 mmol) carefully. 





by adding saturated aq. NH4Cl (10 mL) and saturated aq. sodium potassium tartrate (8 
mL). The mixture was stirred vigorously at room temperature for 1 h and was extracted 
with dichloromethane. The resulting organic extract was washed with brine, dried over 
anhydrous Na2SO4, and concentrated. Purification was performed by flash column 
chromatography on silica gel to deliver the desired hydroxylamine. 
N,N-Dibenzylhydroxylamine (63a). 
The title compound 63a164 (60 mg, 90%) was obtained from compound 62a (100 
mg, 0.32 mmol) following the general procedure B. It was  isolated as a white solid (eluent: 
5 – 15%  of EtOAc in hexane). M.p. 119 – 121 oC; lit164 m.p. 118 – 119 oC;  1H NMR (400 
MHz, CDCl3) δ 7.37 – 7.24 (m, 10H), 6.90 (br s, 1H), 3.69 (s, 4H); 13C NMR (100 MHz, 
CDCl3) δ 137.1, 129.8, 128.3, 127.5, 63.7. 
N-Benzyl-N-methylhydroxylamine (63b). 
The title compound 63b16 (265 mg, 93%) was obtained from compound 62b (500 
mg, 2.07 mmol) following the general procedure B.  It was isolated as a colorless oil 
(eluent :10 – 30%  of EtOAc in hexane). 1H NMR (400 MHz, CDCl3) δ 7.36 – 7.24 (m, 
5H), 3.70 (s, 2H), 2.51 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 136.9, 129.9, 128.3, 127.5, 
66.4, 47.5. 
Piperidin-1-ol (63c). 
The title compound 63c165 (313 mg, 63%) was obtained from  compound 62c (1 g, 
4.87 mmol) following the general procedure B. It was isolated as a colorless oil (eluent: 
ether). 1H NMR (400 MHz, CDCl3) δ 8.09 (br s, 1H), 3.22 (d, J = 9.8 Hz, 2H), 2.41 (t, J = 
11.0 Hz, 2H), 1.70 (d, J = 13.2 Hz, 2H), 1.60 – 1.42 (m, 3H), 1.18 – 1.02 (m, 1H); 13C 






The title compound 63d166 (443 mg, 84%) was obtained from compound 62d (1 g, 
4.56 mmol) following the general procedure B. It was isolated as a colorless oil (eluent: 
ether). The NMR data suggest a mixture of two stereo-isomers in 8.4:1 ratio. Major 
isomer; 1H NMR (400 MHz, CDCl3) δ 8.60 (br s, 1H) 3.22 (d, J = 10.8 Hz, 2H), 2.44 (t, J 
= 11.7 Hz, 2H), 1.71 – 1.62 (m, 2H), 1.42 – 1.30  (m, 1H), 1.30 – 1.17 (m, 2H), 0.86 (d, J 
= 6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 58.7, 34.0, 29.8, 21.3. The minor isomer was 
identified by 1H NMR (400 MHz, CDCl3) δ 3.00 – 2.83 (m, 4H), 1.61 –  1.46 (m, 4H), 0.94 
(d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 54.6, 29.4, 20.0. 
4-Chloropiperidin-1-ol (63e). 
The title compound 63e (1.29 g, 85%) was obtained from compound 62e (2.68 g, 
11.2 mmol) following the general procedure B. It was isolated as a mixture of two 
stereoisomers (63e-1 and 63e-2) in 1:1 ratio in the form of a white solid (eluent: diethyl 
ether). M.p. 97 – 99 oC; NMR of isomer 63e-1: 1H NMR (400 MHz, CDCl3) δ 8.07 (br s, 
1H), 3.91 (s, 1H), 3.32 – 3.22 (m, 2H), 2.62 (t, J = 10.7 Hz, 2H), 2.24 (d, J = 12.8 Hz, 2H), 
1.93 – 1.80 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 56.5, 55.5, 34.4; NMR of isomer 63e-
2: 1H NMR (400 MHz, CDCl3) δ 8.07 (br s, 1H), 4.26 (s, 1H), 3.09 – 2.98 (m, 4H), 2.11 – 
1.97 (m, 4H); 13C NMR (100 MHz, CDCl3) δ 54.9, 53.0, 33.0; ESIHRMS calculated for 
C5H11NOCl [M+H]+, 136.0529; found, 136.0534. 
3-(1-Pyrrolidinyl)propanenitrile (64). 
To a stirred solution of acrylonitrile (4.0 mL, 60.88 mmol) and Amberlyst-15 (1 g, 
30% w/w) was added pyrrolidine (4.0 mL, 48.70 mmol) in an ice-bath. The ice-bath was 





dichloromethane and filtered, and the filtrate was concentrated to yield 64167 (5.57 g, 92%) 
as a light yellow oil. 1H NMR (400 MHz, CDCl3) δ 2.71 (t, J = 7.2 Hz, 2H), 2.53 – 2.44 (m, 
6H), 1.79 – 1.68 (m, 4H); 13C NMR (100 MHz, CDCl3) δ 118.9, 53.8, 51.2, 23.5, 17.6. 
1-Pyrrolidinyloxy 4-phenylbutanoate (62f). 
To a chilled solution of 64 (0.50 g, 4.03 mmol) in dry CH2Cl2 (40 mL) was added 
m-CPBA (0.95 g 77% m-CPBA, 6.05 mmol) and K2CO3 (1.11 g, 8.06 mmol) at –78 oC. 
After stirring for 3 h at –78 oC, the mixture was warmed slowly to ambient temperature, 
stirred for an additional 12 h, and filtered. 4-phenylbutyric acid (0.99 g, 6.05 mmol), DMAP 
(0.10 g, 0.81 mmol), and  N,N'-dicyclohexylcarbodiimide (1.25 g, 6.05 mmol) were added 
to the resulting filtrate. The resultant mixture was stirred for the next 2 h at room 
temperature, filtered through a pad of Celite®, and was washed with saturated aq. 
NaHCO3, brine, dried over anhydrous Na2SO4. The resultant solution was concentrated 
and purified by flash column chromatography on silica gel (10 – 30% of EtOAc in hexane) 
to afford 62f (0.49 g, 52%) as a light red oil. 1H NMR (400 MHz, CDCl3) δ 7.31 – 7.23  (m, 
2H), 7.22 – 7.13 (m, 3H), 3.14 (s, 4H), 2.64 (t, J = 7.5 Hz, 2H), 2.25 (t, J = 7.5 Hz, 2H), 
2.00 – 1.90 (m, 2H), 1.85 (s, 4H); 13C NMR (100 MHz, CDCl3) δ 172.0, 141.2, 128.5, 
128.4, 128.3, 126.0, 57.4, 35.1, 32.4, 26.6, 22.0; ESIHRMS calculated for C14H19NO2Na 
[M+Na]+, 256.1313; found, 256.1319. 
General procedure (C) for the synthesis of O-acyl hydroxylamines 
A solution of N,N'-dicyclohexylcarbodiimide (1.25 – 2.5 mmol) in dry 
dichloromethane (1 mL) was added to a mixture of carboxylic acid (1.25 – 2.5 mmol), 
N,N-disubstituted hydroxylamine (1 mmol), DMAP (0.2 mmol), and dry dichloromethane 





reaction, and the reaction mixture was filtered through a pad of Celite®. The resultant 
filtrate was washed with saturated aq. NaHCO3 and brine, dried over anhydrous Na2SO4, 
and concentrated. After purification by flash column chromatography on silica gel, the 
desired O-acyl hydroxylamine was obtained.  
N,N-Dibenzyl-O-(4-phenylbutanoyl)hydroxylamine (62g). 
Following the general procedure C, the title compound 62g was isolated (1.67 g, 
98%) as a colorless oil by stirring 63a (1 g, 4.69 mmol), N,N'-dicyclohexylcarbodiimide 
(1.22 g, 5.86 mmol), and 4-phenylbutyric acid (0.96 g, 5.86 mmol) for 40 mins. Eluent: 0 
– 5%  of EtOAc in hexane. 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.41 (m, 4H), 7.34 – 7.23  
(m, 8H), 7.19 – 7.16 (m, 1H), 7.02  (d, J = 6.9 Hz, 2H), 4.07 (s, 4H), 2.37 (t, J = 7.6 Hz, 
2H), 2.06 (t, J = 7.3 Hz, 2H), 1.75 – 1.62 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 171.8, 
141.3, 136.1, 129.4, 128.4, 128.3, 128.3, 127.7, 125.8, 62.5, 34.7, 31.9, 26.2; ESIHRMS 
calculated for C24H25NO2Na [M+Na]+, 382.1783; found, 382.1779. 
O-(1-Adamantanecarbonyl)-N,N-dibenzylhydroxylamine (62h). 
Following the general procedure C, the title compound 62h was isolated (1.27 g, 
72%) as a white solid by stirring 63a (1 g, 4.69 mmol), N,N'-dicyclohexylcarbodiimide 
(1.94 g, 9.38 mmol), and 1-adamantanecarboxylic acid (1.69 g, 9.38 mmol) for 28 h. 
Eluent: 0 – 5%  of EtOAc in hexane. M.p. 110 – 111 o C; 1H NMR (400 MHz, CDCl3) δ 
7.40 (d, J = 7.3 Hz, 4H), 7.34 – 7.23 (m, 6H), 4.05 (s, 4H), 1.89 (s, 3H), 1.69 – 1.53 (m, 
12H); 13C NMR (100 MHz, CDCl3) δ 175.2, 136.1, 129.4, 128.1, 127.5, 62.1, 40.4, 38.5, 








Following the general procedure C, the title compound 62i was isolated (0.91 g, 
63%)  as a white solid by stirring 63a (1 g, 4.69 mmol), 3,3-dimethylbutanoic acid (0.75 
mL, 5.86 mmol), and N,N'-dicyclohexylcarbodiimide (1.22 g, 5.86 mmol) for 1.5 h. Eluent: 
0 – 5%  of EtOAc in hexane). M.p. 53 – 54 oC; 1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 
6.9 Hz, 4H), 7.34 – 7.22 (m, 6H), 4.05 (s, 4H), 1.95 (s, 2H), 0.77 (s, 9H); 13C NMR (100 
MHz, CDCl3) δ 170.2, 136.3, 129.3, 128.3, 127.5, 62.2, 46.2, 30.5, 29.3; ESIHRMS 
calculated for C20H25NO2Na [M+Na]+, 334.1783; found, 334.1782. 
N-Benzyl-N-methyl-O-(5-phenylpentanoyl)hydroxylamine (62j). 
Following the general procedure C, the title compound 62j was isolated (396 mg, 
87%)  as a colorless oil by stirring 63b (210 mg, 1.53 mmol), 5-phenylvaleric acid (341 
mg, 1.91 mmol) and N,N'-dicyclohexylcarbodiimide (394 mg, 1.91 mmol) for 0.5 h. Eluent: 
5 – 20%  of EtOAc in hexane. 1H NMR (400 MHz, CDCl3) δ 7.38 – 7.33 (m, 2H), 7.33 – 
7.22 (m, 5H), 7.21 – 7.16 (m, 1H), 7.13 (d, J = 7.3 Hz, 2H), 3.99 (s, 2H), 2.81 (s, 3H), 2.54 
(t, J = 7.0 Hz, 2H), 2.17 (t, J = 7.0 Hz, 2H), 1.58 – 1.45 (m, 4H); 13C NMR (100 MHz, 
CDCl3) δ 171.8, 142.0, 135.9, 129.3, 128.4, 128.3, 128.3, 127.7, 125.8, 65.0, 46.2, 35.4, 
32.7, 30.6, 24.5; ESIHRMS calculated for C19H23NO2Na [M+Na]+, 320.1626; found, 
320.1625. 
1-Piperidinyloxy 4-phenylbutanoate (62k). 
Following the general procedure C, the title compound 62k was isolated (387 mg, 
93%) as a colorless oil by stirring 63c (170 mg, 1.68 mmol), 4-phenylbutyric acid (355 
mg, 2.10 mmol,) and N,N'-dicyclohexylcarbodiimide (433 mg, 2.10 mmol)  for 0.5 h. 





7.21 – 7.14 (m, 3H), 3.35 (br s, 2H), 2.70 – 2.51  (m, 4H), 2.28 (t, J = 7.3 Hz, 2H), 2.01 – 
1.90 (m, 2H), 1.82 – 1.69 (m, 4H), 1.61 (br s, 1H), 1.34 – 1.10 (m, 1H); 13C NMR (100 
MHz, CDCl3) δ 171.5, 141.3, 128.5, 128.4, 126.0, 57.4, 35.1, 32.4, 26.7, 25.0, 23.2; 
ESIHRMS calculated for C15H21NO2Na [M+Na]+, 270.1470; found, 270.1465. 
4-Methyl-1-piperidinyloxy 4-phenylbutanoate (62l). 
Following the general procedure C, the title compound 62l was isolated (740 mg, 
91%) as a colorless oil by stirring 63d (360 mg, 3.13 mmol), 4-phenylbutyric acid (642 
mg, 3.91 mmol), and N,N'-dicyclohexylcarbodiimide (807 mg, 3.91 mmol)  for 0.5 h. 
Eluent: 10 – 20%  of EtOAc in hexane. 1H NMR (400 MHz, CDCl3) δ 7.31 – 7.24 (m, 2H), 
7.21 – 7.14 (m, 3H), 3.36 (d, J = 8.8 Hz, 2H), 2.65 (t, J = 7.6 Hz, 2H), 2.57 (t, J = 10.5 Hz, 
2H), 2.27 (t, J = 7.6 Hz, 2H), 2.02 – 1.90 (m, 2H), 1.70 (d, J = 12.7 Hz, 2H), 1.57 – 1.34 
(m, 3H), 0.91 (d, J = 5.9 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.6, 141.3, 128.5, 
128.4, 126.0, 57.1, 35.1, 33.4, 32.4, 30.0, 26.7, 21.2; ESIHRMS calculated for 
C16H23NO2Na [M+Na]+, 284.1626; found, 284.1630. 
 
4-Chloro-1-piperidinyloxy 4-Phenylbutanoate (62m). 
Following the general procedure C, the title compound 62m was isolated (827 mg, 
80%) as a colorless oil by stirring 63e (500 mg, 3.69 mmol), N,N'-
dicyclohexylcarbodiimide (951 mg, 4.61 mmol), and 4-phenylbutanoic acid (757 mg, 4.61 
mmol) for 1 h. Eluent: 10 – 30% of EtOAc in hexane. IR (neat, cm-1) √ 1757; 1H NMR (400 
MHz, CDCl3) δ 7.32 – 7.25 (m, 2H), 7.23 – 7.14 (m, 3H), 4.30 (s, 0.6H), 3.97 (br s, 0.4H), 
3.42 (br s 0.8H), 3.18 (s, 2.4H), 2.77 (br s, 0.8H), 2.66 (t, J = 7.6 Hz, 2H), 2.35 – 2.18 (m, 





55.0, 51.5, 35.0, 32.9, 32.3, 26.6; ESIHRMS calculated for C15H20NO2ClNa [M+Na]+, 
304.1080; found, 304.1077. 
N,N-Dibenzyl-O-(2-(2-naphthalenyloxy)acetyl)hydroxylamine (62n). 
Following the general procedure C, the title compound 62n was isolated (1.67 g, 
89%) as a white solid by stirring 63a (1 g, 4.69 mmol), 2-(naphthalen-2-yloxy)acetic acid 
(1.19 g, 5.86 mmol), and N,N'-dicyclohexylcarbodiimide (1.22 g, 5.86 mmol) for 0.5 h. 
Eluent: 10 – 45%  of EtOAc in hexane. M.p. 87 – 89 oC; 1H NMR (400 MHz, CDCl3) δ 
7.76 (d, J = 7.8 Hz, 1H), 7.69 (d, J = 9.3 Hz, 1H), 7.60 (d, J = 8.3 Hz, 1H), 7.47 – 7.28 (m, 
12H), 6.99 (dd, J = 8.8, 2.5 Hz, 1H), 6.66 (d, J = 2.5 Hz, 1H), 4.44 (s, 2H), 4.13 (s, 4H); 
13C NMR (100 MHz, CDCl3) δ 168.4, 155.6, 135.5, 134.2, 129.6, 129.5, 129.3, 128.6, 
128.1, 127.6, 127.0, 126.3, 124.0, 118.2, 107.1, 64.6, 63.1; ESIHRMS calculated for 
C26H23NO3Na [M+Na]+, 420.1576; found, 420.1575. 
N,N-Dibenzyl-O-nicotinoylhydroxylamine (62o). 
Following the general procedure C, the title compound 62o was isolated (1.45 g, 
97%) as a white solid by stirring 63a (1 g, 4.69 mmol), nicotinic acid (0.72 g, 5.86 mmol), 
and N,N'-dicyclohexylcarbodiimide (1.22 g, 5.86 mmol)  for 1 h. Eluent: 10 – 45%  of 
EtOAc in hexane. M.p. 117 – 118 oC; 1H NMR (400 MHz, CDCl3) δ 8.99 (d, J = 1.5 Hz, 
1H), 8.70 (dd, J = 4.9, 2.0 Hz, 1H), 8.05 (td, J = 7.9, 2.0 Hz, 1H), 7.44 (d, J = 6.7 Hz, 4H), 
7.34 – 7.22 (m, 7H), 4.22 (s, 4H); 13C NMR (100 MHz, CDCl3) δ 163.6, 153.3, 150.3, 
136.8, 135.7, 129.4, 128.4, 127.8, 125.3, 123.3, 62.4; ESIHRMS calculated for 







General procedure (D) for the synthesis of O-(α-acetoxy) hydroxylamines. 
A solution of O-acyl hydroxylamines (0.5 mmol) in dry dichloromethane (3 mL) was 
chilled at –78 oC. A 1 M DIBAL solution in hexane (0.63 – 1 mmol) was added dropwise 
followed by the sequential addition of pyridine (1.5 mmol), a solution of DMAP (1 mmol) 
in dry dichloromethane (1.5 mL), and Ac2O (3 mmol). After stirring for 12 h (overnight) at 
–78 oC, the reaction mixture was warmed slowly to 0 oC followed by addition of saturated 
aq. NH4Cl (5 mL) and saturated aq. sodium potassium tartrate (4 mL). The mixture was 
stirred vigorously at room temperature for 1 h and was extracted with dichloromethane. 
The organic extract was washed with brine and dried over anhydrous Na2SO4. The 
resultant solution was concentrated and purified by column chromatography on silica gel 
unless otherwise specified. 
4-Phenyl-1-(1-pyrrolidinyloxy)butyl acetate (65f). 
The title compound 65f (75 mg, 63%) was isolated as a colorless oil from 62f (100 
mg, 0.43 mmol) and DIBAL (0.64 mL, 1 M in hexane, 0.64 mmol) by following the general 
procedure D. Eluent: 10 – 20% of EtOAc in hexane. 1H NMR (400 MHz, CDCl3) δ 7.31 – 
7.24 (m, 2H), 7.21 – 7.14 (m, 3H), 6.13 – 6.08 (m, 1H), 3.00 (s, 4H), 2.67 – 2.59 (m, 2H), 
2.09 (s, 3H), 1.76 (s, 4H), 1.71 – 1.64 (m, 4H); 13C NMR (100 MHz, CDCl3) δ 170.4, 142.0, 
128.4, 128.3, 125.8, 100.2, 57.4, 35.5, 32.5, 26.1, 21.9, 21.5; ESIHRMS calculated for 
C16H23NO3Na [M+Na]+, 300.1576; found, 300.1582. 
O-(1-Acetoxy-4-phenylbutyl-N,N-dibenzylhydroxylamine (65g). 
The title compound 65g (102 mg, 88%) was isolated as a colorless oil from 62g 
(100 mg, 0.28 mmol) and DIBAL (0.56 mL, 1 M in hexane, 0.56 mmol) by following general 





7.21 (m, 12H), 7.19 – 7.16 (m, 1H), 7.07 (d, J = 7.3 Hz, 2H), 5.88 (t, J = 5.4 Hz, 1H), 4.01 
(br s, 2H), 3.78 (d, J = 12.7 Hz, 2H), 2.41 (t, J = 7.3 Hz, 2H), 1.85 (s, 3H), 1.51 – 1.22 (m, 
4H); 13C NMR (100 MHz, CDCl3) δ 170.2, 141.9, 137.1, 129.5, 128.4, 128.3, 128.2, 127.4, 
125.7, 100.4, 62.9, 35.3, 32.4, 25.4, 21.2; ESIHRMS calculated for C26H29NO3Na 
[M+Na]+, 426.2045; found, 426.2048. 
O-(1-Acetoxy-1-adamantanylmethyl)-N,N-dibenzylhydroxylamine (65h). 
The title compound 65h (217 mg, 65%) was isolated as a colorless oil from 62h 
(300 mg, 0.80 mmol) and DIBAL (1 mL, 1 M in hexane, 1 mmol) by following the general 
procedure D. Eluent: 0 – 8%  of EtOAc in hexane. 1H NMR (400 MHz, CDCl3) δ 7.36 – 
7.28 (m, 8H), 7.28 – 7.22 (m, 2H), 5.58 (s, 1H), 3.91 (d, J = 13.2 Hz, 2H), 3.82 (d, J = 
13.2 Hz, 2H), 1.89 (s, 3H), 1.82 (s, 3H), 1.65 (d, J = 11.7 Hz, 3H), 1.58 (d, J = 11.7 Hz, 
3H), 1.49 (d, J = 12.2 Hz, 3H), 1.33 (d, J = 12.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 
170.6, 137.2, 129.6, 128.1, 127.2, 103.1, 62.2, 37.0, 36.7, 36.5, 27.9, 21.1; ESIHRMS 
calculated for C27H33NO3Na [M+Na]+, 442.2358; found, 442.2367. 
O-(1-Acetoxy-3,3-dimethylbutyl)-N,N-dibenzylhydroxylamine (65i). 
The title compound 65i (85 mg, 75%) was isolated as a colorless oil from 62i (100 
mg, 0.32 mmol) and DIBAL (0.48 mL, 1 M in hexane, 0.48 mmol) by following the general 
procedure D. Eluent: 0 – 5% of EtOAc in hexane. 1H NMR (400 MHz, CDCl3) δ 7.39 – 
7.29 (m, 8H), 7.28 – 7.22 (m, 2H), 6.00 (t, J = 5.4 Hz, 1H), 4.00 (br s, 2H), 3.77 (d, J = 
13.2 Hz, 2H), 1.88 (s, 3H), 1.40 (dd, J = 14.2, 5.9 Hz, 1H),  1.34 (dd, J = 14.2, 4.9 Hz, 
1H), 0.68 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 170.1, 137.3, 129.4, 128.3, 127.3, 98.5, 







The title compound 65j (51 mg, 89%) was isolated as a colorless oil from 62j (50 
mg, 0.17 mmol) and DIBAL (0.30 mL, 1 M in hexane, 0.30 mmol) by following the general 
procedure D. Eluent: 5 – 10% of EtOAc in hexane. 1H NMR (400 MHz, CDCl3) δ 7.35 – 
7.23 (m, 7H), 7.20 – 7.11 (m, 3H), 5.91 (br s, 1H), 3.88 (br s, 1H), 3.76 (d, J = 12.7 Hz, 
1H), 2.64 (s, 3H), 2.53 (t, J = 7.6 Hz, 2H), 1.99 (s, 3H), 1.52 (s, 4H), 1.22 (br s, 2H); 13C 
NMR (100 MHz, CDCl3) δ 170.3, 142.4, 136.9, 129.6, 128.4, 128.2, 128.2, 127.4, 125.6, 
100.3, 65.4, 46.5, 35.7, 32.7, 31.0, 23.6, 21.3; ESIHRMS calculated for C21H27NO3Na 
[M+Na]+, 364.1889; found, 364.1885. 
4-Phenyl-1-(1-piperidinyloxy)butyl acetate (65k). 
The title compound 65k (64 mg, 55%) was isolated as a colorless oil from 62k (100 
mg, 0.40 mmol) and DIBAL (0.6 mL, 1 M in hexane, 0.60 mmol) by following the general 
procedure D. Flash column chromatography on neutral alumina (0 – 8% of EtOAc in 
hexane). 1H NMR (400 MHz, CDCl3) δ 7.31 – 7.25 (m, 2H), 7.21 – 7.15 (m, 3H), 6.07 (t, 
J = 4.6 Hz, 1H), 3.24 (br s, 2H), 2.63 (t, J = 6.9 Hz, 2H), 2.54 – 2.36 (m, 2H), 2.06 (s, 3H), 
1.79 – 1.62 (m, 6H), 1.55 (br s, 3H), 1.14 (br s, 1H); 13C NMR (100 MHz, CDCl3) δ 170.3, 
142.0, 128.4, 128.3, 125.8, 99.8, 58.2, 57.0, 35.5, 32.6, 26.1, 25.3, 23.4, 21.4; ESIHRMS 
calculated for C17H25NO3Na [M+Na]+, 314.1732; found, 314.1739. 
1-(4-Methyl-1-piperidinyloxy)-4-phenylbutyl acetate (65l). 
The title compound 65l (98 mg, 84%) was isolated as a colorless oil from 62l (100 
mg, 0.38 mmol) and DIBAL (0.57 mL, 1 M in hexane, 0.57 mmol) by following the general 
procedure D. Eluent: 5 – 10% of EtOAc in hexane. 1H NMR (400 MHz, CDCl3) δ 7.31 – 





= 6.9 Hz, 2H), 2.53 – 2.36 (m, 2H), 2.06 (s, 3H), 1.77 – 1.58 (m, 6H), 1.40 – 1.19 (m, 3H), 
0.88 (d, J = 5.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 170.4, 142.0, 128.4, 128.3, 125.8, 
99.9, 57.8, 56.7, 35.5, 34.0, 33.9, 32.6, 30.1, 26.1, 21.4, 21.3; ESIHRMS calculated for 
C18H27NO3Na [M+Na]+, 328.1889; found, 328.1888. 
1-(4-Chloro-1-piperidinyloxy)-4-phenylbutyl acetate (65m).   
The title compound 65m (98 mg, 85%) was isolated as a colorless oil from 62m 
(100 mg, 0.35 mmol) and DIBAL (0.62 mL 1 M in hexane, 0.62 mmol) by following the 
general procedure D. Eluent: 0 – 20% of EtOAc in hexane. IR (neat, cm-1) √ 1738; 1H 
NMR (400 MHz, CDCl3) δ 7.32 – 7.25 (m, 2H), 7.23 – 7.13 (m, 3H), 6.05 (s, 1H), 4.21 (br 
s, 0.5H), 3.92 (s, 0.5H), 3.28 (br s, 1H), 3.05 (br s, 2H), 2.63 (s, 3H), 2.26 – 1.78 (m, 7H), 
1.69 (s, 4H); 13C NMR (100 MHz, CDCl3) δ 170.3, 141.9, 128.4, 128.4, 125.9, 99.6, 55.9, 
55.5, 52.4, 51.3, 35.5, 34.1, 33.0, 32.5, 26.0, 21.4; ESIHRMS calculated for 
C17H24NO3ClNa [M+Na]+, 348.1342; found, 348.1346. 
O-(1-Acetoxy-2-(naphthalen-2-yloxy)ethyl)-N,N-dibenzylhydroxylamine (65n). 
The title compound 65n (100 mg, 90%) was isolated as a colorless oil from 62n 
(100 mg, 0.25 mmol) and DIBAL (0.38 mL, 1 M in hexane, 0.38 mmol) by following the 
general procedure D. Eluent: 0 – 10% of EtOAc in hexane. 1H NMR (400 MHz, CDCl3) δ 
7.76 (d, J = 8.3 Hz, 1H), 7.73 – 7.67 (m, 2H), 7.44 (t, J = 7.1 Hz, 1H), 7.41 – 7.30 (m, 9H), 
7.30 – 7.23 (m, 2H), 7.04 (dd, J = 8.8, 2.5 Hz, 1H), 6.95 (d, J = 2.0 Hz, 1H), 6.26 (t, J = 
5.4 Hz, 1H), 4.04 (d, J = 13.2 Hz, 2H), 3.97 – 3.87 (m, 3H), 3.84 (dd, J = 10.3, 5.4 Hz, 
1H) 1.86 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 169.9, 156.1, 136.9, 134.4, 129.7, 129.3, 
129.1, 128.3, 127.6, 127.5, 126.8, 126.3, 123.8, 118.7, 106.9, 96.7, 66.6, 62.8, 21.0; 





General procedure (E) for the direct synthesis of N,N,O-trisubstituted 
hydroxylamines from O-acyl hydroxylamines. 
A 1 M DIBAL solution in hexane (1 mmol) was added dropwise to a chilled solution 
of O-acyl hydroxylamine (0.5 mmol) in dry dichloromethane (3 mL) at –78 oC. To this 
solution were added sequentially, dropwise, pyridine (1.5 mmol), a solution of DMAP (1 
mmol) in dry CH2Cl2 (1.5 mL), and Ac2O (3 mmol). The reaction mixture was stirred for 
12 h at –78 oC, warmed slowly to 0 oC, and added saturated aq. NH4Cl (5 mL) and 
saturated aq. sodium potassium tartrate (4 mL). The resultant mixture was vigorously 
stirred at room temperature for 1 h. Then the mixture was extracted with dichloromethane, 
and the resultant organic extract was washed with brine, dried over anhydrous Na2SO4, 
and concentrated under reduced pressure. The so-obtained intermediate residue was 
dissolved in dry dichloromethane (10 mL) and cooled to –78 oC. Et3SiH (1.25 mmol) and 
BF3.OEt2 (1.25 mmol) were added one after the other, and the reaction mixture was 
warmed slowly to  0 oC followed by the addition of saturated aq. NaHCO3. The mixture 
was then extracted with pentane, and the resulting organic extract was dried over 
anhydrous Na2SO4. Subsequent concentration followed by the purification of the resultant 
residue by flash column chromatography on silica gel (0 – 5%  of EtOAc in hexane) gave 
the desired hydroxylamines. 
N,N,O-Tribenzylhydroxylamine (66a). 
According to general procedure E, compound 66a168 (143 mg, 50%) was isolated 
as a colorless oil from 62a (300 mg, 0.95 mmol). 1H NMR (400 MHz, CDCl3) δ 7.43 – 7.42 





(s, 4H); 13C NMR (100 MHz, CDCl3) δ 137.8, 137.0, 129.8, 129.1, 128.1, 127.7, 127.3, 
76.1, 62.9. 
N,O-Dibenzyl-N-methylhydroxylamine (66b). 
According to general procedure E, compound 66b (34 mg, 53%) was isolated as 
a colorless oil from 62b (68 mg, 0.28 mmol). 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.24 (m, 
8H), 7.24 – 7.19 (m, 2H), 4.51 (s, 2H), 3.83 (s, 2H), 2.65 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 137.5, 129.7, 128.8, 128.2, 128.2, 127.7, 127.3, 74.9, 65.2, 45.6; ESIHRMS 
calculated for C15H18NO [M+H]+, 228.1388; found, 228.1385. 
General procedure (F) for the synthesis of N,N,O-trisubstituted hydroxylamines 
from O-(α-acetoxy)hydroxylamines. 
To a chilled solution of O-(α-acetoxy)hydroxylamine (0.25 mmol) in dry 
dichloromethane (5 mL) were added Et3SiH (0.63 mmol) and BF3.OEt2 (0.63 mmol) 
dropwise at –78 oC. The reaction mixture was warmed slowly to  0 oC or room temperature 
in 2.5 h and stirring was continued until completion. The reaction was quenched by 
saturated aq. NaHCO3 and was extracted with pentane. The so-obtained organic extract 
was dried over anhydrous Na2SO4, concentrated, and purified by flash column 
chromatography on silica gel to afford the trisubstituted hydroxylamines.  
1-(4-Phenylbutoxy)pyrrolidine (66f). 
Compound 66f (30 mg, 77%) was prepared according to general procedure F 
using 65f (50 mg, 0.18 mmol) with warming to room temperature and stirring for an 
additional 3 h. It was isolated  as a colorless oil (0 – 10% EtOAc in hexane). 1H NMR (400 
MHz, CDCl3) δ 7.31 – 7.24 (m, 2H), 7.21 – 7.15 (m, 3H), 3.71 (t, J = 6.4 Hz, 2H), 3.01 – 





MHz, CDCl3) δ 142.5, 128.4, 128.2, 125.7, 72.1, 56.6, 35.8, 28.6, 28.1, 21.9; ESIHRMS 
calculated for C14H22NO [M+H]+, 220.1701; found, 220.1702. 
N,N-Dibenzyl-O-(4-phenylbutyl)hydroxylamine (66g). 
Compound 66g (33 mg, 83%) was prepared according to general procedure F 
using 65g (47 mg, 0.12 mmol) with warming to 0 oC. It was isolated  as a colorless oil (0 
– 5% EtOAc in hexane). 1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 6.9 Hz, 4H), 7.34 – 
7.24 (m, 8H), 7.22 – 7.14 (m, 1H), 7.09 (d, J = 6.9 Hz, 2H), 3.86 (s, 4H), 3.34 (t, J = 6.4 
Hz, 2H), 2.42 (t, J = 7.6 Hz, 2H), 1.44 – 1.37 (m, 2H), 1.34 – 1.27 (m, 2H); 13C NMR (100 
MHz, CDCl3) δ 142.5, 137.9, 129.6, 128.4, 128.1, 128.1, 127.2, 125.5, 72.9, 62.6, 35.5, 
28.1, 27.8; ESIHRMS calculated for C24H28NO [M+H]+, 346.2171; found, 346.2177. 
O-(1-Adamantanylmethyl)-N,N-dibenzylhydroxylamine (66h). 
Compound 66h (39 mg, 89%) was prepared according to general procedure F 
using 65h (50 mg, 0.12 mmol) with warming 0 oC. It was isolated as a white solid (0 – 5% 
EtOAc in hexane). M.p. 48 – 49 oC; 1H NMR (400 MHz, CDCl3) δ 7.37 (d, J = 6.9 Hz, 4H), 
7.34 – 7.22 (m, 6H), 3.83 (s, 4H), 2.91 (s, 2H), 1.85 (s, 3H), 1.64 (d, J = 12.2 Hz, 3H), 
1.56 (d, J = 11.3 Hz, 3H), 1.30 (d, J = 2.0 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 137.9, 
129.8, 128.0, 127.0, 83.5, 62.5, 39.6, 37.2, 33.4, 28.2; ESIHRMS calculated for C25H32NO 
[M+H]+, 362.2484; found, 362.2498. 
N,N-Dibenzyl-O-(3,3-dimethylbutyl)hydroxylamine (66i). 
Compound 66i (50 mg, 81%) was prepared according to general procedure F 
using 65i (75 mg, 0.21 mmol) with warming to 0 oC and stirring for an additional 0.5 h. It 
was isolated as a colorless oil (0 – 5% EtOAc in hexane). 1H NMR (400 MHz, CDCl3) δ 





(t, J = 7.6 Hz, 2H), 0.69 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 137.9, 129.7, 128.1, 127.1, 
70.5, 62.7, 41.5, 29.5, 29.3; ESIHRMS calculated for C20H28NO [M+H]+, 298.2171; found, 
298.2175. 
N-Benzyl-N-methyl-O-(5-phenylpentyl)hydroxylamine (66j). 
Compound 66j (35 mg, 85%) was prepared according to general procedure F 
using 65j (50 mg, 0.15 mmol) with warming to 0 oC and stirring for an additional 45 min 
at 0 oC. It was isolated as a colorless oil (0 – 5% EtOAc in hexane). 1H NMR (400 MHz, 
CDCl3) δ 7.39 – 7.25 (m, 7H), 7.21 – 7.14 (m, 3H), 3.79 (s, 2H), 3.52 (t, J = 6.4 Hz, 2H), 
2.62 (s, 3H), 2.57 (t, J = 7.8 Hz, 2H), 1.60 – 1.51  (m, 2H), 1.51 – 1.42 (m, 2H), 1.32 – 
1.21 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 142.7, 137.6, 129.7, 128.4, 128.2, 128.1, 
127.2, 125.6, 72.1, 65.1, 45.5, 35.9, 31.3, 28.6, 25.8; ESIHRMS calculated for C19H26NO 
[M+H]+, 284.2014; found, 284.2016. 
1-(4-Phenylbutoxy)piperidine (66k). 
Compound 66k (37 mg, 75%) was prepared according to general procedure F 
using 65k (61 mg, 0.21 mmol) with warming to 0 oC and stirring for an additional 2 h. It 
was isolated as a colorless oil (0 – 10% EtOAc in hexane). 1H NMR (400 MHz, CDCl3) δ 
7.31 – 7.24 (m, 2H), 7.21 – 7.13 (m, 3H), 3.71 (t, J = 6.4 Hz, 2H), 3.26 (br s, 2H), 2.63 (t, 
J = 7.6 Hz, 2H), 2.34 (br s, 2H), 1.80 – 1.45 (m, 9H), 1.14 (br s, 1H); 13C NMR (100 MHz, 
CDCl3) δ 142.5, 128.4, 128.2, 125.6, 71.2, 56.9, 35.8, 28.6, 28.2, 25.5, 23.5; ESIHRMS 
calculated for C15H24NO [M+H]+, 234.1858; found, 234.1863. 
4-Methyl-1-(4-phenylbutoxy)piperidine (66l). 
Compound 66l (60 mg, 76%) was prepared according to general procedure F 





was isolated as a colorless oil (0 – 5% EtOAc in hexane). 1H NMR (500 MHz, toluene-d8, 
T = 363 K) δ 7.14 – 6.95 (m, 5H), 3.66 (t, J = 6.2 Hz, 2H), 3.17 (d, J = 10.4 Hz, 2H), 2.50 
(t, J = 7.5 Hz, 2H), 2.39 (t, J = 9.6 Hz, 2H), 1.67 – 1.59 (m, 2H), 1.59 – 1.52 (m, 2H), 1.43 
(d, J = 13.1 Hz, 2H), 1.30 – 1.13 (m, 3H), 0.76 (d, J = 6.1 Hz, 3H); 13C NMR (125 MHz, 
toluene-d8) δ 143.2, 129.1, 128.9, 126.3, 71.7, 57.3, 36.6, 34.9, 31.1, 29.5, 29.1, 22.0; 
ESIHRMS calculated for C16H26NO [M+H]+, 248.2014; found, 248.2009. 
4-Chloro-1-(4-phenylbutoxy)piperidine (66m). 
Compound 66m (52 mg, 74%) was prepared according to general procedure F 
using 65m (85 mg, 0.26 mmol) with warming to room temperature and stirring for an 
additional 2 h. It was isolated as a colorless oil (eluent: 0 – 10% of EtOAc in hexane). 1H 
NMR (400 MHz, CDCl3) δ 7.32 – 7.25 (m, 2H), 7.22 – 7.15 (m, 3H), 4.25 (br s, 0.45H), 
3.89 (br s, 0.55H), 3.69 (t, J = 6.3 Hz, 2H), 3.26 (br s, 1H), 3.01 (br s, 1.8H), 2.63 (t, J = 
7.5 Hz, 2H), 2.51 (br s, 1H), 2.27 – 1.80 (m, 4H), 1.76 – 1.54 (m, 4H); 13C NMR (100 MHz, 
CDCl3) δ 142.4, 128.4, 128.3, 125.7, 71.5, 56.1, 55.8, 54.4, 51.0, 35.8, 34.7, 33.1, 28.5, 
28.1; ESIHRMS calculated for C15H23NOCl [M+H]+, 268.1468; found, 268.1470. 
N,N-Dibenzyl-O-(2-(2-naphthalenyloxy)ethyl)hydroxylamine (66n). 
To an ice-cold solution of 65n (160 mg, 0.36 mmol) in dry dichloromethane (7.2 
mL) were added Et3SiH (290 μL, 1.80 mmol) and BF3.OEt2 (230 μL, 1.80 mmol). The ice-
bath was removed and the reaction mixture was stirred for 7 days. After quenching the 
reaction with saturated aq. NaHCO3, the mixture was extracted with pentane. The 
resulting organic extract was dried over anhydrous Na2SO4, concentrated, and purified 
by flash column chromatography on silica gel (0 – 5% EtOAc in hexane) to give 66n (52 





– 7.65 (m, 2H), 7.46 – 7.38 (m, 5H), 7.36 – 7.28 (m, 5H), 7.28 – 7.22 (m, 2H), 7.06 (dd, J 
= 8.8, 2.5 Hz, 1H), 6.87 (d, J = 2.5 Hz, 1H), 3.93 (s, 4H), 3.78 (t, J = 4.9 Hz, 2H), 3.71 (t, 
J = 4.9 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 156.6, 137.4, 134.5, 129.8, 129.1, 128.9, 
128.2, 127.6, 127.4, 126.6, 126.2, 123.5, 119.0, 106.5, 71.3, 65.8, 62.7; ESIHRMS 
calculated for C26H25NO2Na [M+Na]+, 406.1783; found, 406.1778. 
N,N-Dibenzyl-O-(pyridin-3-ylmethyl)hydroxylamine (66o). 
A 1M solution of DIBAL in hexane (0.63 mL, 0.63 mmol) was added dropwise to a 
stirred solution of 62o (100 mg, 0.31 mmol) in dry dichloromethane (1.9 mL) at –78 oC. 
Subsequently, pyridine (76 μL, 0.94 mmol), a solution of DMAP (77 mg, 0.63 mmol) in 
dry dichloromethane (0.9 mL), and Ac2O (178 μL, 1.88 mmol) were added dropwise and 
sequentially. The reaction mixture was then allowed to stir for 12 h at –78 oC, and it was 
warmed slowly to 0 oC in 2.5 h followed by the additions of saturated aq. NH4Cl (3.2 mL) 
and saturated aq. sodium potassium tartrate (2.4 mL). The resultant mixture was 
vigorously stirred at room temperature for 1 h before the extraction with dichloromethane. 
The resulting organic extract was washed with brine, dried over anhydrous Na2SO4, and 
concentrated. The so-obtained crude residue 65o was dissolved in dry dichloromethane 
(6.3 mL) and again cooled to –78 oC. Et3SiH (252 μL, 1.58 mmol)  and BF3.OEt2 (200 μL, 
1.58 mmol) were added dropwise and sequentially to this chilled solution, and the 
resulting solution was warmed to room temperature and stirring was continued for an 
additional 36 h. After quenching with saturated aqueous NaHCO3, the reaction mixture 
was extracted with pentane. The organic extract was then dried over anhydrous Na2SO4, 
concentrated, and purified by column chromatography on neutral alumina (5 – 20% of 





MHz, CDCl3) δ 8.45 (s, 1H), 8.16 (s, 1H), 7.41 – 7.24 (m, 10H), 7.20 – 7.15 (m, 1H), 7.13 
– 7.07 (m, 1H), 4.12 (s, 2H), 3.88 (s, 4H); 13C NMR (100 MHz, CDCl3) δ 150.3, 149.0, 
137.5, 136.7, 132.4, 129.8, 128.2, 127.4, 123.2, 73.3, 63.1; ESIHRMS calculated for 
C20H21N2O [M+H]+, 305.1654; found, 305.1657. 
N,N-Dibenzyl-O-(2-azidoacetyl)hydroxylamine (62p).  
Following the general procedure C, the title compound 62p was isolated (1.38 g, 
65%) as a yellow oil by stirring 63a (1.53 g, 7.17 mmol), 2-azidoacetic acid 67 (1.45 g, 
14.35 mmol), and N,N’-dicyclohexylcarbodiimide (2.97 g, 14.35 mmol) for 2 h. Eluent: 0 
– 5%  of EtOAc in hexane. IR (neat, cm-1) √ 2108, 1765; 1H NMR (400 MHz, CDCl3) δ 
7.47 – 7.22 (m, 10H), 4.10 (s, 4H), 3.47 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 167.6, 
135.3, 129.5, 128.5, 128.1, 63.0, 49.5; ESIHRMS calculated for C16H16N4O2Na [M+Na]+, 
319.1171; found 319.1169. 
N,N-Dibenzyl-O-(3-azidopropionyl)hydroxylamine (62q). 
Following the general procedure C, the title compound 62q was isolated (1.30 g, 
52%) as a yellow oil by stirring 63a (1.74 g, 8.15 mmol), 3-azidopropionic acid 68 (1.41 
g, 12.23 mmol), and N,N’-dicyclohexylcarbodiimide (2.52 g, 12.23 mmol) for 2 h.  Eluent: 
0 – 10% EtOAc in hexane.  IR (neat, cm-1) √ 2098, 1756; 1H NMR (400 MHz, CDCl3) δ 
7.40 (d, J = 6.8 Hz, 4H), 7.37 – 7.25 (m, 6H), 4.08 (s, 4H), 3.26 (t, J = 6.7 Hz, 2H), 2.26 
(t, J = 6.7 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 169.6, 135.7, 129.4, 128.4, 127.8, 62.6, 
46.4, 32.4; ESIHRMS calculated for C17H19N4O2 [M+H]+, 311.1508; found 311.1518.  
N,N-Dibenzyl-O-(4-azidobutanoyl)hydroxylamine (62r). 
Following the general procedure C, the title compound 62r was isolated (813 mg, 





mg, 4.83 mmol), and N,N’-dicyclohexylcarbodiimide (996 mg, 4.83 mmol) for 2 h.  Eluent: 
0 – 5% EtOAc in hexane. IR (neat, cm-1) √ 2096, 1756; 1H NMR (400 MHz, CDCl3) δ 7.43 
– 7.37 (m, 4H), 7.30 (m, 6H), 4.07 (s, 4H), 2.93 (t, J = 6.8 Hz, 2H), 2.09 (t, J = 7.1 Hz, 
2H), 1.57 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 171.2, 135.9, 129.5, 128.3, 127.7, 62.7, 
50.0, 29.5, 24.1; ESIHRMS calculated for C18H21N4O2 [M+H]+, 325.1665; found 325.1673. 
N,N-Dibenzyl-O-(1-acetoxy-2-azidoethyl)hydroxylamine (65p). 
The title compound 65p (298 mg, 86%) was isolated as a colorless oil from 62p 
(300 mg, 1.01 mmol) and DIBAL (1.77 mL, 1 M in hexane, 1.77 mmol) by following the 
general procedure D. Eluent: 0 – 5% EtOAc in hexane. IR (neat, cm-1) √ 2102, 1751; 1H 
NMR (400 MHz, CDCl3) δ 7.44 – 7.22 (m, 10H), 5.89 (ap t, J = 4.9 Hz, 1H), 4.01 (br d, J 
= 13.1 Hz, 2H), 3.87 (d, J = 13.1 Hz, 2H), 2.96 (m, 2H), 1.83 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 169.7, 136.8, 129.6, 128.4, 127.6, 97.4, 63.1, 51.2, 21.0; ESIHRMS calculated 
for C18H20N4O3Na [M+Na]+, 363.1433; found 363.1434. 
N,N-Dibenzyl-O-(1-acetoxy-3-azidopropyl)hydroxylamine (65q). 
The title compound 65q (210 mg, 61%) was isolated as a colorless oil from 62q 
(300 mg, 0.97 mmol) and DIBAL (1.70 mL, 1 M in hexane, 1.70 mmol) by following the 
general procedure D. Eluent: 0 – 5% EtOAc in hexane. IR (neat, cm-1) √ 2098, 1743; 1H 
NMR (400 MHz, CDCl3) δ 7.44 – 7.12 (m, 10H), 5.87 (ap t, J = 5.4 Hz, 1H), 4.04 (br m, 
2H), 3.79 (d, J = 13.0 Hz, 2H), 3.00 (dt, J= 12.5, 7.2 Hz 1H), 2.89 (dt, J = 12.5, 7.2 Hz, 
1H), 1.87 (s, 3H), 1.72 – 1.53 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 169.9, 136.9, 129.5, 
128.4, 127.5, 98.1, 62.9, 46.1, 32.3, 21.1; ESIHRMS calculated for C19H22N4O3Na 







The title compound 65r (693 mg, 87%) was isolated as a colorless oil from 62r 
(700 mg, 2.16 mmol) and DIBAL (3.78 mL, 1 M in hexane, 3.78 mmol) by following the 
general procedure D. Eluent: 0 – 5% EtOAc in hexane. IR (neat, cm-1) √ 2097, 1741; 1H 
NMR (400 MHz, CDCl3) δ 7.44 – 7.16 (m, 10H), 5.80 (dd, J= 6.0, 5.3 Hz, 1H), 4.05 (br m, 
2H), 3.77 (d, J = 13.6 Hz, 2H), 3.00 (t, J = 6.6 Hz, 2H), 1.88 (s, 3H), 1.49 – 1.41 (m, 2H), 
1.37 – 1.16 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 170.2, 137.0, 129.4, 128.3, 127.5, 
100.0, 63.0, 50.7, 29.9, 23.2, 21.2; ESIHRMS calculated  for C20H24N4O3Na [M+Na]+, 
391.1746; found 391.1748. 
N,N-Dibenzyl-O-(2-azidoethyl)hydroxylamine (66p). 
To an ice-cold solution of 65p (50 mg, 0.15 mmol) in dry dichloromethane (3 mL) 
were added Et3SiH (118 μL, 0.74 mmol) and BF3 . OEt2 (90 μL, 0.74 mmol). The ice-bath 
was removed and the reaction mixture was allowed to stir for 4 days. After quenching with 
saturated aq. NaHCO3, the resultant mixture was extracted with pentane, and the so-
obtained organic extract was dried over anhydrous Na2SO4.  Concentration followed by 
the purification of the residue by flash column chromatography on silica gel afforded 66p 
(7 mg, 17%) as a yellow oil (eluent: 0 – 5% EtOAc in hexane). IR (neat, cm-1) √ 2102; 1H 
NMR (600 MHz, CDCl3) δ 7.43 – 7.21 (m, 10H), 3.88 (s, 4H), 3.38 (t, J = 5.2 Hz, 2H), 2.96 
(t, J = 5.2 Hz, 2H); 13C NMR (150 MHz, CDCl3) δ 137.5, 129.7, 128.2, 127.4, 71.6, 62.8, 
49.7; ESIHRMS calculated for C16H19N4O [M+H]+, 283.1559; found 283.1567. 
N,N-Dibenzyl-O-(3-azidopropyl)hydroxylamine (66q). 
Compound 66q (20 mg, 48%) was prepared according to general procedure F 





additional 24 h.  It was isolated as a yellow oil (eluent: 0 – 5% EtOAc in hexane). IR (neat, 
cm-1) √ 2096; 1H NMR (400 MHz, CDCl3) δ 7.45 – 7.20 (m, 10H), 3.85 (s, 4H), 3.34 (t, J 
= 5.9 Hz, 2H), 2.91 (t, J = 7.0 Hz, 2H), 1.51 – 1.41 (m, 2H); 13C NMR (100 MHz, CDCl3) 
δ 137.7, 129.6, 128.2, 127.3, 69.7, 62.7, 48.4, 28.0; ESIHRMS calculated for C17H21N4O 
[M+H]+, 297.1715; found 297.1716. 
N,N-Dibenzyl-O-(4-azidobutyl)hydroxylamine (66r). 
Compound 66r  (45 mg, 54%) was prepared according to general procedure F 
using 65r (100 mg, 0.27 mmol) with warming to 0 oC and stirring for an additional 3 h.  It 
was isolated as a yellow oil (eluent: 0 – 5% EtOAc in hexane). IR (neat,cm-1) √ 2095; 1H 
NMR (400 MHz, CDCl3) δ 7.42 – 7.36 (m, 4H), 7.36 – 7.24 (m, 6H), 3.85 (s, 4H), 3.28 (t, 
J = 5.7 Hz, 2H), 2.95 (t, J = 6.5 Hz, 2H), 1.30 – 1.25 (m, 4H); 13C NMR (100 MHz, CDCl3) 
δ 137.8, 129.6, 128.1, 127.2, 72.0, 62.7, 50.9, 25.6, 25.5; ESIHRMS calculated for 
C18H23N4O [M+H]+, 311.1872; found 311.1885. 
N,N-Dibenzyl-O-(1-phenyl-3-buten-1-yl)hydroxylamine (70a). 
A solution of 62a (51 mg, 0.16 mmol) in dry CH2Cl2 (1 mL) was cooled to –78 oC. 
A 1 M solution of DIBAL in hexane (0.32 mL, 0.32 mmol), pyridine (39 μL, 0.48 mmol), a 
solution of DMAP (39 mg, 0.32 mmol) in dry CH2Cl2 (0.5 mL), and Ac2O (91 μL, 0.96 
mmol) were added sequentially, while maintaining the reaction temperature at –78 oC. 
The reaction temperature was maintained for the next 12 h and was warmed to 0 oC in 
2.5 h. After quenching reaction by the additions of saturated aq. NH4Cl and saturated aq. 
sodium potassium tartrate at 0 oC, the resultant mixture was vigorously stirred vigorously 
at room temperature for 1 h. Then the mixture was extracted with dichloromethane, and 





concentrated. The crude residue 65a was dissolved in dry dichloromethane (3.2 mL) and 
cooled to –78 oC. Allyltributylstannane (124 μL, 0.40 mmol) and BF3.OEt2 (51 μL, 0.40 
mmol) were added one after the other, and the reaction mixture was warmed to 0oC in 
2.5 h. The reaction was quenched by the addition of saturated aq. NaHCO3 and was 
extracted with pentane. Then the obtained organic extract was dried over anhydrous 
Na2SO4, concentrated, and purified in flash column chromatography on silica gel (0 – 5% 
of EtOAc in hexane). The desired product 70a (45 mg, 82%) was obtained as a colorless 
oil. 1H NMR (400 MHz, CDCl3) δ 7.35 – 7.18 (m, 15H), 5.45 – 5.32 (m, 1H), 4.90 – 4.81 
(m, 2H), 4.18 (t, J = 7.1 Hz, 1H), 3.83 (d, J = 13.2 Hz, 2H), 3.71 (d, J = 12.7 Hz, 2H), 2.56 
– 2.46 (m, 1H), 2.25 – 2.15 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 141.7, 137.8, 134.7, 
129.7, 128.1, 128.0, 127.7, 127.5, 127.2, 116.5, 84.7, 62.5, 39.5; ESIHRMS calculated 
for C24H26NO [M+H]+, 344.2014; found, 344.2012. 
N-Benzyl-N-methyl-O-(1-phenylbut-3-en-1-yl)hydroxylamine (70b). 
A solution of 62b (100 mg, 0.41 mmol) in dry CH2Cl2 (2.5 mL) was cooled to –78 
oC. A 1 M solution of DIBAL in hexane (0.83 mL, 0.83 mmol), pyridine (101 μL, 1.24 
mmol), a solution of DMAP (101 mg, 0.83 mmol) in dry CH2Cl2 (1.2 mL), and Ac2O (234 
μL, 2.49 mmol) were added sequentially, while maintaining the reaction temperature at –
78 oC. The reaction temperature was maintained for the next 12 h and was warmed 0 oC 
in 2.5 h. After quenching reaction by the additions of saturated aq. NH4Cl and saturated 
aq. sodium potassium tartrate at 0 oC, the resultant mixture was vigorously stirred at room 
temperature for 1 h. Then the mixture was extracted with CH2Cl2, and the obtained 
organic extract was washed with brine, dried over anhydrous Na2SO4, and concentrated. 





to –78 oC. Allyltributylstannane (322 μL, 1.04 mmol) and BF3.OEt2 (131 μL, 1.04 mmol) 
were added one after the other, and the mixture was warmed to  0 oC in 2.5 h. The reaction 
was quenched by the addition of saturated aq. NaHCO3 and was extracted with pentane. 
Then the obtained organic layer was dried over anhydrous Na2SO4, concentrated, and 
purified in flash column chromatography on silica gel (0 – 5% of EtOAc in hexane). The 
desired product 70b (59 mg, 54%) as obtained as a colorless oil. 1H NMR (500 MHz, 
toluene-d8, T = 323 K) δ 7.25 – 6.99 (m, 10H), 5.70 – 5.58 (m, 1H), 4.95 – 4.86 (m, 2H), 
4.46 (t, J = 6.9 Hz, 1H), 3.66 (s, 2H), 2.62 – 2.53 (m, 1H), 2.40 – 2.25 (m, 4H); 13C NMR 
(125 MHz, toluene-d8, T = 323 K) δ 143.5, 138.5, 135.7, 130.4, 128.7, 128.6, 127.9, 127.8, 
117.0, 84.6, 66.1, 45.9, 41.0; ESIHRMS calculated for C18H22NO [M+H]+, 268.1701; 
found, 268.1699. 
O-(1-(Adamantan-1-yl)but-3-en-1-yl)-N,N-dibenzylhydroxylamine (70c). 
A solution of 65h (100 mg, 0.24 mmol) in dry CH2Cl2 (4.8 mL) was cooled to –78 
oC.  Allyltributylstannane (186 μL, 0.60 mmol) and BF3.OEt2 (76 μL, 0.60 mmol) were 
added sequentially maintaining the reaction temperature at –78 oC, and the reaction was 
warmed to  0 oC in 2.5 h. After quenching reaction by the addition of aq. NaHCO3, the 
resultant mixture was extracted with pentane. The so-obtained organic layer was dried 
over anhydrous Na2SO4, concentrated, and passed through a small pad of silica buffered 
with 2% triethyl amine in 2:98 mixture of EtOAc and hexane (200 mL). Then the filtrate 
was concentrated and purified by column chromatography on silica gel (eluent: same 
buffered solution of EtOAc in hexane).  The desired product 70c (76 mg, 79%) was 
isolated as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.36 – 7.21 (m, 10H), 5.88 – 5.77 





(dd, J = 4.4, 5.3  Hz, 1H), 2.23 – 2.14 (m, 1H), 2.03 – 1.95 (m, 1H), 1.90 (s, 3H), 1.70 – 
1.54 (m, 9H), 1.47 – 1.39 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 139.2, 137.9, 129.8, 
128.0, 127.1, 113.9, 87.6, 61.4, 38.6, 37.3, 37.0, 33.4, 28.4; ESIHRMS calculated for 
C28H36NO [M+H]+, 402.2797; found, 402.2809. 
1-(Dibenzylaminoxy)-4,4-dimethyl-1-phenylpentan-3-one (70d). 
A solution of 62a (100 mg, 0.32 mmol) in dry CH2Cl2 (1.9 mL) was cooled to –78 
oC. A 1 M DIBAL solution in hexane DIBAL (0.64 mL, 0.64 mmol), pyridine (78 μL, 0.96 
mmol), a solution of DMAP (78 mg, 0.64 mmol) in dry CH2Cl2 (0.9 mL), and Ac2O (182 
μL, 1.92 mmol) were added one after the other, while maintaining the reaction 
temperature at –78 oC. The reaction temperature was maintained for 12 h at –78 oC, and 
then the mixture was warmed to 0 oC in 2.5 h. After quenching the reaction with saturated 
aq. NH4Cl (3.2 mL) and saturated aq. sodium potassium tartrate (2.4 mL), the resultant 
suspension was vigorously stirred at room temperature for 1 h followed by extraction with 
dichloromethane. Then the obtained organic layer was washed with brine, dried over 
anhydrous Na2SO4, and concentrated. The so-obtained crude intermediate 65a was 
dissolved in dry CH2Cl2 (6.4 mL) was cooled to –78 oC, and  3,3-dimethyl-2-
(trimethylsilyloxy)butene (173 μL, 0.80 mmol) and BF3.OEt2 (101 μL, 0.80 mmol) were 
added sequentially, dropwise. The reaction was then warmed to  0 oC in 2.5 h before 
quenching with saturated aq. NaHCO3. The reaction mixture extracted with pentane, and 
the organic layer was dried over anhydrous Na2SO4, concentrated, and purified in flash 
column chromatography on neutral alumina (10 – 25% of CH2Cl2 in hexane). The desired 
product 70d (85 mg, 66%) was isolated as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 





Hz, 2H), 3.74 (d, J = 12.7 Hz, 2H), 2.80 (dd, J = 16.6, 5.4 Hz, 1H), 2.38 (dd, J = 16.6, 8.3 
Hz, 1H), 0.87 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 213.2, 141.3, 137.5, 129.9, 128.1, 
128.0, 127.6, 127.4, 127.2, 79.6, 61.9, 44.1, 42.2, 25.8; ESIHRMS calculated for 
C27H32NO2 [M+H]+, 402.2433; found, 402.2431. 
N,N-Dibenzyl-O-((5-methylfuran-2-yl)benzyl)hydroxylamine (70e). 
A solution of 62a (100 mg, 0.32 mmol) in dry CH2Cl2 (1.9 mL) was cooled to –78 
oC, and DIBAL (0.64 mL, 1 M in hexane, 0.64 mmol), pyridine (78 μL, 0.96 mmol), a 
solution of DMAP (78 mg, 0.64 mmol) in dry CH2Cl2 (0.9 mL), and Ac2O (182 μL, 1.92 
mmol)  were added one after the other maintaining the reaction temperature at –78 oC. 
The reaction was allowed to stir for the next 12 h at –78 oC, and was warmed to 0 oC in 
2.5 h. After quenching the reaction by the addition of saturated aq. NH4Cl (3.2 mL) and 
saturated aq. sodium potassium tartrate (2.4 mL), the resultant suspension was 
vigorously stirred at room temperature for 1 h. The mixture was then extracted with 
dichloromethane, and the organic layer was washed with brine, dried over anhydrous 
Na2SO4, and concentrated. The so-obtained crude intermediate 65a was dissolved in dry 
CH2Cl2 (6.4 mL) and cooled to –78 oC. 2-methylfuran (72 μL, 0.80 mmol) and BF3.OEt2 
(101 μL, 0.80 mmol) were added sequentially, and the reaction mixture was quenched by 
adding saturated aq. NaHCO3 after stirring for 45 min at –78 oC. The resultant suspension 
was extracted with pentane, and the organic layer was dried over anhydrous Na2SO4, 
concentrated, and purified in flash column chromatography on neutral alumina (0 – 5% of 
EtOAc in hexane). Product 70e (63 mg, 51%) was obtained as a colorless oil. 1H NMR 
(400 MHz, CDCl3) δ 7.32 – 7.23 (m, 15H), 5.96 (d, J = 2.9 Hz, 1H), 5.87 (dd, J = 2.9, 1.0 





Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 152.2, 151.9, 139.0, 137.8, 129.7, 128.1, 128.0, 
127.9, 127.7, 127.1, 110.5, 106.0, 80.3, 62.4, 13.7; ESIHRMS calculated for C26H26NO2 
[M+H]+, 384.1964; found, 384.1965. 
N,N-Dibenzyl-O-(1-(5-methylfuran-2-yl)-4-phenylbutyl)hydroxylamine (70f). 
A solution of 65g (50 mg, 0.12 mmol) in dry CH2Cl2 (2.5 mL) was cooled to –78 oC. 
2-methylfuran (28 μL, 0.31 mmol) and BF3.OEt2 (40 μL, 0.31 mmol) were added one after 
the other maintaining the reaction temperature at –78 oC. The reaction was warmed to 0 
oC in 2.5 h and was quenched by adding saturated aq. NaHCO3. The resultant suspension 
was extracted with pentane, and the organic layer was dried over anhydrous Na2SO4, and 
concentrated. On purification of the residue by flash column chromatography on neutral 
alumina (0 – 5% of EtOAc in hexane), product 70f (11 mg, 20%) was obtained as a 
colorless oil along with the recovered starting material 65g (35 mg, 70%). 1H NMR (400 
MHz, CDCl3) δ 7.32 – 7.19 (m, 12H), 7.16 (t, J = 7.3 Hz, 1H), 7.04 (d, J = 6.9 Hz, 2H), 
6.06 (d, J = 2.9 Hz, 1H), 5.87 – 5.85 (m, 1H), 4.12 (t, J = 7.1 Hz, 1H), 3.78 (d, J = 12.7 
Hz, 2H), 3.62 (d, J = 13.2 Hz, 2H), 2.45 – 2.30 (m, 2H), 2.24 (s, 3H), 1.76 – 1.64 (m, 1H), 
1.61 – 1.49 (m, 1H), 1.44 – 1.31 (m, 1H), 1.30 – 1.13 (m, 1H); 13C NMR (100 MHz, CDCl3) 
δ 153.1, 151.4, 142.3, 137.9, 129.6, 128.4, 128.1, 128.0, 127.1, 125.5, 109.1, 105.9, 77.7, 
62.4, 35.4, 31.6, 27.2, 13.6; ESIHRMS calculated for C29H32NO2 [M+H]+, 426.2433; 
found, 426.2426. 
(R)-N,N-Dibenzyl-O-(2-methyl-3-phenylpropanoyl)hydroxylamine (72). 
To an ice-cold solution (<5 oC) of 71 (1 g, 3.09 mmol) in THF-H2O (3:1, 48 mL) 
were added LiOH.H2O (0.26 g, 6.18 mmol) and H2O2 (3.50 g, 30 wt% in water, 30.90 





(<5 oC), and the reaction was quenched with Na2SO3 (30 mL 1.5 M in water, 45.00 mmol). 
The volatile organic components were evaporated in a rotary evaporator (<25 oC bath 
temperature), and the aqueous residue was washed out with CH2Cl2 to discard non-polar 
impurities. Then the aqueous layer was cooled in an ice-bath (<5 oC), acidified to pH 1 by 
addition of 2 M HCl, saturated with NaCl, and extracted with ether. The ether extract was 
dried over anhydrous Na2SO4 and concentrated under reduced pressure. The so-
obtained crude intermediate acid was dissolved in dry CH2Cl2 (20 mL) together with N,N-
dibenzylhydroxylamine 63a (0.99 g, 4.64 mmol) and the resulting solution was cooled in 
an ice-bath (<5 oC). To this solution were added HOBt (0.78 g wetted with 20 wt% water, 
4.64 mmol), EDCI.HCl (0.89 g, 4.64 mmol), and DIPEA (0.81 mL, 4.64 mmol), and the 
reaction was allowed to stir for 4 h at room temperature. The mixture was washed with 
water followed by brine, dried over anhydrous Na2SO4, concentrated under reduced 
pressure, and purified by flash column chromatography on silica gel (0 – 5% EtOAc in 
hexane) to give 72 (0.96 g, 87%) as a colorless oil. [α]20D –8.7 (c 0.9, CHCl3); 1H NMR 
(400 MHz, CDCl3) δ 7.43 – 7.13 (m, 13H), 7.05 (d, J = 7.7 Hz, 2H), 3.99 (ABq, J = 13.4 
Hz, 4H), 2.73 (dd, J = 13.1, 6.7 Hz, 1H), 2.54 – 2.44 (m, 1H), 2.40 (dd, J = 13.1, 7.6 Hz, 
1H), 0.82 (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 174.1, 139.3, 135.9, 129.4, 
129.0, 128.3, 128.2, 127.6, 126.3, 62.1, 40.2, 39.3, 16.6; ESIHRMS calculated for 
C24H25NO2Na [M+Na]+, 382.1783; found, 382.1798.   
(2R)-N,N-Dibenzyl-O-(1-acetoxy-2-methyl-3-phenylpropyl)hydroxylamine (73). 
A solution of 72 (200 mg, 0.56 mmol) in dry CH2Cl2 (3.5 mL) was chilled at –78 oC. 
A 1 M DIBAL solution in hexane (0.98 mL, 0.98 mmol), pyridine (135 μL, 1.68 mmol), a 





mmol) were added one after the other, while maintaining the reaction temperature at –78 
oC . The reaction temperature was maintained for next 12 h at –78 oC, and then it was 
warmed to 0 oC in 2.5 h followed by the addition of saturated aq. NH4Cl (5 mL) and 
saturated aq. sodium potassium tartrate (4 mL). The resultant suspension was vigorously 
stirred for 1 h, and was extracted with CH2Cl2. The organic extract was washed with brine, 
dried over anhydrous Na2SO4, concentrated, and purified by flash column 
chromatography on silica gel (0 – 5% EtOAc in hexane). The desired product 73 (145 mg, 
65%, dr 56:44) was obtained as a colorless oil. [α]20D +7.2 (c 2, CH2Cl2); 1H NMR (400 
MHz, CDCl3), both diastereomers, δ 7.48 – 6.96 (m, 15H), 5.91 (d, J = 4.7 Hz, 0.44H), 
5.87 (d, J = 4.7 Hz, 0.56H), 4.02 (br s, 1.76H), 3.88 – 3.80  (m, 2.24H), 2.74 (dd, J = 13.5, 
4.3 Hz, 0.56H), 2.58 (dd, J = 13.6, 4.1 Hz, 0.44H), 2.11 (dd, J = 13.6, 10.6 Hz,  0.44H), 
1.99 (dd, J = 13.5, 10.3 Hz, 0.56H), 1.92 – 1.78 (m, 4H), 0.71 – 0.60 (m, 3H); 13C NMR 
(100 MHz, CDCl3), both diastereomers, δ 170.4, 170.4, 140.4, 140.3, 137.1, 129.5, 129.0, 
129.0, 128.3, 128.2, 127.4, 125.8, 125.8, 102.0, 62.6, 38.5, 38.3, 37.3, 37.2, 21.20, 21.17, 
13.6, 13.3; ESIHRMS calculated for C26H29NO3Na [M+Na]+, 426.2045; found, 426.2044. 
N,N-Dibenzyl-O-((2R)-2-methyl-1-phenylhex-5-en-3-yl)hydroxylamine (74). 
To a stirred solution of 73 (100 mg, 0.25 mmol) in dry CH2Cl2 (5 mL) were added 
allyltributylstannane (194 μL, 0.63 mmol) and BF3.OEt2 (77 μL, 0.63 mmol) one after the 
other at -78 oC. The reaction mixture was warmed slowly to 0 oC in 2.5 h, quenched by 
saturated aq. NaHCO3, and extracted with CH2Cl2. The organic extract was dried over 
anhydrous Na2SO4, concentrated, and purified by flash column chromatography on silica 
gel (0 – 4% EtOAc in hexane). The desired product 74 (83 mg, 87%) was isolated as a 





(major) in a ratio of  1:1.2 (74a:74b) from the NMR spectra. [α]20D –0.6 (c 3.25, CHCl3); 
1H NMR (600 MHz, CDCl3), both diastereomers, δ 7.63 – 6.84 (m, 15H), 5.67 – 5.53 (m, 
1H), 5.01 – 4.87 (m, 2H), 4.00 – 3.71 (m, 4H), 3.43 (td, J = 6.3, 3.6 Hz, 0.55H), 3.37 (dt, 
J = 6.8, 4.9 Hz, 0.45H), 2.65 (dd, J = 13.4, 4.4 Hz, 0.55H), 2.60 (dd, J = 13.6, 6.0 Hz, 
0.45H), 2.32 (dt, J = 14.0, 6.3 Hz, 0.55H), 2.26 (dd, J = 13.4, 10.5 Hz, 0.55H), 2.16 (dd, 
J = 13.6, 9.0 Hz, 0.45H), 2.13 – 2.08 (m, 0.90H), 2.02 – 1.89 (m, 1.55H), 0.69 (d, J = 6.9 
Hz, 1.65H), 0.57 (d, J = 6.8 Hz, 1.35H); 13C NMR (150 MHz, CDCl3) both diastereomers, 
δ 141.6, 141.5, 137.8, 136.2, 136.0, 129.7, 129.7, 129.6, 129.04, 129.02, 128.10, 128.09, 
128.06, 128.04, 127.2, 127.1, 125.6, 125.5, 116.0, 115.9, 83.71, 83.69, 62.2, 62.1, 39.1, 
38.9, 36.5, 36.4, 34.6, 33.3, 14.2, 13.6; ESIHRMS calculated for C27H32NO [M+H]+, 
386.2484; found, 386.2485.   
N,N-Dibenzyl-O-((3R)-3-methyl-4-phenylbutan-2-yl)hydroxylamine (75). 
To a stirred solution of 73 (40 mg, 0.10 mmol) in dry CH2Cl2 (2 mL) were added 
Me2Zn (250 μL, 1 M in heptane, 0.25 mmol) and BF3.OEt2 (31 μL, 0.25 mmol) one after 
the other at -78 oC. The reaction mixture was warmed slowly to 0 oC in 2.5 h, quenched 
by slow addition of saturated aq. NaHCO3, and extracted with pentane. The organic 
extract was dried over anhydrous Na2SO4, concentrated, and purified by flash column 
chromatography on silica gel (0 – 5% EtOAc in hexane). Product 75 (28 mg, 77%) was 
isolated as a colorless oil and was revealed as an uncharacterized mixture of two 
diastereomers in a ratio of 1:1. [α]20D +2.1 (c 1.25, CHCl3); 1H NMR (600 MHz, CDCl3), 
both diastereomers, δ 7.47 – 6.98 (m, 15H), 4.00 – 3.73 (m, 4H), 3.44 (dq, J = 6.3, 3.6 
Hz, 0.48H), 3.34 (dq, J = 6.5, 4.1 Hz, 0.52H), 2.73 (dd, J = 13.4, 3.9 Hz, 0.48H), 2.52 (dd, 





0.52H), 1.98 – 1.89 (m, 0.52H), 1.90 – 1.80 (m, 0.48H), 0.89 (d, J = 6.3 Hz, 1.44H), 0.85 
(d, J = 6.4 Hz, 1.56H), 0.66 (d, J = 6.9 Hz, 1.44H), 0.60 (d, J = 6.8 Hz, 1.56H); 13C NMR 
(150 MHz, CDCl3), both diasteromers, δ 141.8, 141.4, 137.9, 129.8, 129.7, 129.1, 128.9, 
128.10, 128.06, 128.02, 127.2, 127.1, 125.6, 125.5, 80.6, 80.1, 62.7, 62.5, 39.7, 39.0, 
38.1, 37.9, 15.4, 14.6, 14.1, 13.7; ESIHRMS calculated for C25H30NO [M+H]+, 360.2327; 
found, 360.2325.  
1-Boc-1-methyl-2,2-dibenzylhydrazine (77). 
A mixture of N-Boc-N-methylhydrazine (1 g, 6.84 mmol), NaHCO3 (1.44 g, 17.10 
mmol), BnBr (2.03 mL, 17.10 mmol), DMF (2 mL), and toluene (6 mL) was stirred for 21 
h at 85 oC. The reaction was cooled to room temperature, diluted with toluene, washed 
with water followed by brine, dried over anhydrous Na2SO4, and concentrated under 
reduced pressure. The residue was purified by flash column chromatography on silica gel 
(0 ‒ 8% EtOAc in hexane) to give 77 (1.88 g, 84%) as a colorless oil. 1H NMR (400 MHz, 
CDCl3) δ 7.51 – 7.01 (m, 10H), 4.34 (d, J = 11.3 Hz, 1H), 4.01 (d, J = 12.0 Hz, 2H), 3.87 
(d, J = 12.5 Hz, 1H), 2.69 (s, 3H, rotamer), 2.45 (s, 3H, rotamer), 1.47 (s, 9H); 13C NMR 
(100 MHz, CDCl3) δ 156.3, 154.9, 138.5, 137.9, 129.4, 129.3, 128.1, 127.3, 79.8, 79.6, 
58.1, 57.6, 39.2, 32.3, 28.6; ESIHRMS calculated for C20H26N2O2Na [M+Na]+, 349.1892; 
found, 349.1898. 
1,1-Dibenzyl-2-methylhydrazine (78). 
Trifluoroacetic acid (15 ml) was added dropwise to a solution of 77 (940 mg, 2.88 
mmol) in CH2Cl2 (15 mL) at 0 oC. After stirring for 1 h at 0 oC and 1 h at room temperature, 
more trifluoroacetic acid (5 mL) was added dropwise. The stirring was continued for the 





dissolved in CH2Cl2 (10 mL), washed with 1 N NaOH followed by brine, dried over 
anhydrous Na2SO4, and concentrated to give desired product 78 (652 mg, 100% yield) 
as colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.58 – 7.23 (m, 10H), 3.79 (s, 4H), 2.66 (br 
s, 1H), 2.56 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 138.4, 128.9, 128.3, 127.1, 59.4, 35.1; 
ESIHRMS calculated for C15H19N2 [M+H]+, 227.1548; found, 227.1545. 
N',N'-Dibenzyl-N-methyl-4-phenylbutanehydrazide (79). 
To a stirred solution of  78 (347 mg, 1.53 mmol), 4-phenylbutyric acid (251 mg, 
1.53 mmol), and DMAP (38 mg, 0.31 mmol) in dry dichloromethane (15 mL) was added 
DCC (316 mg, 1.53 mmol) at room temperature. The reaction mixture was allowed to stir 
for 2 h and filtered through a pad of Celite®. The resulting filtrate was concentrated and 
purified by flash column chromatography on silica gel (0 ‒ 10% EtOAc in hexane)  to 
afford 79 (549 mg, 96% yield) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.37 – 7.06 
(m, 15H), 3.81 (ABq, J = 12.8 Hz, 4H), 3.06 (s, 3H), 2.39 (t, J = 7.6 Hz, 2H), 2.16  (t, J = 
7.7 Hz, 2H), 1.60 – 1.43 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 176.0, 142.3, 136.4, 
129.5, 129.4, 128.6, 128.2, 127.9, 125.7, 57.8, 35.5, 31.3, 26.2, 24.0; ESIHRMS 
calculated for C25H28N2ONa [M+Na]+, 395.2099; found, 395.2105. 
1,1-Dibenzyl-2-methyl-2-(4-phenylbutyl)hydrazine (81) and N',N'-dibenzyl-N-
methylacetohydrazide (82). 
To a stirred solution of  79 (93 mg, 0.25 mmol) in dry dichloromethane (1.5 mL) 
was added DIBAL (0.38 mL 1 M in cyclohexane, 0.38 mmol) dropwise at -78 oC. The 
reaction mixture was stirred for 30 min, and pyridine (60 µL, 0.75 mmol), a solution of 
DMAP (61 mg, 0.50 mmol) in dry dichloromethane (0.7 mL), and acetic anhydride (142 





oC for 12 h and allowed to warm to 0 oC in 2.5 h. After addition of saturated aq. NH4Cl 
(2.5 mL) and saturated aq. Rochelle’s salt (2 mL), the resulting suspension was stirred 
vigorously at room temperature. The suspension was extracted with dichloromethane and 
the obtained organic extract was dried over anhydrous Na2SO4, concentrated, and 
purified by flash column chromatography on silica gel (0 ‒ 60% EtOAc in hexane). Two 
unknown products were isolated, which were characterized as 81 (30 mg colorless oil, 
33% yield) and 82 (20 mg colorless oil, 30% yield) from NMR analysis. 
Data for 81; 1H NMR (400 MHz, CDCl3) δ 7.41 – 7.05 (m, 15H), 3.64 (s, 4H), 2.56 
(t, J = 6.4 Hz, 2H), 2.51 – 2.45 (m, 2H), 2.42 (s, 3H), 1.49 – 1.34 (m, 4H); 13C NMR (100 
MHz, CDCl3) δ 142.9, 140.2, 129.0, 128.5, 128.1, 128.0, 126.6, 125.5, 54.4, 53.1, 35.8, 
35.4, 28.9, 27.4; ESIHRMS calculated for C25H31N2O [M+H]+, 359.2487; found, 359.2498. 
Data for 82; 1H NMR (400 MHz, CDCl3) δ 7.44 – 7.18 (m, 10H), 3.82 (ABq, J = 
12.7 Hz, 4H), 3.03 (s, 3H), 1.72 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 174.0, 136.4, 129.4, 
128.6, 127.9, 57.9, 23.9, 20.7; ESIHRMS calculated for C17H20N2ONa [M+Na]+, 291.1473; 
found, 291.1471. 
Alternative synthesis of 1,1-dibenzyl-2-methyl-2-(4-phenylbutyl)hydrazine (81). 
To a stirred solution of  79 (50 mg, 0.13 mmol) in dry dichloromethane (1 mL) was 
added DIBAL (0.39 mL 1 M in cyclohexane, 0.39 mmol) dropwise at -78 oC. The reaction 
mixture was warmed to 0 oC in 2.5 h and quenched with saturated aq. NH4Cl (2 mL) and 
saturated aq. Rochelle’s salt (1.5 mL). The resulting suspension was stirred vigorously at 
room temperature and extracted with dichloromethane. The so-obtained organic extract 





chromatography on silica gel (0 ‒ 5% EtOAc in hexane) to afford 81 (31 mg, 65% yield) 
as a colorless oil. The spectral data were identical with above sample. 
1,1-Dibenzyl-2-methyl-2-(7-phenylhept-1-en-4-yl)hydrazine (83). 
To an ice-cold (<5 oC) solution of 79 (60 mg, 0.16 mmol) and allyltributylstannane 
(150 µL, 0.48 mmol) in dry dichloromethane (1 mL) was added DIBAL (0.20 mL 1M DIBAL 
in hexane, 0.20 mmol) dropwise. After stirring for 5 min, BF3.OEt2 (59 µL, 0.48 mmol) was 
added dropwise and the ice-bath was removed. The reaction was allowed to stir for 16 h 
at room temperature, and then quenched by adding saturated aq. NH4Cl (2 mL) and 
saturated Rochelle’s salt (1.5 mL). The resulting suspension was stirred vigorously for 1 
h and was extracted with dichloromethane. The so-obtained organic extract was 
concentrated and purified by thin layer chromatography on silica gel (0 ‒ 5% EtOAc in 
hexane) to give 83 (20 mg, 31% yield) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 
7.37 – 7.02 (m, 15H), 5.49 (ddt, J = 17.1, 10.1, 7.0 Hz, 1H), 4.96 – 4.81 (m, 2H), 3.64 
(ABq, J = 13.1 Hz, 4H), 2.65 – 2.56 (m, 1H), 2.52 – 2.33 (m, 6H), 2.08 – 1.96 (m, 1H), 
1.58 – 1.42 (m, 1H), 1.38 – 1.19 (m, 3H). 13C NMR (100 MHz, CDCl3) δ 142.8, 139.8, 
137.0, 129.4, 128.4, 128.1, 127.9, 126.7, 125.5, 115.4, 62.7, 55.0, 36.1, 34.8, 30.4, 29.9, 
26.8; ESIHRMS calculated for C28H35N2 [M+H]+, 399.2800; found, 399.2804. 
N',N'-Dibenzyl-N-methylbenzohydrazide (84). 
To a stirred solution of  78 (227 mg, 1.23 mmol), benzoic acid (173 mg, 1.41 mmol), 
and DMAP (31 mg, 0.25 mmol) in dry dichloromethane (12 mL) was added DCC (291 
mg, 1.41 mmol) at room temperature. The reaction mixture was allowed to stir for 12 h 
and filtered through a pad of Celite®. The resulting filtrate was concentrated and purified 





(327 mg, 81% yield) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.12 (m, 9H), 
6.99 (d, J = 7.0 Hz, 4H), 6.83 (d, J = 7.6 Hz, 2H), 3.99 – 3.72 (ABq, J = 13.0 Hz, 4H), 3.26 
(s, 3H); 13C NMR (100 MHz, CDCl3) δ 173.7, 137.0, 136.0, 129.3, 128.7, 128.4, 127.8, 
127.2, 127.0, 57.4, 25.0; ESIHRMS calculated for C22H22N2ONa [M+Na]+, 353.1630; 
found, 363.1622. 
1,1,2-Tribenzyl-2-methylhydrazine (85). 
To a stirred solution of  84 (50 mg, 0.15 mmol) in dry dichloromethane (1 mL) was 
added DIBAL (0.45 mL 1 M in hexane, 0.45 mmol) dropwise at -78 oC. The reaction 
mixture was warmed to 0 oC in 2.5 h and quenched with saturated aq. NH4Cl (2 mL) and 
saturated aq. Rochelle’s salt (1.5 mL). The resulting suspension was stirred vigorously at 
room temperature and extracted with dichloromethane. The so-obtained organic extract 
was dried over anhydrous Na2SO4, concentrated, and purified by flash column 
chromatography on silica gel (0 ‒ 5% EtOAc in hexane) to afford 85 (29 mg, 61% yield) 
as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.45 – 7.14 (m, 13H), 7.11 – 6.98 (m, 2H), 
3.83 (s, 2H), 3.77 (s, 4H), 2.38 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 140.0, 139.4, 
128.82, 128.82, 128.02, 127.99, 126.7, 126.6, 58.8, 53.7, 35.4; ESIHRMS calculated for 
C22H25N2 [M+H]+, 317.2018; found, 317.2029. 
N,N'-Dimethyl-4-phenyl-N'-(4-phenylbutanoyl)butanehydrazide (86). 
To a stirred solution of  sym-dimethylhydrazine dihydrochloride (100 mg, 0.75 
mmol) and 4-phenylbutyric acid (309 mg, 1.88 mmol) in dry dichloromethane (8 mL) was 
added triethylamine (230 µL, 1.65 mmol) dropwise at room temperature. After stirring for 
5 min, DMAP (37 mg, 0.30 mmol) and DCC (389 mg, 1.88 mmol) were added and the 





Celite®, and the resulting filtrate was washed with saturated aq. NaHCO3 and brine, dried 
over anhydrous Na2SO4, and concentrated. After purification via flash column 
chromatography on silica gel (20 ‒ 60% EtOAc in hexane), the desired hydrazide 86 (181 
mg, 69% yield) was isolated as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.03 
(m, 10H), 3.04 (s, 6H), 2.62 (t, J = 7.6 Hz, 4H), 2.19 (t, J = 7.4 Hz, 4H), 2.00 – 1.86 (m, 
4H); 13C NMR (100 MHz, CDCl3) δ 174.6, 141.2, 128.6, 128.4, 126.1, 35.0, 33.5, 30.6, 
25.9; ESIHRMS calculated for C22H28N2O2Na [M+Na]+, 375.2048; found, 375.2052. 
1,2-Dimethyl-1,2-bis(4-phenylbutyl)hydrazine (87). 
To a stirred solution of  86 (50 mg, 0.14 mmol) in dry dichloromethane (1.7 mL) 
was added DIBAL (0.84 mL 1 M in hexane, 0.84 mmol) dropwise at -78 oC. The reaction 
mixture was warmed to 0 oC in 2.5 h and quenched with saturated aq. NH4Cl (3 mL) and 
saturated aq. Rochelle’s salt (2 mL). The resulting suspension was stirred vigorously at 
room temperature and extracted with dichloromethane. The so-obtained organic extract 
was dried over anhydrous Na2SO4, concentrated, and purified by flash column 
chromatography on silica gel (0 ‒ 20% EtOAc in hexane) to afford 87 (21 mg, 46% yield) 
as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.39 – 7.06 (m, 10H), 2.62 (t, J = 7.7 Hz, 
4H), 2.46 (t, J = 7.1 Hz, 4H), 2.23 (s, 3H), 1.72 – 1.58 (m, 4H), 1.58 – 1.45 (m, 4H); 13C 
NMR (100 MHz, CDCl3) δ 142.8, 128.4, 128.2, 125.6, 53.8, 35.9, 34.6, 29.3, 27.7; 
ESIHRMS calculated for C22H33N2 [M+H]+, 325.2644; found, 325.2640. 
Experimental section for chapter 3 
VT-NMR study of nitrogen inversion in N-hydroxy and N-alkoxypiperidines: 
Variable temperature (VT) NMR spectroscopy technique was used to determine 





compound were recorded in 500 MHz instrument over the temperature range of 223 K to 
363 K in Toluene-d8 and 233 K to 363 K in DMF-d7 (233 K to 393 K for 93 and 88). Eyring 
equation (1) was applied to calculate inversion barriers.  
∆GC≠ = 4.575 x 10-3 TC[9.972 + log (TC/∆v)]             (1) 
Table 9. Inversion barriers of N-alkoxy and N-hydroxypiperidines. 
Entry Compound Inversion barrier (∆GC≠) in kcal.mol-1 















No coalescence below 
363 K 





















Figure 36. 1H NMR spectra (Toluene-d8) of 94 recorded at variable temperatures 
























Figure 37. 1H NMR spectra (DMF-d7) of 94 recorded at variable temperatures ranging 





















Figure 38. 1H NMR spectra (Toluene-d8) of 91 recorded at variable temperatures 






























Figure 39. 1H NMR spectra (DMF-d7) of 91 recorded at variable temperatures ranging 


























Figure 40. 1H NMR spectra (Toluene-d8) of 92 recorded at variable temperatures 










∆v = 266.12 Hz 
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Figure 41. 1H NMR spectra (DMF-d7) of 92 recorded at variable temperatures ranging 
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Figure 42. 1H NMR spectra (Toluene-d8) of 88 recorded at variable temperatures 
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Figure 43. 1H NMR spectra (DMF-d7) of 88 recorded at variable temperatures ranging 
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Figure 44. 1H NMR (500 MHz, DMF-d7, T = 393 K) spectrum of (88) 
 
 
Experimental section for chapter 4 
Synthesis of Kalkitoxin (107): 
(R)-4-Benzyl-3-(4-(benzyloxy)butanoyl)oxazolidin-2-one (121).  
Triethylamine (4.17 mL, 29.68 mmol) was added dropwise to a solution of acid 
119145 in ether (220 mL), and the mixture was stirred for 20 min at room temperature. The 
reaction flask was cooled in ice-bath and ethyl chloroformate (2.46 mL, 25.74 mmol) was 
added slowly. After stirring for 1 h at room temperature, the resulting suspension was 









was added dropwise to a solution of (4R)-benzyloxazolidinone (4.56 g, 25.74 mmol) in 
THF (40 mL) at −78 °C. The resulting mixture was stirred for 30 min and was transferred 
to a reaction flask containing acid 119 via cannula. After stirring for 1 h at −78 oC, the 
reaction was allowed to warm to room temperature in 2.5 h and quenched with  half-
saturated aq. NH4Cl (200 mL). The organic phase was separated, and the aqueous phase 
was extracted with ether. The combined organic phase was washed with brine, dried over 
anhydrous Na2SO4, and concentrated. Purification of the residue by flash column 
chromatography on silica gel (10 – 20% EtOAc in hexane) afforded 121169 (6.07 g, 67% 
yield) as a colorless oil. [α]20D –46.8 (c 1, CHCl3); lit169 [α]20D –42.8 (c 1, CHCl3); 1H NMR 
(400 MHz, CDCl3) δ 7.43 – 7.10 (m, 10H), 4.66 – 4.56 (m, 1H), 4.51 (s, 2H), 4.16 – 4.03 
(m, 2H), 3.59 (t, J = 6.2 Hz, 2H), 3.26 (dd, J = 13.4, 3.3 Hz, 1H), 3.07 (t, J = 7.2 Hz, 2H), 
2.70 (dd, J = 13.4, 9.6 Hz, 1H), 2.10 – 1.98 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 173.1, 
153.5, 138.5, 135.4, 129.4, 128.9, 128.4, 127.7, 127.6, 127.3, 72.9, 69.2, 66.1, 55.2, 37.9, 
32.5, 24.5. 
(R)-4-Benzyl-3-((R)-4-(benzyloxy)-2-methylbutanoyl)oxazolidin-2-one (122).  
To a stirred solution of 121 (12.46 g, 35.26 mmol) in dry THF (50 mL) was added 
NaHMDS (50 mL, 1 M in THF, 50.00 mmol) via cannula dropwise at −78 oC. The reaction 
mixture was stirred for 1 h at −78 oC and methyl iodide (10.97 mL, 176. 30 mmol) was 
added dropwise. After stirring for 3 h at −78 oC, the reaction was quenched with acetic 
acid (2.5 mL), and the resulting mixture was warmed to room temperature and extracted 
with EtOAc. The so-obtained organic extract was washed with brine, dried over 
anhydrous Na2SO4, and concentrated. Purification was performed via flash column 





84% yield, dr 95:5) as a colorless oil. [α]20D –61.6 (c 1, CHCl3); lit169 [α]20D –81.3 (c 1, 
CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.09 (m, 10H), 4.53 – 4.31 (m, 3H), 4.01 – 
3.86 (m, 2H), 3.73 (t, J = 8.4, 1H), 3.61 – 3.46 (m, 2H), 3.19 (dd, J = 13.4, 3.4 Hz, 1H), 
2.71 (dd, J = 13.4, 9.6 Hz, 1H), 2.25 – 2.18 (m, 1H), 1.82 – 1.67 (m, 1H), 1.25 (d, J = 6.9 
Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 177.1, 153.3, 138.5, 135.4, 129.4, 128.8, 128.3, 
127.6, 127.5, 127.2, 72.8, 68.5, 65.8, 55.2, 38.0, 35.1, 33.6, 18.1. 
(2R)-4-Benzyloxy-2-methylbutanol (123). 
To an ice-cold solution of 122 (10.50 g, 28.58 mmol) in anhydrous diethyl ether 
(275 mL) was added dry ethanol (2.5 mL, 42.86 mmol) and lithium borohydride (0.93 g, 
42.86 mmol) portion wise. After stirring for 2 h in ice-bath, the reaction was quenched by 
slow addition of 1 N NaOH (200 mL). The resulting mixture was stirred for 10 min at room 
temperature and was extracted with ether. The ether extract was washed with saturated 
aq. NH4Cl, water, and brine and dried over Na2SO4. After concentration, the resulting 
residue was purified by flash column chromatography (20 – 30% EtOAc in hexane) to 
afford the desired alcohol 12399 (4.99 g, 90% yield) as a colorless oil. [α]20D +10.5 (c 1, 
CHCl3); lit99 [α]20D +10.4 (c 7.5, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.45 – 7.18 (m, 5H), 
4.52 (s, 2H), 3.66 – 3.32 (m, 4H), 2.64 (br s, 1H), 1.86 – 1.75 (m, 1H), 1.75 – 1.64 (m, 
1H), 1.62 – 1.51  (m, 1H), 0.92 (d, J = 6.8 Hz, 3H); 13C NMR (101 MHz, CDCL3) δ 138.0, 
128.5, 127.8, 127.7, 73.2, 68.7, 68.1, 34.1, 34.0, 17.2. 
(2R)-4-Benzyloxy-1-bromo-2-methylbutane (113). 
To an ice-cold solution of 123 (5 g, 25.74 mmol) in dry dichloromethane was added 
CBr4 (8.95 g, 27.03 mmol) and PPh3 (7.06 g, 27.03 mmol). After stirring for 30 min in ice-





was dropped in the stirring hexane (50 mL). The resulting white suspension was filtered, 
and the resulting filtrate was concentrated. After purification of the resulting residue by 
flash column chromatography on silica gel (0 – 5% EtOAc in hexane), compound 11399 
(6.16 g, 93% yield) was isolated as a colorless oil. [α]20D –4.5 (c 1, CHCl3); lit99 [α]20D –4.7 
(c 0.32, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.43 – 7.21 (m, 5H), 4.51 (s, 2H), 3.56 – 
3.49 (m, 2H), 3.44 (dd, J = 9.9, 4.6 Hz, 1H), 3.37 (dd, J = 9.9, 5.8 Hz, 1H), 2.12 – 1.95 
(m, 1H), 1.87 – 1.72 (m, 1H), 1.64 – 1.47 (m, 1H), 1.04 (d, J = 6.7 Hz, 3H); 13C NMR (100 
MHz, CDCl3) δ 138.4, 128.4, 127.62, 127.60, 73.0, 67.8, 41.6, 34.6, 32.1, 18.7. 
(3’S,4S,5’S)-3-(7’-Benzyloxy-3’,5’-dimethylheptanoyl)-4-phenyloxazolidin-2-one 
(126). 
To a suspension of magnesium (2.25 g, 61.70 mmol) in dry THF (12 mL) was 
added a solution of 113 (2.66 g, 10.34 mmol) in dry THF (3 mL) at room temperature. A 
DIBAL solution (1.56 mL, 1 M in THF, 1.56 mmol) was added dropwise and stirred 
vigorously for 20 min. This solution was added to a chilled suspension of CuBr.DMS (2.04 
g, 10.34 mmol) in dry THF (12 mL) at −78 oC. The resulting suspension was warmed 
slowly to −20 oC, stirred for 25 min, and cooled back again to −78 oC. A solution of (S)-N-
(trans-crotonyl)-4-phenyloxazolidin-2-one 125 in dry THF (9 mL) was added dropwise, 
and the stirring was continued for 2.5 h at −78 oC. Then the reaction mixture was warmed 
slowly to −30 oC, quenched  with saturated aq. NH4Cl, and extracted with ether. This ether 
extract was washed with brine, dried over anhydrous Na2SO4, and concentration. 
Purification of the residual oil by flash column chromatography on silica gel (10 – 20% 
EtOAc in hexane) gave 12699 (1.19 g, 80% yield, dr 85:15) as a colorless oil. [α]20D +29.5 





7.44 – 7.22 (m, 10H), 5.42 (dd, J = 8.7, 3.6 Hz, 1H), 4.67 (t, J = 8.7 Hz, 1H), 4.48 (s, 2H), 
4.26 (dd, J = 9.0, 3.9 Hz, 1H), 3.46 (td, J = 6.7, 1.9 Hz, 2H), 2.92 (dd, J = 15.9, 5.4 Hz, 
1H), 2.72 (dd, J = 15.9, 8.1 Hz, 1H), 2.17 – 2.02 (m, 1H), 1.71 – 1.50 (m, 2H), 1.46 – 1.35 
(m, 1H), 1.18 (ddd, J = 13.5, 9.6, 4.5 Hz, 1H), 1.05 (ddd, J = 13.8, 9.3, 4.8 Hz, 1H), 0.84 
(d, J = 6.6 Hz, 3H), 0.81 (d, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 172.2, 153.7, 
139.2, 138.7, 129.1, 128.7, 128.4, 127.6, 127.5, 126.0, 72.9, 69.8, 68.5, 57.6, 44.3, 43.3, 
37.4, 27.11, 27.08, 19.2. 
(4S,2’S,3’S,5’S)-3-(7’-Benzyloxy-2’,3’,5’-trimethylheptanoyl)-4-phenyloxazolidin-2-
one (127) and (4S,2’R,3’S,5’S)-3-(7’-benzyloxy-2’,3’,5’-trimethylheptanoyl)-4-
phenyloxazolidin-2-one (128). 
To a solution of 126 (826 mg, 2.02 mmol) in dry THF (8 mL) was added NaHMDS 
(2.32 mL, 1 M in THF, 2.32 mmol) dropwise at −78 oC. The reaction mixture was stirred 
for 1 h at −78 oC and methyl iodide (0.63 mL, 10.10 mmol) was added dropwise. After 
stirring for 3 h at −78 oC, the reaction was quenched with saturated aq. NH4Cl, and the 
resulting mixture was warmed to room temperature and extracted with ether. The so-
obtained organic extract was dried over anhydrous Na2SO4, and concentrated. 
Purification was performed via flash column chromatography on silica gel (10 – 15% 
EtOAc in hexane) to isolate 12799 (529 mg, 62% yield) and 12899 (172 mg, 20% yield) as 
colorless oils. 
Data for diastereomer 127; [α]20D +50.2 (c 1.05, CHCl3); lit99 [α]20D +49.7 (c 1.65, 
CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.43 – 7.23 (m, 10H), 5.40 (dd, J = 8.4, 3.3 Hz, 1H), 
4.63 (t, J = 8.7 Hz, 1H), 4.50 (s, 2H), 4.22 (dd, J = 9.0, 3.3 Hz, 1H), 3.71 – 3.64 (m, 1H), 





(d, J = 6.9 Hz, 3H), 0.92 (d, J = 6.6 Hz, 3H), 0.83 (d, J = 6.6 Hz, 3H); 13C NMR (100 MHz, 
CDCl3) δ 176.3, 153.5, 139.4, 138.6, 129.2, 128.6, 128.4, 127.7, 127.5, 125.7, 73.0, 69.7, 
68.5, 57.8, 43.2, 39.7, 38.0, 32.8, 27.1, 19.0, 17.9, 13.7. 
Data for diastereomer 128; [α]20D -18.5 (c 1, CHCl3); lit99 [α]20D -20.6 (c 1.88, 
CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.45 – 7.23 (m, 10H), 5.45 (dd, J = 9.0, 4.5 Hz, 1H), 
4.67 (t, J = 9.0 Hz, 1H), 4.49 (s, 2H), 4.28 (dd, J = 9.0, 4.5 Hz, 1H), 3.70 – 3.62 (m, 1H), 
3.45 (t, J = 6.6 Hz, 2H), 1.97 – 1.85 (m, 1H), 1.65 – 1.44 (m, 2H), 1.42 – 1.32 (m, 1H), 
1.14 (ddd, J = 13.5, 10.5, 3.6 Hz, 1H), 1.03 (d, J = 6.9 Hz, 3H), 0.89 – 0.79 (m, 1H), 0.71 
(d, J = 6.3 Hz, 3H), 0.59 (d, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 176.6, 153.4, 
139.2, 138.7, 129.0, 128.7, 128.3, 127.6, 127.5, 126.4, 72.9, 69.5, 68.5, 57.7, 42.9, 42.5, 
37.7, 32.9, 27.2, 18.9, 14.3, 11.9. 
(4S,2’S,3’S,5’S)-3-(7’-Hydroxy-2’,3’,5’-trimethylheptanoyl)-4-phenyloxazolidin-2-
one (129). 
To a solution of 127 (1.85 g, 4.37 mmol) in EtOAc (30 mL) was added Pd(OH)2 on 
carbon (0.37 g). The resultant heterogeneous mixture was stirred under hydrogen 
atmosphere at 1 atm pressure for 3 h. Then the reaction mixture was filtered to discard 
catalyst, and the filtrate was concentrated to give 12999 (1.46 g, 100% yield) as a colorless 
oil. [α]20D +65.2 (c 1, CHCl3); lit99 [α]20D +68.6 (c 2.5, CHCl3); 1H NMR (400 MHz, CDCl3) 
δ 7.41 – 7.25 (m, 5H), 5.42 (dd, J = 8.4, 3.3 Hz, 1H), 4.66 (t, J = 8.7 Hz, 1H), 4.24 (dd, J 
= 9.0, 3.3 Hz, 1H), 3.74 – 3.61 (m, 3H), 1.93 – 1.81 (m, 1H), 1.70 – 1.57 (m, 1H), 1.56 – 
1.33 (m, 3H), 1.27 – 1.05 (m, 2H), 1.03 (d, J = 6.9 Hz, 3H), 0.92 (d, J = 6.6 Hz, 3H), 0.83 
(d, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 176.4, 153.5, 139.3, 129.2, 128.6, 







To a solution of oxalyl chloride (337 µL, 3.93 mmol) in dry dichloromethane (4 mL) 
was  added a solution of dry DMSO (361 µL, 5.08 mmol) in dry dichloromethane (4 mL) 
dropwise at −78 oC, and the resulting mixture was stirred for 15 min. A solution of 129 
(770 mg, 2.31 mmol) in dichloromethane (10 mL) was added dropwise followed by stirring 
for 15 min while maintaining the reaction temperature at −78 oC. A solution of 
triethylamine (1.45 mL, 10.40 mmol) in dry dichloromethane (5 mL) was added dropwise, 
and the reaction was stirred in ice-bath (<5 oC) for 50 min and quenched with saturated 
aq. NH4Cl. The resulting mixture was extracted with dichloromethane, and the 
dichloromethane extract was washed with brine, dried over anhydrous Na2SO4, and 
concentrated. After purification of the residual oil by flash column chromatography on 
silica gel (20 – 25% EtOAc in hexane), the desired aldehyde 13099 (686 mg, 90% yield) 
was isolated as a colorless oil. [α]20D +70.0 (c 0.45, CHCl3); lit99 [α]20D +69.3 (c 1, CHCl3); 
1H NMR (600 MHz, CDCl3) δ 9.73 (t, J = 2.2 Hz, 1H), 7.40 – 7.22 (m, 5H), 5.41 (dd, J = 
8.7, 3.3 Hz, 1H), 4.66 (t, J = 8.8 Hz, 1H), 4.24 (dd, J = 8.8, 3.6, 1.1 Hz, 1H), 3.70 – 3.63 
(m, 1H), 2.35 – 2.24 (m, 2H), 2.16 – 2.07 (m, 1H), 1.91 – 1.82 (m, 1H), 1.30 – 1.21 (m, 
1H), 1.09 (ddd, J = 13.8, 11.0, 3.6 Hz, 1H), 1.02 (d, J = 7.0 Hz, 3H), 0.94 (d, J = 6.7 Hz, 
3H), 0.88 (dd, J = 6.6 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 202.5, 176.1, 153.4, 139.2, 









To a stirred solution of 130 (686 mg, 2.07 mmol) in dry MeOH (16 mL) were added 
methylamine hydrochloride (280 mg, 4.14 mmol), methylamine solution (3.11 mL, 2 M in 
THF, 6.21 mmol), and anhydrous Na2SO4 at room temperature. After stirring for 20 min, 
NaCNBH3 (195 mg, 3.11 mmol) was added by cooling the reaction mixture in ice-bath. 
The resulting mixture was stirred for 1 h at room temperature and concentrated. The 
residual oil was dissolved in DMF (20 mL) and cooled in ice-bath. Then, (R)-methylbutyric 
acid (408 mg, 4.00 mmol), HOBt (688 mg, 80% in water, 4.00 mmol), EDCI.HCl (756 mg, 
4.00 mmol), and Hunig’s base (0.69 mL, 4.00 mmol) were added to this ice-cold solution 
one after the other, and the resulting mixture was stirred for 10 h at room temperature. 
The reaction was diluted with EtOAc, washed with 1 M HCl and brine, dried over 
anhydrous Na2SO4, and concentrated. Purification of the residual oil by flash column 
chromatography on silica gel (20 – 40% EtOAc in hexane) afforded a mixture of rotamers 
of compound 13399 (50% yield in two steps) as a colorless oil. [α]20D +43.1 (c 0.45, CHCl3); 
lit99 [α]20D +40.0 (c 0.5, CHCl3); 1H NMR (600 MHz, CDCl3), both rotamers, δ 7.39 – 7.25 
(m, 5H), 5.42 (dt, J = 8.6, 3.2 Hz, 1H), 4.66 (t, J = 8.8, 1H), 4.24 (td, J = 9.1, 3.5 Hz, 1H), 
3.72 – 3.63 (m, 1H), 3.43 – 3.20 (m, 2H), 2.99 (s, 3H, rotamer), 2.90 (s, 3H, rotamer), 
2.61 – 2.48 (m, 1H), 1.90 – 1.80 (m, 1H), 1.74 – 1.62 (m, 1H), 1.53 – 1.30 (m, 4H), 1.25 
– 1.05 (m, 5H), 1.05 – 0.99 (m, 3H), 0.92 – 0.81 (m, 9H); 13C NMR (150 MHz, CDCl3) , 
both rotamers, δ 176.5, 176.3, 176.2, 176.1, 153.5, 153.4 139.4, 139.2, 129.20, 129.15, 
128.7, 128.6, 125.7, 69.72, 69.68, 57.82, 57.79, 48.0, 46.1, 43.1, 39.81, 39.78, 37.43, 









To an ice-cold solution of 133 (442 mg, 1.03 mmol) in dry THF (11 mL) was added 
lithium borohydride (67 mg, 3.09 mmol) portion wise. Dry methanol (0.21 mL, 5.15 mmol)  
was added dropwise in 5 min, and the stirring was continued for next 40 min in ice-bath 
and 10 min at room temperature. The reaction was quenched with water after cooling the 
reaction mixture in ice-bath, and the resulting mixture was extracted with EtOAc. The so-
obtained organic extract was washed with brine, dried over Na2SO4, concentrated, and 
purified by flash column chromatography (10 – 50% EtOAc in hexane) to afford a mixture 
of rotamers of alcohol 13499 (247 mg, 89% yield) as a colorless oil. [α]20D –40.9 (c 0.55, 
CHCl3); lit99 [α]20D  –36.2 (c 0.5, CHCl3); 1H NMR (400 MHz, CDCl3) , both rotamers, δ 
3.64 – 3.55 (m, 1H), 3.50 – 3.21 (m, 3H), 3.00 (s, 3H, rotamer), 2.92 (s, 3H, rotamer), 
2.63 – 2.49 (m, 1H), 1.76 – 1.29 (m, 8H), 1.14 – 1.05 (m, 5H), 0.91 – 0.81 (m, 12H); 13C 
NMR (100 MHz, CDCl3) , both rotamers, δ 176.5, 176.2, 66.0, 65.9, 48.1, 46.3, 41.1, 41.0, 
40.1, 39.8, 37.4, 37.2, 35.32, 35.26, 33.7, 31.4, 31.2, 28.4, 28.2, 27.4, 27.0, 19.2, 19.0, 
17.8, 17.11, 17.06, 16.9, 13.3, 13.2, 12.2, 12.0. 
(2R,3’S,5’S,6’S)-2,N-Dimethyl-N-[8’-methoxy-3’,5’,6’-tri-methyloct-7-enyl]-
butyramide (135). 
To a solution of oxalyl chloride (131 µL, 1.50 mmol) in dry dichloromethane (1.5 
mL) was  added a solution of dry DMSO (142 µL, 2.00 mmol) in dry dichloromethane (1.5 





134 (272 mg, 1.00 mmol) in dichloromethane (3.5 mL) was added dropwise followed by 
stirring for 15 min while maintaining the reaction temperature at −78 oC. A solution of 
triethylamine (566 µL, 4.00 mmol) in dry dichloromethane (1.5 mL) was added dropwise, 
and the reaction was stirred in ice-bath (<5 oC) for 50 min and quenched with saturated 
aq. NH4Cl. The resulting mixture was extracted with dichloromethane, and the 
dichloromethane extract was washed with brine, dried over anhydrous Na2SO4, and 
concentrated to give a corresponding crude aldehyde intermediate. 
(Methoxymethyl)triphenylphosphonium chloride (1.72 g, 5.00 mmol) was dried 
under high vacuum at 60 oC for 3 h and cooled in argon atmosphere. Then, it was charged 
with dry THF (8 mL) and the resulting suspension was cooled in ice-bath. After adding n-
BuLi (1.8 mL, 2.5 M in hexane, 4.50 mmol) dropwise to this suspension, the mixture was 
stirred for 30 min at room temperature followed by cooling to –2.0 oC. A solution of above 
prepared crude aldehyde in dry THF (3.5 mL) was added dropwise, and the resulting 
mixture was stirred for 20 min at –2.0 oC and 1 h at room temperature. The reaction was 
quenched with MeOH (5 mL), diluted with ether, washed with saturated aq. NH4Cl and 
brine, dried over anhydrous Na2SO4, and concentrated. After purification of the residue 
by flash chromatography on silica gel (10 – 20% EtOAc in hexane), the desired alkene 
13599 (mixture of E and Z isomers, 215 mg, 72% yield in two steps ) was isolated as a 
yellow oil. [α]20D –20.88 (c 0.9, CHCl3); lit99 [α]20D  –20.04 (c 1.6, CHCl3); 1H NMR (400 
MHz, CDCl3) , both E/Z isomers and rotamers, δ 6.17 (dd, J = 12.6, 5.4 Hz, 1H), 5.82 (dd, 
J = 9.5, 6.3 Hz, 1H), 4.57 (dd, J = 12.6, 8.9 Hz, 1H), 4.15 (dd, J = 9.9, 6.3 Hz, 1H), 3.51 
(d, J = 3.8 Hz, 3H), 3.47 (d, J = 4.0 Hz, 3H), 3.39 – 3.18 (m, 4H), 2.98 (s, 6H, rotamer), 





– 1.20 (m, 10H), 1.16 – 0.98 (m, 10H), 0.97 – 0.80 (m, 18H), 0.79 – 0.70 (m, 6H); 13C 
NMR (100 MHz, CDCl3) , both E/Z isomers and rotamers, δ 176.5, 176.1, 146.7, 146.5, 
145.5, 145.4, 110.8, 110.3, 106.4, 106.1, 59.4, 55.93, 55.86, 48.1, 48.0, 46.2, 42.04, 
41.98, 37.8, 37.7, 37.3, 37.2, 37.1, 36.9, 35.51, 35.45, 35.3, 35.2, 33.64, 33.58, 33.4, 




To a stirred solution of 135 (180 mg, 0.61 mmol) in acetonitrile (6 mL) was added 
1 N HCl (6 mL) at room temperature, and the mixture was allowed to stir for 1 h . The 
reaction was diluted with ether, washed with brine, dried over anhydrous Na2SO4, and 
concentrated to give the crude aldehyde. To a solution of the so-obtained crude aldehyde 
in MeOH (20 mL) was added 2-methyl-2-butene (3.19 mL, 30.50 mmol) followed by a 
freshly prepared solution of NaClO2 (1.25 M in 20% NaH2PO4 solution, 2.4 mL, 3.05 
mmol) at room temperature. The resultant mixture was stirred vigorously for 1 h at room 
temperature, diluted with ether, washed with brine, dried over anhydrous Na2SO4, 
concentrated under reduced pressure, and purified by flash column chromatography on 
silica gel (0 – 5 % MeOH in 1:1 mixture of EtOAc and hexane) to afford 11199 (175 mg, 
97% yield) as a yellow oil. [α]20D –37.57 (c 0.7, CHCl3); lit99 [α]20D  –35.0 (c 0.4, CHCl3); 
1H NMR (600 MHz, CDCl3) , both rotamers, δ 3.38 (t, J = 7.5 Hz, 1H), 3.34 – 3.22 (m, 
1H), 3.00 (s, 3H, rotamer), 2.91 (s, 3H, rotamer), 2.61 – 2.50 (m, 1H), 2.34 (dd, J = 15.1, 
5.0 Hz, 1H), 2.08 (dt, J = 14.9, 9.6 Hz, 1H), 2.01 – 1.88 (m, 1H), 1.73 – 1.62 (m, 1H), 1.58 





(m, 3H); 13C NMR (150 MHz, CDCl3) , both rotamers, δ 178.73, 178.68, 176.7, 176.4, 
48.1, 46.2, 40.4, 40.2, 38.0, 37.9, 37.4, 37.2, 37.1, 35.3, 35.2, 35.0, 34.2, 33.8, 28.2, 27.4, 
27.0, 19.09, 19.06, 17.7, 17.0, 16.6, 16.5, 16.02, 16.00, 12.1, 12.0; ESIHRMS calculated 
for C17H34NO3 [M+H]+, 300.2539; found, 300.2537. 
N-((2R)-3-Butenol-2-yl)-[(3R,4S,6S)-trimethyl-8-((2R)-N-methyl-2-
methylbutyramido)]octanamide (136).  
To a mixture of 111 (175 mg, 0.58 mmol) and 112 (143 mg, 1.16 mmol) in dry 
CH2Cl2 (5 mL) were added DIPEA (303 μL, 1.74 mmol) and DMAP (35 mg, 0.29 mmol) 
at room temperature. After stirring for 10 min, EDCI.HCl (334 mg, 1.74 mmol) was added 
and stirring was continued for 14 h. The reaction was then diluted with water (5 mL), 
acidified with 1 M HCl (10 mL), and extracted with EtOAc. The so-obtained organic extract 
was washed with brine, dried over anhydrous Na2SO4, and concentrated. Purification of 
the residue by flash column chromatography on silica gel (0 – 5 % MeOH in CH2Cl2) 
afforded 136101 (210 mg, 98%) as a colorless oil:  [α]20D –10.9 (c 1, CHCl3); lit101 [α]20D  –
10.8 (c 0.8, CHCl3); 1H NMR (400 MHz, CDCl3) , both rotamers, δ 6.42 (d, J = 7.9 Hz, 1H, 
rotamer), 6.27 (d, J = 7.9 Hz, 1H, rotamer), 5.90 – 5.75 (m, 1H), 5.27 – 5.12 (m, 2H), 4.54 
(br s, 1H), 3.75 – 3.57 (m, 2H), 3.46 – 3.20 (m, 2H), 2.99 (s, 3H, rotamer), 2.90 (s, 3H, 
rotamer), 2.63 – 2.47 (m, 1H), 2.30 – 2.18 (m, 1H), 2.05 – 1.85 (m, 2H), 1.74 – 1.29 (m, 
6H), 1.19 – 0.99 (m, 5H), 0.91 – 0.74 (m, 12H); 13C NMR (100 MHz, CDCl3) , both 
rotamers, δ 176.7, 176.6, 173.4, 173.1, 135.5, 135.3, 116.5, 116.4, 65.0, 53.6, 53.5, 48.1, 
46.1, 40.6, 40.5, 40.4, 40.0, 37.4, 37.2, 37.1, 35.5, 35.4, 35.3, 35.0, 34.3, 34.1, 33.8, 28.2, 
28.1, 27.4, 27.0, 19.3, 19.2, 17.8, 17.1, 16.7, 16.5, 16.2, 15.8, 12.2, 12.0; ESIHRMS 







To a stirred solution of 136 (210 mg, 0.57 mmol) in dry CH2Cl2 (14 mL) was added 
DAST (150 μL, 1.14 mmol) at –78 oC. The reaction was quenched with saturated aq. 
NaHCO3 after stirring for 10 min and warmed to room temperature followed by extraction 
with CH2Cl2. The organic extract was dried over anhydrous Na2SO4, concentrated under 
reduced pressure, and purified by flash column chromatography on silica gel (50 – 75 % 
EtOAc in hexane) to give 137101 (185 mg, 92%) as a colorless oil. [α]20D +18.4 (c 1, 
CHCl3); lit101 [α]20D  +18.6 (c 0.76, CHCl3); 1H NMR (400 MHz, CDCl3) , both rotamers, δ 
5.78 (ddd, J = 17.2, 10.3, 6.9 Hz, 1H), 5.21 (d, J = 17.2 Hz, 1H), 5.11 (dd, J = 10.3, 3.5 
Hz, 1H), 4.60 – 4.50 (m, 1H), 4.37 – 4.25 (m, 1H), 3.89 (td, J = 8.1, 4.4 Hz, 1H), 3.41 – 
3.18 (m, 2H), 2.98 (s, 3H, rotamer), 2.89 (s, 3H, rotamer), 2.60 – 2.47 (m, 1H), 2.32 – 
2.20 (m, 1H), 2.10 – 1.99 (m, 1H), 1.95 – 1.81 (m, 1H), 1.75 – 1.59 (m, 1H), 1.58 – 1.27 
(m, 5H), 1.16 – 1.00 (m, 5H), 0.94 – 0.76 (m, 12H); 13C NMR (100 MHz, CDCl3) , both 
rotamers, δ 176.4, 176.1, 168.3, 168.2, 138.2, 138.2, 116.2, 116.1, 71.91, 71.87, 68.2, 
48.0, 46.1, 40.1, 37.3, 37.19, 37.16, 36.0, 35.8, 35.4, 35.2, 34.23, 34.15, 33.7, 31.83, 
31.77, 28.18, 28.15, 27.4, 27.0, 19.0, 17.8, 17.1, 16.31, 16.25, 16.03, 15.98, 12.2, 12.00; 
ESIHRMS calculated for C21H39N2O2 [M+H]+, 351.3012; found, 351.3017. 
N-((2R)-3-Butenol-2-yl)-[(3R,4S,6S)-trimethyl-8-((2R)-N-methyl-2-
methylbutyramido)]octanethioamide (138). 
Compound 137 (170 mg, 0.48 mmol) was dissolved in MeOH–Et3N (1:1, 14 mL, 
saturated with H2S), and stirred for 16 h at room temperature. The mixture was 





neutral alumina (10 – 35 % acetone in hexane) to afford 138101 (132 mg, 71%) as a 
colorless oil. [α]20D +7.6 (c 1, CHCl3); lit101 [α]20D  +9.6 (c 0.44, CHCl3); 1H NMR (400 MHz, 
CDCl3) , both rotamers, δ 8.20 (d, J = 6.6 Hz, 1H, rotamer ), 7.99 (d, J = 6.6 Hz, 1H, 
rotamer), 5.87 (ddd, J = 16.4, 10.5, 5.2 Hz, 1H), 5.41 – 5.20 (m, 3H), 3.93 – 3.73 (m, 2H), 
3.53 – 3.23 (m, 2H), 3.01 (s, 3H, rotamer), 2.91 (s, 3H, rotamer), 2.77 – 2.50 (m, 2H), 
2.44 – 2.30 (m, 1H), 2.30 – 2.19 (m, 1H), 1.75 – 1.31 (m, 6H), 1.19 – 1.00 (m, 5H), 0.93 
– 0.75 (m, 12H). 13C NMR (100 MHz, CDCl3) , both rotamers, δ 205.6, 205.4, 176.9, 
176.8, 133.7, 133.6, 117.5, 117.3, 63.9, 58.6, 58.5, 50.9, 50.7, 48.2, 46.0, 40.6, 39.6, 
38.6, 38.5, 37.4, 37.2, 36.9, 35.3, 34.8, 34.3, 33.9, 33.8, 28.2, 28.1, 27.4, 27.0, 19.4, 19.3, 
17.8, 17.0, 16.4, 16.2, 15.7, 12.1, 12.0; ESIHRMS calculated for C21H41N2O2S [M+H]+, 
385.2889; found, 385.2896. 
(+)-Kalkitoxin (107). 
To a stirred solution of 138 (128 mg, 0.33 mmol) in dry CH2Cl2 (8 mL) was added 
DAST (88 μL, 0.67 mmol) at –78 oC. The reaction was quenched with saturated aq. 
NaHCO3 after stirring for 10 min and warmed to room temperature followed by extraction 
with CH2Cl2. The organic extract was dried over anhydrous Na2SO4, concentrated under 
reduced pressure, and purified by flash column chromatography on neutral alumina (10 
– 30 % EtOAc in hexane) to give kalkitoxin 10795 (94 mg, 77%) as a colorless oil. [α]20D 
+9.1 (c 1, CHCl3); lit95 [α]20D  +16.0 (c 0.07, CHCl3); 1H NMR (400 MHz, CDCl3) , both 
rotamers, δ 5.92 (ddd, J = 17.1, 10.3, 6.7 Hz, 1H), 5.27 (dt, J = 17.1, 1.4 Hz, 1H), 5.20 – 
5.06 (m, 1H), 4.99 – 4.82 (m, 1H), 3.47 – 3.33 (m, 2H), 3.32 – 3.21 (m, 1H), 3.09 – 3.01 
(m, 1H), 2.99 (s, 3H, rotamer), 2.90 (s, 3H, rotamer), 2.62 – 2.46 (m, 2H), 2.37 – 2.24 (m, 





0.92 – 0.79 (m, 12H); 13C NMR (100 MHz, CDCl3) , both rotamers, δ 176.5, 176.1, 171.6, 
171.4, 137.3, 137.2, 116.1, 116.0, 78.57, 78.55, 48.0, 46.1, 40.0, 38.60, 38.57, 38.3, 38.2, 
37.41, 37.36, 37.21, 37.18, 35.4, 35.2, 34.2, 34.1, 33.7, 28.24, 28.22, 27.4, 27.0, 19.09, 
19.07, 17.7, 17.1, 16.20, 16.16, 16.00, 15.95, 12.1, 12.0; ESIHRMS calculated for 
C21H39N2OS [M+H]+, 367.2783; found, 367.2784. 
Synthesis of 9-oxa-10-azakalkitoxin (108): 
O-Benzoyl-N-methyl-N-(2-(1-methyl-3-phenyltriaz-2-en-1-yl)ethyl)hydroxylamine 
(146). 
To a stirred solution of N,N’-dimethylethylenediamine (1.32 g, 15 mmol) in water 
(100 mL) were sequentially added a solution of benzenediazonium tetrafluoroborate (0.96 
g, 5 mmol) in water (30 mL) dropwise in 20 min and  a KOH solution (2 M, 5 mL) dropwise 
in 10 min at room temperature. The reaction was stirred for 5 min and extracted with 
CH2Cl2. The organic extract was dried over Na2SO4 and concentrated under reduced 
pressure to afford crude intermediate. This crude intermediate was then dissolved in dry 
DMF (2 mL) and was added to a stirred suspension of K2HPO4 (1.31 g, 7.50 mmol) and 
benzoyl peroxide (2.66 g 50 % w/w blended with dicyclohexyl phthalate, 5.50 mmol) in 
dry DMF (10 mL) at room temperature. After stirring for 1.5 h, the resultant suspension 
was diluted with water (50 mL), stirred for 1 h, and extracted with EtOAc. The organic 
extract was then washed with saturated aq. NaHCO3, water, and brine, dried over 
anhydrous Na2SO4, and concentrated under reduced pressure. Purification of the residue 
by flash column chromatography on silica gel (10 – 40 % EtOAc in hexane) afforded 146 
(0.82 g, 53% in 2 steps) as a red oil. 1H NMR (400 MHz, CDCl3) δ 8.02 (d, J = 7.3 Hz, 





Hz, 1H), 4.00 (t, J = 6.2 Hz, 2H), 3.38 – 3.21 (m, 5H), 2.94 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 165.0, 150.7, 133.3, 129.5, 128.9, 128.8, 128.5, 125.5, 120.6, 58.9, 53.2, 47.4, 
35.8; ESIHRMS calculated for C17H20N4O2Na [M+Na]+, 335.1484; found, 335.1481. 
1-((Methyl(2-(1-methyl-3-phenyltriaz-2-en-1-yl)ethyl)amino)oxy)ethyl acetate (148). 
To a stirred solution of 146 (125 mg, 0.40 mmol) in dry CH2Cl2 (2.5 mL) were added 
sequentially, dropwise DIBAL (0.60 mL 1 M in hexane, 0.60 mmol), pyridine (97 μL, 1.20 
mmol), a solution of DMAP (97 mg, 0.80 mmol) in dry CH2Cl2 (1 mL), and Ac2O (227 μL, 
2.40 mmol) at –78 oC. The reaction mixture was stirred for 12 h (overnight) at –78 oC, 
warmed slowly to 0 oC in 2.5 h, and quenched by addition of saturated aq. NH4Cl (4 mL) 
and saturated aq. sodium potassium tartrate (3 mL) at 0 oC. The resultant mixture was 
warmed to room temperature, stirred vigorously for 1 h, and extracted with CH2Cl2. The 
organic extract was washed with brine, dried over anhydrous Na2SO4, and concentrated 
under reduced pressure. The so-obtained crude intermediate 147 was then forwarded to 
next reaction without further purification. 
To a stirred solution of the crude intermediate 147 in dry CH2Cl2 (2.5 mL) were 
added sequentially, dropwise DIBAL (0.60 mL 1 M in hexane, 0.60 mmol), pyridine (97 
μL, 1.20 mmol), a solution of DMAP (97 mg, 0.80 mmol) in dry CH2Cl2 (1 mL), and Ac2O 
(227 μL, 2.40 mmol) at –78 oC. The reaction mixture was stirred for 12 h (overnight) at –
78 oC, warmed slowly to 0 oC in 2.5 h, and quenched by addition of saturated aq. NH4Cl 
(4 mL) and saturated aq. sodium potassium tartrate (3 mL) at 0 oC. The resultant mixture 
was warmed to room temperature, stirred vigorously for 1 h, and extracted with CH2Cl2. 
The organic extract was washed with brine, dried over anhydrous Na2SO4, concentrated 





20 % EtOAc in hexane) to give 148 (91 mg, 78%, uncharacterized single diastereomer) 
as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 7.4 Hz, 2H), 7.33 (t, J = 7.7 Hz, 
2H), 7.14 (t, J = 7.2 Hz, 1H), 6.13 (q, J = 5.4 Hz, 1H), 3.94 (t, J = 6.3 Hz, 2H), 3.28 (br s, 
3H), 2.97 (t, J = 6.3 Hz, 2H), 2.68 (s, 3H), 2.06 (s, 3H), 1.36 (d, J = 5.4 Hz, 3H). 13C NMR 
(100 MHz, CDCl3) δ 170.1, 150.7, 128.8, 125.5, 120.6, 97.2, 58.9, 52.9, 47.0, 36.1, 21.4, 
19.1; ESIHRMS calculated for C14H22N4O3Na [M+Na]+, 317.1590; found, 317.1589.  
Benzyl (2-((benzoyloxy)(methyl)amino)ethyl)(methyl)carbamate (150). 
To a solution of N,N’-dimethylethylenediamine (4.77 mL, 45 mmol) in dry CH2Cl2 
(200 mL) was added a solution of benzyl chloroformate (2.14 mL, 15 mmol) in dry CH2Cl2 
(20 mL) in 1 h at 0 oC. The mixture was stirred for 3 h at 0 oC followed by 2 h at room 
temperature. The reaction was quenched by water (200 mL), and the volatile portion was 
evaporated under reduced pressure. The aqueous residue was acidified to pH 1 by 
adding 2 M HCl, and the nonpolar impurities were washed out with CH2Cl2. Then the 
aqueous phase was basified to pH 9 by adding 10% aq. NaOH and extracted with ether. 
The ether extract was dried over anhydrous Na2SO4 and concentrated under reduced 
pressure. The so-obtained intermediate was then dissolved in dry DMF (17 mL). To this 
solution were added K2HPO4 (1.79 g, 10.32 mmol) and benzoyl peroxide (3.34 g 50 % 
w/w blended with dicyclohexyl phthalate, 6.88 mmol) at room temperature. After stirring 
for 24 h, the resultant suspension was diluted with water (50 mL), stirred for 1 h, and 
extracted with EtOAc. The organic extract was washed with saturated aq. NaHCO3, water, 
and brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. 
Purification of the residue by flash column chromatography on silica gel (10 – 50 % EtOAc 





CDCl3), both rotamers, δ 8.18 – 7.89 (m, 2H), 7.56 (t, J = 7.4 Hz, 1H), 7.49 – 7.16 (m, 
7H), 5.09 (s, 2H), 3.52 (t, J = 6.6 Hz, 2H), 3.20 (t, J = 6.1 Hz, 2H, 1 rotamer), 3.12 (t, J = 
6.6 Hz, 2H, 1 rotamer), 2.97 (s, 3H), 2.94 – 2.86 (m, 3H); 13C NMR (100 MHz, CDCl3), 
both rotamers, δ 165.1, 165.0, 156.3, 156.0, 136.7, 133.2, 130.0, 129.4, 128.5, 128.4, 
128.3, 127.93, 127.87, 127.79, 67.2, 67.1, 58.8, 58.7, 47.4, 47.2, 46.5, 35.5; ESIHRMS 
calculated for C19H22N2O4Na [M+Na]+, 365.1477; found, 365.1478. 
Benzyl (2-(hydroxy(methyl)amino)ethyl)(methyl)carbamate (151).  
To a stirred solution of 150 (500 mg, 1.46 mmol) in dry CH2Cl2 (9 mL) was added 
DIBAL (2.92 mL 1 M in hexane, 2.92 mmol) in 20 min at –78 oC. The reaction was stirred 
for 20 min at –78 oC and quenched by addition of saturated aq. NH4Cl (15 mL) and 
saturated aq. sodium potassium tartrate (10 mL). The resultant mixture was warmed to 
room temperature, stirred vigorously for 1 h, and extracted with ether. The organic extract 
was dried over anhydrous Na2SO4, concentrated under reduced pressure, and purified 
by flash column chromatography on silica gel (50 – 100 % EtOAc in hexane) to give 151 
(180 mg, 52%) as a colorless oil: 1H NMR (400 MHz, CDCl3), both rotamers, δ 7.49 – 
7.19 (m, 5H), 5.14 (s, 2H), 3.48 (br s, 2H), 2.93 (s, 3H), 2.80 – 2.48 (m, 5H); 13C NMR 
(100 MHz, CDCl3) both rotamers, δ 157.8, 136.7, 128.5, 128.0, 127.7, 67.4, 67.2, 59.4, 
58.8, 48.8, 47.9, 46.8, 46.5, 35.1, 34.2; ESIHRMS calculated for C12H19N2O3 [M+H]+, 
239.1396; found, 239.1398. 
Alternative synthesis by transesterification: A solution of 150 (1.30 g, 3.80 mmol) 
in dry MeOH (15 mL) was treated with NaOMe (47 mg, 0.95 mmol) for 2 h at room 
temperature. The reaction was quenched by stirring with Amberlyst® 15 hydrogen form 





concentrated under reduced pressure, and purified by flash column chromatography on 
silica gel (50 – 100 % EtOAc in hexane) to give 151 (0.83 g, 92%) as a colorless oil. The 
spectral data were identical with above sample. 
(R)-4-(tert-Butyldimethylsilyloxy)-2-methylbutanoic acid (153). 
To an ice-cold solution (<5 oC) of 152148 (300 mg, 0.77 mmol) in THF-H2O (1:1, 4 
mL) were added LiOH.H2O (64 mg, 1.54 mmol) and H2O2 (0.34 mL, 30 wt% in water, 3.06 
mmol). After stirring for 3 h in ice-bath (<5 oC), the reaction was quenched with Na2SO3 
(6 mL 1.5 M in water, 8.58 mmol). The resultant mixture was diluted with water, and 
nonpolar impurities were washed out with CH2Cl2. The aqueous layer was acidified to pH 
6-7 by addition of 1 M HCl, saturated with NaCl, and extracted with ether. The ether 
extract was dried over anhydrous Na2SO4 and concentrated under reduced pressure to 
give the desired acid 153148 (168 mg, 94%) as a colorless oil: [α]20D –13.21 (c 8.25, EtOH); 
lit148 [α]20D +13.51 (c 1.8, EtOH) and –14.06 for (S)-enantiomer of 153; 1H NMR (400 MHz, 
CDCl3) δ 3.72 – 3.61 (m, 2H), 2.63 (td, J = 7.5, 6.0 Hz, 1H), 2.03 – 1.85 (m, 1H), 1.68 – 
1.53 (m, 1H), 1.20 (d, J = 7.1 Hz, 3H), 0.88 (s, 9H), 0.04 (s, 6H); 13C NMR (100 MHz, 
CDCl3) δ 183.1, 60.7, 36.2, 36.0, 25.7, 18.3, 16.9, -5.5. 
Benzyl (R)-(3,6,10,10,11,11-hexamethyl-5-oxo-4,9-dioxa-3-aza-10-
siladodecyl)(methyl)carbamate (154). 
To an ice-cold solution of hydroxylamine 151 (142 mg, 0.59 mmol) and  acid 153 
(125 mg, 0.54 mmol) in dry CH2Cl2 (3.5 mL) were added HOBt (136 mg wetted with 20 
wt% water, 0.81 mmol), EDCI.HCl (155 mg, 0.81 mmol), and DIPEA (141 μL, 0.81 mmol), 
and the resultant mixture was stirred for 4 h at room temperature. The mixture was 





reduced pressure, and purified by flash column chromatography on silica gel (20 – 30 % 
EtOAc in hexane) to give 154 (187 mg, 77%) as a colorless oil: [α]20D –12.4 (c 6.5, CHCl3); 
1H NMR (400 MHz, CDCl3), both rotamers, δ 7.43 – 7.14 (m, 5H), 5.10 (s, 2H), 3.71 – 
3.50 (m, 2H), 3.50 – 3.35 (m, 2H), 3.03 (t, J = 6.3 Hz, 1H), 2.99 – 2.91 (m, 4H), 2.79 – 
2.70 (m, 3H), 2.67 – 2.52 (m, 1H), 1.99 – 1.80 (m, 1H), 1.65 – 1.50 (m, 1H), 1.26 – 1.06 
(m, 3H), 0.87 (s, 9H), 0.02 (s, 6H); 13C NMR (101 MHz, CDCl3), both rotamers, δ 174.9, 
174.8, 156.2, 156.0, 136.7, 128.4, 127.9, 127.8, 67.2, 67.0, 60.5, 58.6, 58.5, 47.1, 46.8, 
46.4, 36.2, 35.5, 35.3, 34.8, 25.9, 18.3, 17.2, 17.1, -5.4; ESIHRMS calculated for 
C23H41N2O5Si [M+H]+, 453.2785; found, 453.2780.   
(10R)-4,7,10,14,14,15,15-Heptamethyl-3-oxo-1-phenyl-2,8,13-trioxa-4,7-diaza-14-
silahexadecan-9-yl acetate (155). 
To a chilled solution of 154 (130 mg, 0.29 mmol) at –78 oC in dry CH2Cl2 (2 mL) 
were added sequentially, dropwise DIBAL (0.50 mL1 M in hexane, 0.50 mmol), pyridine 
(70 μL, 0.87 mmol), a solution of DMAP (71 mg, 0.58 mmol) in dry CH2Cl2 (0.8 mL), and 
Ac2O (164 μL, 1.74 mmol). The reaction mixture was stirred for 12 h (overnight) at –78 
oC, warmed slowly to 0 oC in 2.5 h, and quenched by addition of saturated aq. NH4Cl (3 
mL) and saturated aq. sodium potassium tartrate (2.5 mL) at 0 oC. The resultant mixture 
was warmed to room temperature, stirred vigorously for 1 h, and extracted with CH2Cl2. 
The organic extract was washed with brine, dried over anhydrous Na2SO4, concentrated 
under reduced pressure, and purified by flash column chromatography on silica gel (20 – 
25 % EtOAc in hexane) to give 155 (86 mg, 60%, uncharacterized single diastereomer) 
as a colorless oil. [α]20D +2.7 (c 1.5, CHCl3); 1H NMR (400 MHz, CDCl3), rotamers, δ 7.41 





2H), 2.95 (s, 3H), 2.91 – 2.72 (m, 2H), 2.66 – 2.53 (m, 3H), 2.11 – 1.99 (m, 3H), 1.91 (br 
s, 1H), 1.72 (br s, 1H), 1.37 – 1.21 (m, 1H), 0.97 – 0.85 (m, 12H), 0.04 (s, 6H); 13C NMR 
(100 MHz, CDCl3), rotamers, δ 170.3, 156.2, 156.1, 136.8, 128.4, 127.9, 127.8, 101.1, 
67.04, 67.01, 60.9, 60.82, 60.76, 60.70, 58.6, 58.3, 46.8, 46.4, 35.3, 34.8, 34.3, 33.82, 
33.77, 33.2, 33.0, 25.92, 25.91, 21.3, 18.29, 18.26, 14.3, 14.2, 13.8, 13.7, -5.3, -5.4; 
ESIHRMS calculated for C25H44N2O6SiNa [M+Na]+, 519.2866; found, 519.2852.   
Benzyl ((6R)-3,5,6,10,10,11,11-heptamethyl-4,9-dioxa-3-aza-10-
siladodecyl)(methyl)carbamate (156) and benzyl methyl(2-(methyl(((3R)-3-
methyltetrahydrofuran-2-yl)oxy)amino)ethyl)carbamate (157). 
To a stirred solution of 155 (50 mg, 0.10 mmol) in dry CH2Cl2 (2 mL) were added 
Me2Zn (0.25 mL 1 M in heptane, 0.25 mmol) and BF3.OEt2 (31 μL, 0.25 mmol) one after 
the other at –78 oC. The reaction mixture was warmed slowly to 0 oC in 2.5 h, quenched 
by slow addition of saturated aq. NaHCO3, and extracted with ether. The organic extract 
was dried over anhydrous Na2SO4, concentrated under reduced pressure, and purified 
by flash column chromatography on silica gel (10 – 40 % EtOAc in hexane) to give desired 
product 156 (12 mg, 27%, dr 63:37) as a colorless oil along with 157 (16 mg, 50%, dr 4:1) 
as a colorless oil.  
Data for 156: [α]20D +3.3 (c 0.6, CHCl3); 1H NMR (500 MHz, toluene-d8, T = 353 K), 
both diastereomers, δ 7.25 (d, J = 7.4 Hz, 2H), 7.13 (t, J = 7.4 Hz, 2H), 7.08 – 7.04 (m, 
1H), 5.09 (s, 2H), 3.75 – 3.53 (m, 3H), 3.35 (br s, 2H), 2.82 – 2.69 (m, 5H), 2.41 (s, 3H), 
1.87 – 1.79 (m, 1H), 1.40 – 1.26 (m, 2H), 1.09 (d, J = 6.2 Hz, 1.9H), 1.06 (d, J = 6.2 Hz, 
1.1H), 0.96 (s, 9H), 0.92 – 0.88 (m, J = 6.8, 3.5 Hz, 3H), 0.08 (s, 6H). 13C NMR (150 MHz, 





67.0, 66.9, 61.6, 61.5, 60.0, 58.7, 58.3, 46.9, 46.5, 46.3, 36.24, 36.17, 35.2, 34.7, 34.6, 
33.1, 26.0, 25.9, 18.33, 18.29, 15.5, 15.4, 14.8, 14.3, -5.29, -5.32, -5.34; ESIHRMS 
calculated for C24H44N2O4SiNa [M+Na]+, 475.2968; found, 475.2975.   
Data for 157: [α]20D +60.6 (c 0.8, CHCl3); 1H NMR (500 MHz, toluene-d8, T = 263 
K) δ 7.21 (d, J = 7.0 Hz, 2H), 7.13 – 7.00 (m, 3H), 5.13 (d, J = 4.8 Hz, 0.8H), 5.06 (s, 2H), 
5.00 (br s, 0.2H), 3.83 (dt, J = 8.7, 3.0 Hz, 0.8H), 3.78 – 3.67 (m, 0.4H), 3.64 – 3.56 (m, 
0.8H), 3.49 (br s, 1H), 3.37 – 3.26 (m, 1H), 2.80 (s, 3H), 2.75 – 2.65 (m, 2H), 2.53 – 2.45 
(m, 3H), 1.88 – 1.76 (m, 1H), 1.69 – 1.56 (m, 1H), 1.50 – 1.38 (m, 1H), 0.95 (d, J = 6.7 
Hz, 2.4H), 0.85 (d, J = 7.0 Hz, 0.6H); 13C NMR (100 MHz, CDCl3) δ 156.3, 136.9, 128.4, 
127.9, 127.8, 106.9, 67.1, 66.9, 66.8, 66.7, 58.8, 58.6, 47.4, 46.7, 46.4, 38.2, 37.9, 37.8, 
35.2, 34.7, 32.4, 31.2, 29.7, 12.9, 12.8; ESIHRMS calculated for C17H26N2O4Na [M+Na]+, 
345.1790; found, 345.1792.     
(S)-4-Benzyl-3-((R,E)-2-methyl-5-phenylpent-4-enoyl)oxazolidin-2-one (159). 
To a stirred solution of diisopropylamine (5.09 mL, 36.31 mmol) in dry THF (42 mL) 
was added n-BuLi (13.20 mLof 2.5 M solution in hexane, 33.01 mmol) dropwise in 10 min 
at –78 oC. The resultant mixture was stirred in ice-bath (<5 oC) for 20 min and chilled back 
to –78 oC. A solution of 158 (7.00 g, 30.01 mmol) in dry THF (42 mL) was added dropwise 
(40 min) and allowed to stir for additional 30 min at –78 oC. Then a solution of cinnamyl 
bromide (8.87 g, 45.01 mmol) in dry THF (10 mL) was added dropwise (15 min). Stirring 
was continued for additional 90 min at –78 oC followed by gradually warming to 0 oC in 
2.5 h. The reaction was quenched by saturated aq. NH4Cl solution (50 mL), and the 
volatile components were evaporated under reduced pressure. The residue was 





and concentrated under reduced pressure. Purification was performed by flash column 
chromatography on silica gel to afford 159170 (7.52 g, 72%, dr 95:5) as a white solid 
(eluent: 0 – 25% EtOAc in hexane): Mp. 89-91 oC; [α]20D +10.8 (c 1, CHCl3); 1H NMR (400 
MHz, CDCl3) δ 7.46 – 7.13 (m, 10H), 6.47 (d, J = 15.8 Hz, 1H), 6.25 (dt, J = 15.8, 7.0 Hz, 
1H), 4.78 –  4.60 (m, 1H), 4.18 (t, J = 9.0 Hz, 1H), 4.12 (dd, J = 9.0, 2.9 Hz, 1H), 4.03 – 
3.91  (m, 1H), 3.26 (dd, J = 13.4, 3.1 Hz, 1H), 2.73 – 2.64 (m, 1H), 2.62 (dd, J = 13.4, 9.8 
Hz, 1H), 2.46 – 2.35 (m, 1H), 1.24 (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 
176.6, 153.2, 137.3, 135.3, 132.5, 129.3, 128.9, 128.5, 127.3, 127.2, 127.0, 126.1, 66.0, 
55.3, 38.0, 37.7, 37.5, 16.6; ESIHRMS calculated for C22H24NO3 [M+H]+, 350.1756; 
found, 350.1755. 
(R,E)-2-Methyl-5-phenylpent-4-enoic acid (160). 
To an ice-cold solution (<5 oC) of 159 (1g, 2.86 mmol) in THF-H2O (4:1, 10 mL) 
were added LiOH.H2O (0.48 g, 11.44 mmol) and H2O2 (0.6 mL, 30 wt% in water, 5.72 
mmol). After stirring for 1.5 h in ice-bath (<5 oC), the reaction was quenched with Na2SO3 
(17 mL 1M in water, 8.58 mmol). The resultant mixture was diluted with water, and 
nonpolar impurities were washed out with CH2Cl2. The aqueous layer was acidified to pH 
2 by addition of 2 M HCl, saturated with NaCl, and extracted with ether. The ether extract 
was dried over anhydrous Na2SO4 and concentrated under reduced pressure to give the 
desired acid 160149 (0.37 g, 68%) as a colorless oil: [α]20D –18.0 (c 1, EtOH); lit149 [α]20D –
20.3 (c 1.04, EtOH)  1H NMR (400 MHz, CDCl3) δ 11.27 (br s, 1H), 7.53 – 7.11 (m, 5H), 
6.47 (d, J = 15.7 Hz, 1H), 6.19 (dt, J = 15.7, 7.0 Hz, 1H), 2.75 – 2.50 (m, 2H), 2.44 – 2.33 
(m, 1H), 1.26 (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 182.7, 137.3, 132.4, 







To an ice-cold solution of hydroxylamine 151 (695 mg, 2.92 mmol) and acid 160 
(370 mg, 1.94 mmol) in dry CH2Cl2 (12 mL) were added HOBt (491 mg wetted with 20 
wt% water, 2.92 mmol), EDCI.HCl (559 mg, 2.92 mmol), and DIPEA (510 μL, 2.91 mmol), 
and the resultant mixture was stirred for 5 h at room temperature. The mixture was 
washed with water followed by brine, dried over anhydrous Na2SO4, concentrated under 
reduced pressure, and purified by flash column chromatography on silica gel (20 – 50 % 
EtOAc in hexane) to give 161 (497 mg, 62%) as a colorless oil. [α]20D –15.0 (c 2.5, CHCl3); 
1H NMR (400 MHz, CDCl3), both rotamers, δ 7.40 – 7.16 (m, 10H), 6.41 (t, J = 14.6 Hz, 
1H), 6.22 – 6.03 (m, 1H), 5.10 (s, 2H), 3.43 – 3.31  (m, 2H), 3.01 (t, J = 5.4 Hz, 1H), 2.92 
(t, J = 6.9 Hz, 1H), 2.87 (s, 3H), 2.76 – 2.68 (m, 3H), 2.65 – 2.44 (m, 2H), 2.41 – 2.26 (m, 
1H), 1.27 – 1.14 (m, 3H); 13C NMR (100 MHz, CDCl3), both rotamers, δ 174.34, 174.27, 
156.2, 155.9, 137.1, 136.8, 132.5, 132.4, 128.50, 128.45, 127.9, 127.8, 127.3, 127.2, 
126.7, 126.6, 126.0, 67.1, 67.0, 58.5, 58.4, 47.2, 46.9, 46.4, 38.7, 37.1, 35.4, 35.2, 16.9; 
ESIHRMS calculated for C24H31N2O4 [M+H]+, 411.2284; found, 411.2279.   
(10R,E)-4,7,10-Trimethyl-3-oxo-1,13-diphenyl-2,8-dioxa-4,7-diazatridec-12-en-9-yl 
acetate (162). 
To a chilled solution of 161 (300 mg, 0.73 mmol) at –78 oC in dry CH2Cl2 (4.5 mL) 
were added sequentially, dropwise DIBAL (1.46 mL1 M in hexane, 0.1.46 mmol), pyridine 
(176 μL, 2.19 mmol), a solution of DMAP (178 mg, 1.46 mmol) in dry CH2Cl2 (2 mL), and 
Ac2O (414 μL, 4.38 mmol). The reaction mixture was stirred for 12 h (overnight) at –78 





mL) and saturated aq. sodium potassium tartrate (5 mL) at 0 oC. The resultant mixture 
was warmed to room temperature, stirred vigorously for 1 h, and extracted with CH2Cl2. 
The organic extract was washed with brine, dried over anhydrous Na2SO4, concentrated 
under reduced pressure, and purified by flash column chromatography on silica gel (20 – 
30 % EtOAc in hexane) to give 162 (133 mg, 40%) as a colorless oil. [α]20D +5.8 (c 2.5, 
CHCl3); 1H NMR (400 MHz, CDCl3), both rotamers δ 7.42 – 7.10 (m, 10H), 6.46 – 6.31 
(m, 1H), 6.24 – 6.05 (m, 1H), 6.04 – 5.90 (m, 1H), 5.13 (s, 2H), 3.47 (t, J = 7.0 Hz, 2H), 
2.95 (s, 3H), 2.92 – 2.75 (m, 2H), 2.71 – 2.56 (m, 3H), 2.52 – 2.19 (m, 1H), 2.17 – 1.82 
(m, 5H), 1.04 – 0.91 (m, 3H); 13C NMR (100 MHz, CDCl3), both rotamers, δ 170.3, 156.2, 
156.1, 137.5, 136.8, 131.7, 131.6, 128.49, 128.45, 128.2, 128.1, 127.9, 127.8, 127.0, 
126.0, 100.7, 67.1, 67.0, 58.6, 58.3, 46.8, 46.4, 36.8, 36.6, 35.3, 34.8, 34.6, 21.3, 14.2, 
13.8; ESIHRMS calculated for C26H34N2O5Na [M+Na]+, 477.2365; found, 477.2363.   
Benzyl methyl(2-(methyl(((3R,E)-3-methyl-6-phenylhex-5-en-2-
yl)oxy)amino)ethyl)carbamate (163). 
To a stirred solution of 162 (50 mg, 0.11 mmol) in dry CH2Cl2 (2 mL) were added 
Me2Zn (0.23 mL 1.2 M in toluene, 0.28 mmol) and BF3.OEt2 (34 μL, 0.28 mmol) one after 
the other at –78 oC. The reaction mixture was warmed slowly to 0 oC in 2.5 h, quenched 
by slow addition of saturated aq. NaHCO3, and extracted with CH2Cl2. The organic extract 
was dried over anhydrous Na2SO4, concentrated under reduced pressure, and purified 
by flash column chromatography on silica gel (10 – 20 % EtOAc in hexane) to give desired 
product 163 (28 mg, 62%, dr 55:45) as a colorless oil. [α]20D –6.4 (c 1.4, CHCl3); 1H NMR 
(500 MHz, toluene-d8, T = 363 K) δ 7.31 – 6.92 (m, 10H), 6.37 (d, J = 11.6 Hz, 0.45H), 





– 3.29 (m, 2H), 2.83 – 2.68 (m, 5H), 2.47 – 2.36 (m, 3.45H), 2.35 – 2.24 (m, 0.55H), 2.04 
– 1.93 (m, 1H), 1.88 – 1.79 (m, 0.45H), 1.79 – 1.67 (m, 0.55H), 1.11 (d, J = 6.3 Hz, 1.65H), 
1.09 (d, J = 6.3 Hz, 1.35H), 0.95 – 0.88 (m, J = 7.4 Hz, 3H); 13C NMR (100 MHz, CDCl3), 
rotamers and diastereomers, δ 156.2, 137.8, 136.9, 131.0, 129.8, 129.6, 129.5, 128.5, 
128.4, 127.9, 127.8, 126.9, 125.9, 80.2, 80.0, 67.04, 66.98, 58.7, 58.4, 46.9, 46.5, 46.3, 
37.1, 36.9, 36.8, 35.5, 35.2, 34.7, 15.8, 15.3, 15.2, 14.4; ESIHRMS calculated for 
C25H34N2O3Na [M+Na]+, 433.2467; found, 433.2460.   
O-((2S,3R,4S,5R)-5-(Benzyloxy)-1,2-bis((tert-butyldimethylsilyl)oxy)-4-
methylhexan-3-yl) 1H-imidazole-1-carbothioate (169). 
A mixture of 167151 (1.72 g, 3.56 mmol) and 1,1’-thiocarbonyldiimidazole (3.50 g, 
19.66 mmol) was stirred in dry THF (8.5 mL) at 60 oC. After 5 h, additional 1,1’-
thiocarbonyldiimidazole (1.50 g, 8.43 mmol) was added, and the resultant mixture was 
allowed to stir for 15 h. The mixture was then cooled to room temperature, concentrated 
under reduced pressure, and purified by flash column chromatography on silica gel (5 – 
15 % EtOAc in hexane) to give 169 (1.80 g, 85%) as a colorless oil. [α]20D +2.5 (c 1, 
CHCl3); 1H NMR (600 MHz, CDCl3) δ 8.26 (s, 1H), 7.54 (s, 1H), 7.27 – 7.18 (m, 5H), 6.97 
(s, 1H), 5.96 (dd, J = 3.9, 3.1 Hz 1H), 4.53 (d, J = 11.6 Hz, 1H), 4.32 (d, J = 11.6 Hz, 1H), 
4.14 (td, J = 6.4, 3.9 Hz, 1H), 3.66 (dd, J = 10.5, 6.4 Hz, 1H), 3.60 – 3.52 (m, 2H), 2.35 – 
2.27 (m, 1H), 1.19 (d, J = 6.2 Hz, 3H), 1.17 (d, J = 7.0 Hz, 3H), 0.86 (s, 9H), 0.84 (s, 9H), 
0.02 (s, 3H), 0.01 (s, 3H), 0.00 (s, 3H), -0.06 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 183.8, 
138.6, 136.8, 130.5, 128.1, 127.3, 127.2, 117.8, 85.5, 77.2, 73.4, 70.6, 64.9, 38.3, 25.9, 
25.7, 18.3, 17.9, 16.7, 10.6, -4.5, -5.1, -5.5, -5.6; ESIHRMS calculated for C30H53N2O4SSi2 






A degassed solution of 169 (1.78 g, 3.00 mmol), Bu3SnH (2.42 mL, 9.00 mmol), 
and AIBN (49 mg, 0.3 mmol) in dry toluene (75 mL) was stirred for 2.5 h at 85 oC. The 
reaction was cooled to room temperature, concentrated under reduced pressure, and 
eluted through a short column of silica gel (5% EtOAc in hexane). The so-obtained 
intermediate (impure) was stirred with a mixture of 10% Pd/C and Pd(OH)2 (1:1, 1.6 g) in 
THF–isopropanol (3:1, 60 mL) under hydrogen gas atmosphere (1 atm) for 18 h. After 
filtering through a pad of Celite®, the resulting filtrate was concentrated and purified by 
flash column chromatography on silica gel (5 – 10% EtOAc in hexane) to afford 170 (0.57 
g, 50% in 2 steps) as a colorless oil. [α]20D +30.9 (c 1, CHCl3); 1H NMR (600 MHz, CDCl3) 
δ 3.76 – 3.65 (m, 2H), 3.55 (dd, J = 9.9, 5.2 Hz, 1H), 3.36 (dd, J = 9.9, 6.8 Hz, 1H), 1.77 
– 1.68 (m, 1H), 1.55 (d, J = 4.4 Hz, 1H), 1.47 (ddd, J = 13.6, 8.9, 3.8 Hz, 1H), 1.40 – 1.33 
(ddd, J = 13.6, 9.4, 3.2 Hz, 1H), 1.12 (d, J = 6.4 Hz, 3H), 0.89 – 0.87 (m, 12H), 0.86 (s, 
9H), 0.06 (s, 3H), 0.05 (s, 3H), 0.04 (s, 3H), 0.03 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 
71.8, 71.4, 67.9, 37.4, 35.6, 25.9, 25.9, 19.8, 18.3, 18.1, 14.6, -4.0, -4.8, -5.3, -5.4; 
ESIHRMS calculated for C19H45O3Si2 [M+H]+, 377.2907; found, 377.2906.   
(2S,3R,5R)-5,6-Bis((tert-butyldimethylsilyl)oxy)-3-methylhexan-2-yl 4-
nitrobenzoate (171). 
To a stirred solution of 170 (350 mg, 0.93 mmol), p-nitrobenzoic acid (187 mg, 1.12 
mmol), and PPh3 (294 mg, 1.12 mmol) in dry THF (4.5 mL) was added a solution of DIAD 
(227 mg, 1.12 mmol) in dry THF (0.9 mL) at 0 oC. The resultant mixture was stirred for 3 
h at room temperature and concentrated under reduced pressure. The residue was 





171 (450 mg, 92%) as a yellow oil. [α]20D +37.8 (c 1, CHCl3); 1H NMR (400 MHz, CDCl3) 
δ 8.27 (d, J = 8.8 Hz, 2H), 8.19 (d, J = 8.8 Hz, 2H), 5.18 – 5.00 (m, 1H), 3.80 – 3.68 (m, 
1H), 3.57 (dd, J = 9.9, 5.1 Hz, 1H), 3.37 (dd, J = 9.9, 6.9 Hz, 1H), 2.12 – 1.96 (m, 1H), 
1.62 – 1.51 (m, 1H), 1.47 – 1.38 (m, 1H), 1.32 (d, J = 6.4 Hz, 3H), 0.99 (d, J = 6.8 Hz, 
3H), 0.89 (s, 9H), 0.88 (s, 9H), 0.09 – 0.06 (m, 6H), 0.05 (s, 3H), 0.04 (s, 3H); 13C NMR 
(100 MHz, CDCl3) δ 164.2, 150.4, 136.3, 130.6, 123.5, 76.9, 70.7, 67.7, 36.8, 33.6, 25.9, 
25.9, 18.3, 18.1, 16.7, 15.4, -3.9, -4.8, -5.31, -5.34; ESIHRMS calculated for 
C26H47NO6Si2Na [M+Na]+, 548.2840; found, 548.2833. 
(2S,3R,5R)-5,6-Bis((tert-butyldimethylsilyl)oxy)-3-methylhexan-2-ol (172). 
To a stirred solution of 171 (440 mg, 0.84 mmol) in dry MeOH (3.5 mL) was added 
NaOMe (90 mg, 1.67 mmol) in portion wise at room temperature. After stirring for 12 h at 
room temperature, the reaction mixture was concentrated, and the residue was purified 
by flash column chromatography on silica gel (5 – 50 % EtOAc in CH2Cl2) to give 172 
(280 mg, 89%) as a colorless oil. [α]20D +33.0 (c 2.7, CHCl3); 1H NMR (400 MHz, CDCl3) 
δ 3.77 – 3.66 (m, 1H), 3.65 – 3.58 (m, 1H), 3.56 (dd, J = 9.9, 5.2 Hz, 1H), 3.37 (dd, J = 
9.9, 6.8 Hz, 1H), 1.77 (s, 1H), 1.74 – 1.62 (m, 1H), 1.51 (ddd, J = 13.7, 8.9, 3.3 Hz, 1H), 
1.35 (ddd, J = 13.7, 9.2, 3.1 Hz, 1H), 1.12 (d, J = 6.3 Hz, 3H), 0.92 – 0.88 (m, 12H), 0.87 
(s, 9H), 0.07 (s, 6H), 0.05 – 0.03 (m, 6H). 13C NMR (100 MHz, CDCl3) δ 72.3, 71.4, 67.8, 
37.3, 36.1, 25.94, 25.89, 19.9, 18.3, 18.1, 15.7, -4.1, -4.7, -5.32, -5.34; ESIHRMS 









To a stirred solution of 172 (340 mg, 0.90 mmol), N-hydroxyphthalimide (177 mg, 
1.08 mmol), and PPh3 (286 mg, 1.08 mmol) in dry THF (5 mL) was added a solution of 
DIAD (220 mg, 1.08 mmol) in dry THF (1 mL) at 0 oC. After stirring for 30 min at 0 oC and 
1.5 h at room temperature, the reaction mixture was concentrated under reduced 
pressure. The residue was purified by flash column chromatography on silica gel (0 – 5 
% EtOAc in hexane) to afford 173 (419 mg, 89%) as a yellow oil. [α]20D +19.6 (c 1.3, 
CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.85 – 7.77 (m, 2H), 7.76 – 7.68 (m, 2H), 4.41 – 
4.19 (m, 1H), 3.85 – 3.73 (m, 1H), 3.59 (dd, J = 10.0, 5.4 Hz, 1H), 3.43 (dd, J = 10.0, 6.2 
Hz, 1H), 2.16 – 2.00  (m, 1H), 1.72 (ddd, J = 13.7, 9.4, 3.1 Hz, 1H), 1.53 (ddd, J = 13.7, 
10.7, 3.0 Hz, 1H), 1.28 (d, J = 6.4 Hz, 3H), 1.06 (d, J = 6.8 Hz, 3H), 0.89 (s, 9H), 0.85 (s, 
9H), 0.08 (s, 3H), 0.07 (s, 3H), 0.06 – 0.04 (m, 6H); 13C NMR (100 MHz, CDCl3) δ 164.3, 
134.3, 129.1, 123.3, 88.1, 71.0, 68.1, 37.0, 33.0, 26.0, 25.9, 18.4, 18.1, 15.8, 14.6, -4.0, 
-4.8, -5.31, -5.31; ESIHRMS calculated for C27H51N2O5Si2 [M+NH4]+, 539.3337; found, 
539.3335. 
(R)-N-Allyl-N,2-dimethylbutanamide (174). 
To an ice-cold solution (<5 oC) of an acid (R)-2-methylbutyric acid 132 (0.52 g, 
5.00 mmol) in dry CH2Cl2 (20 mL) were added N-allylmethylamine (530 mg, 7.50 mmol), 
HOBt (80% in water, 1.35 g, 7.50 mmol), EDCI.HCl (1.44 g, 7.50 mmol), and DIPEA (1.31 
mL, 7.50 mmol), and the resulting solution was stirred for 16 h at room temperature. The 
mixture was diluted with CH2Cl2, washed with 1 M HCl followed by saturated aq. NaHCO3, 





the residue by flash column chromatography on silica gel (10 – 30 % EtOAc in hexane) 
afforded 174 (0.68 g, 87%) as a colorless oil. [α]20D –38.0 (c 1, CHCl3); 1H NMR (400 
MHz, CDCl3), both rotamers, δ 5.82 – 5.63 (m, 1H), 5.25 – 4.97 (m, 2H), 4.10 – 3.80 (m, 
2H), 2.94 (s, 3H, 1 rotamer), 2.88 (s, 3H, 1 rotamer), 2.65 – 2.53 (m, 1H, 1 rotamer), 2.53 
– 2.41 (m, 1H, 1 rotamer), 1.74 – 1.57 (m, 1H), 1.44 – 1.27 (m, 1H), 1.09 – 1.02 (m, 3H), 
0.88 – 0.78 (m, 3H); 13C NMR (100 MHz, CDCl3), both rotamers, δ 177.1, 176.5, 133.5, 
133.2, 117.0, 116.5, 52.1, 50.2, 37.5, 37.3, 34.8, 33.9, 27.5, 27.2, 17.9, 17.3, 12.2, 12.1. 
ESIHRMS calculated for C9H18NO [M+H]+, 156.1388; found, 156.1393.  
(R)-N,2-Dimethyl-N-(2-oxoethyl)butanamide (166). 
Ozone was bubbled in a solution of 174 (189 mg, 1.20 mmol) in MeOH-CH2Cl2 
(1:5, 12 mL) until blue color wasn’t observed (20 min) at –78 oC. Argon was bubbled to 
decolorize the solution, and dimethyl sulfide (0.44 mL, 6.00 mmol) was added. The 
resultant mixture was stirred in an ice-bath (<5 oC) for 1 h and concentrated under 
reduced pressure (water bath <25 oC). The so-obtained crude aldehyde 166 was then 
used immediately in next reaction without purification. 
Formaldehyde O-((2R,3R,5R)-5,6-bis((tert-butyldimethylsilyl)oxy)-3-methylhexan-
2-yl) oxime (175). 
Hydrazine monohydrate (88 μL, 1.76 mmol) was added to a solution of 173 (230 
mg, 0.44 mmol) in MeOH-CH2Cl2 (1:1, 7 mL) at room temperature, and the resultant 
mixture was stirred for 1 h. The reaction mixture was diluted with CH2Cl2, washed with 
5% aq. NaHCO3 solution and brine, dried over anhydrous Na2SO4, and concentrated 
under reduced pressure. The so-obtained O-alkylhydroxylamine intermediate was then 





3.3 mL) at room temperature. After 1 h, the resultant mixture was concentrated and 
purified by flash column chromatography on silica gel (0 – 3 % EtOAc in hexane) to give 
oxime 175 (161 mg, 90%) as a colorless oil. [α]20D +25.4 (c 1.3, CHCl3); 1H NMR (600 
MHz, CDCl3) δ 6.98 (d, J = 8.8 Hz, 1H), 6.35 (d, J = 8.8, 1H), 4.17 – 4.05 (m, 1H), 3.74 – 
3.66 (m, 1H), 3.53 (dd, J = 9.9, 5.4 Hz, 1H), 3.36 (dd, J = 9.9, 6.3 Hz, 1H), 2.03 – 1.91 
(m, 1H), 1.46 (ddd, J = 13.6, 9.1, 3.3 Hz, 1H), 1.33 (ddd, J = 13.6, 10.5, 3.2 Hz, 1H), 1.15 
(d, J = 6.5 Hz, 3H), 0.91 – 0.83 (m, 21H), 0.05 (s, 3H), 0.04 (s, 3H), 0.04 – 0.02 (m, 6H); 
13C NMR (150 MHz, CDCl3) δ 136.1, 83.3, 71.1, 68.1, 36.6, 32.9, 26.0, 25.9, 18.3, 18.1, 
15.8, 15.1, -4.0, -4.8, -5.30, -5.34; ESIHRMS calculated for C20H46NO3Si2 [M+H]+, 
404.3016; found, 404.3014. 
(R)-N-((5R,6R,8R)-8-((tert-Butyldimethylsilyl)oxy)-3,5,6,11,11,12,12-heptamethyl-
4,10-dioxa-3-aza-11-silatridecyl)-N,2-dimethylbutanamide (176). 
NaCNBH3 (75 mg, 1.20 mmol) was added carefully to a stirred solution of 175 (161 
mg, 0.40 mmol) in a mixture of 0.1 M HCl and EtOH (1:3, 6 mL, pH = 2-3) at room 
temperature. After stirring for 1 h, the reaction was quenched with saturated aq. NaHCO3 
and extracted with ether. The organic extract was washed with brine, dried over 
anhydrous NaSO4, and concentrated under reduced pressure. The so-obtained crude 
N,O-dialkylhydroxylamine was then treated with a aldehyde 166 (189 mg, 1.20 mmol) in 
dry MeOH–CH2Cl2 (5:3, 8 mL) at room temperature. After stirring for 2 h, NaCNBH3 (75 
mg, 1.20 mmol) and acetic acid (137 μL, 2.40 mmol) were added sequentially, and the 
mixture was stirred for next 45 min. The reaction was quenched with saturated aq. 
NaHCO3 and extracted with EtOAc. The Organic extract was washed with brine, dried 





residue by flash column chromatography on silica gel (10 – 30 % EtOAc in hexane) 
afforded 176 (161 mg, 74%) as a colorless oil. [α]20D +10.8 (c 1, CHCl3); 1H NMR (600 
MHz, CDCl3), both rotamers, δ 3.73 – 3.31 (m, 6H), 3.05 (s, 3H, 1 rotamer), 2.93 (s, 3H, 
1 rotamer), 2.85 – 2.68 (m, 2H), 2.65 – 2.50 (m, 4H), 1.90 (s, 1H), 1.74 – 1.62 (m, 1H), 
1.49 – 1.26 (m, 3H), 1.12 – 1.02 (m, 6H), 0.90 – 0.82 (m, 24H), 0.06 – 0.01 (m, 12H); 13C 
NMR (150 MHz, CDCl3), both rotamers, δ 176.7, 176.4, 81.3, 71.2, 71.1, 68.2, 68.1, 59.5, 
58.2, 47.4, 46.5, 46.2, 45.7, 37.3, 37.1, 36.6, 36.4, 36.1, 34.1, 32.3, 32.1, 27.3, 27.0, 26.0, 
25.93, 25.91, 25.89, 18.3, 18.1, 17.8, 17.0, 15.7, 15.6, 15.1, 14.9, 12.1, 12.0, -4.0, -4.7, -
5.30, -5.34; ESIHRMS calculated for C28H63N2O4Si2 [M+H]+, 547.4326; found, 547.4328. 
(3R,4R)-4-(((2-((R)-N,2-Dimethylbutanamido)ethyl)(methyl)amino)oxy)-3-
methylpentanoic acid (164). 
To an ice-cold solution (< 5 oC) of 176 (161 mg, 0.29 mmol) in dry THF (8 mL) was 
added TBAF (1 M THF solution, 1.16 mL, 1.16 mmol), and the resultant solution was 
stirred for 1 h at room temperature. The reaction mixture was diluted with EtOAc, washed 
with water followed by brine, dried over anhydrous Na2SO4, and concentrated under 
reduced pressure. The so-obtained crude diol intermediate was treated with NaIO4 (94 
mg, 0.44 mmol) in CH2Cl2–water (4:1, 5 mL) for 1 h in an ice-bath (<5 oC). The reaction 
mixture was diluted with CH2Cl2, washed with water followed by brine, dried over 
anhydrous Na2SO4, and concentrated under reduced pressure to give crude aldehyde 
intermediate. To a stirred solution of this crude aldehyde in MeOH (11 mL) was added 2-
methyl-2-butene (1.54 mL. 14.50 mmol) followed by a freshly prepared solution of NaClO2 
(1.25 M in 20% NaH2PO4 solution, 1.16 mL, 1.45 mmol) at room temperature. The 





washed with brine, dried over anhydrous Na2SO4, concentrated under reduced pressure, 
and purified by flash column chromatography on silica gel (0 – 5 % MeOH in CH2Cl2) to 
afford 164 (71 mg, 80%) as a colorless oil. [α]20D –27.4 (c 0.35, CHCl3); 1H NMR (600 
MHz, CDCl3), both rotamers, δ 3.68 – 3.55 (m, 3H, rotamer), 3.55 – 3.40 (m, 3H, rotamer), 
3.04 (s, 3H, rotamer), 2.93 (s, 3H, rotamer), 2.87 – 2.69 (m, 2H), 2.62 – 2.45 (m, 5H), 
2.28 – 2.18 (m, 1H), 2.15 – 2.04 (m, 1H), 1.72 – 1.59 (m, 1H), 1.44 – 1.31 (m, 1H), 1.10 
– 1.01 (m, 6H), 0.95 – 0.88 (m, 3H), 0.88 – 0.81 (m, 3H); 13C NMR (150 MHz, CDCl3) , 
both rotamers, δ 178.1, 178.0, 177.0, 176.9, 79.3, 79.2, 59.3, 57.8, 47.4, 46.3, 45.8, 45.5, 
37.4, 37.2, 36.8, 36.6, 36.0, 34.2, 33.82, 33.76, 27.2, 27.0, 17.6, 16.9, 15.32, 15.25, 12.0, 
11.9; ESIHRMS calculated for C15H31N2O4 [M+H]+, 303.2284; found, 303.2292. 
(3R,4R)-4-(((2-((R)-N,2-Dimethylbutanamido)ethyl)(methyl)amino)oxy)-N-((R)-1-
hydroxybut-3-en-2-yl)-3-methylpentanamide (177). 
To a mixture of 164 (71 mg, 0.23 mmol), and 112147 (58 mg, 0.47 mmol) in dry 
CH2Cl2 (2 mL) were added DIPEA (123 μL, 0.70 mmol) and DMAP (14 mg, 0.12 mmol) 
at room temperature. After stirring for 10 min, EDCI.HCl (134 mg, 0.70 mmol) was added. 
The mixture was stirred for 14 h and concentrated under reduced pressure. Purification 
of the residue by flash column chromatography on silica gel (25 – 50 % EtOAc in hexane) 
afforded 177 (86 mg, 99%) as a yellow oil. [α]20D –5.7 (c 0.35, CHCl3); 1H NMR (600 MHz, 
CDCl3), both rotamers, δ 6.82 (s, 1H, rotamer), 6.15 (s, 1H, rotamer), 5.87 – 5.79 (m, 1H), 
5.37 – 5.05 (m, 2H), 4.61 – 4.49 (m, 1H), 3.89 – 3.26 (m, 6H), 3.05 (s, 3H, rotamer), 2.94 
(s, 3H, rotamer), 2.83 – 2.69 (m, 2H), 2.65 – 2.51 (m, 5H, rotamer), 2.41 (dd, J = 14.1, 
4.5 Hz, 1H, rotamer), 2.30 – 2.19 (m, 1H), 2.07 (dd, J = 14.1, 7.3 Hz, 1H, rotamer), 1.98 





(m, 6H), 0.90 (d, J = 7.0 Hz, 3H), 0.88 – 0.84 (m, 3H); 13C NMR (150 MHz, CDCl3), both 
rotamers, δ 177.1, 177.0, 173.2, 172.6, 135.4, 135.2, 116.6, 116.4, 79.4, 79.0, 65.2, 65.1, 
59.5, 57.8, 53.8, 53.5, 47.4, 46.4, 46.0, 45.5, 39.7, 39.6, 37.4, 37.1, 36.1, 34.6, 34.4, 34.3, 
27.3, 27.0, 17.6, 17.0, 16.3, 15.9, 14.8, 14.6, 12.1, 11.9; ESIHRMS calculated for 
C19H38N3O4 [M+H]+, 372.2862; found, 372.2861.  
(R)-N,2-Dimethyl-N-(2-(methyl(((2R,3R)-3-methyl-4-((R)-4-vinyl-4,5-dihydrooxazol-
2-yl)butan-2-yl)oxy)amino)ethyl)butanamide (178). 
To a stirred solution of 177 (56 mg, 0.15 mmol) in dry CH2Cl2 (5 mL) was added 
DAST (40 μL, 0.30 mmol) at –78 oC. The reaction was quenched with saturated aq. 
NaHCO3 after stirring for 10 min and warmed to room temperature followed by extraction 
with CH2Cl2. The organic extract was dried over anhydrous Na2SO4, concentrated under 
reduced pressure, and purified by flash column chromatography on neutral alumina (25 
– 50 % EtOAc in hexane) to give 178 (42 mg, 79%) as a colorless oil. [α]20D +26.7 (c 0.27, 
CHCl3); 1H NMR (600 MHz, CDCl3) , both rotamers, δ 5.79 (ddd, J = 17.2, 10.2, 7.1 Hz, 
1H), 5.26 – 5.17 (m, 1H), 5.12 (dd, J = 10.2, 4.6 Hz, 1H), 4.57 (dt, J = 14.8, 7.1 Hz, 1H), 
4.38 – 4.27 (m, 1H), 3.94 – 3.87 (m, 1H), 3.68 – 3.34 (m, 3H), 3.05 (s, 3H, rotamer), 2.93 
(s, 3H, rotamer), 2.87 – 2.70 (m, 2H), 2.60 – 2.51 (m, 4H), 2.49 – 2.41 (m, 1H), 2.21 – 
2.14 (m, 1H), 2.14 – 2.04 (m, 1H), 1.72 – 1.60 (m, 1H), 1.45 – 1.31 (m, 1H), 1.11 – 1.04 
(m, 6H), 0.94 – 0.89 (m, 3H), 0.88 – 0.83 (m, 3H); 13C NMR (150 MHz, CDCl3), both 
rotamers, δ 176.7, 176.4, 168.1, 167.8, 138.2, 138.1, 116.2, 116.1, 79.4, 72.0, 71.9, 68.2, 
59.4, 58.1, 47.4, 46.4, 46.0, 45.6, 37.3, 37.1, 36.0, 34.6, 34.5, 34.1, 30.5, 30.4, 27.3, 27.0, 
17.7, 17.0, 15.4, 15.3, 15.1, 15.0, 12.1, 12.0; ESIHRMS calculated for C19H36N3O3 







Compound 178 (34 mg, 0.01 mmol) was dissolved in MeOH–Et3N (1:1, 3 mL, 
saturated with H2S), and stirred for 16 h at room temperature. The mixture was 
concentrated under reduced pressure and purified by flash column chromatography on 
neutral alumina (25 – 50 % acetone in hexane) to afford 179 (29 mg, 78%) as a colorless 
oil. [α]20D +28.8 (c 1, CHCl3); 1H NMR (600 MHz, CDCl3), both rotamers, δ 8.81 (br s, 1H, 
rotamer), 8.15 (br s, 1H, rotamer), 5.86 (ddd, J = 17.3, 10.5, 5.4 Hz, 1H), 5.35 – 5.27 (m, 
1H),  5.27 (d, J = 17.3 Hz, 1H), 5.24 (d, J = 10.5 Hz, 1H), 3.91 – 3.60 (m, 4H), 3.57 – 3.44 
(m, 1H, rotamer), 3.40 – 3.30 (m, 1H, rotamer), 3.05 (s, 3H, rotamer), 2.96 (s, 3H, 
rotamer), 2.92 (dd, J = 13.6, 7.4 Hz, 1H), 2.85 – 2.75 (m, 2H), 2.66 – 2.55 (m, 5H), 2.48 
– 2.37 (m, 1H), 1.70 – 1.57 (m, 1H), 1.47 – 1.34 (m, 1H), 1.13 – 1.08 (m, 3H), 1.06 (d, J 
= 6.8 Hz, 3H), 0.92 (d, J = 7.1 Hz, 3H), 0.88 – 0.83 (m, 3H); 13C NMR (150 MHz, CDCl3), 
major rotamer only, δ 205.1, 177.3, 133.7, 117.2, 78.9, 64.0, 58.9, 57.7, 50.1, 46.6, 45.5, 
38.2, 37.4, 36.2, 27.0, 17.1, 17.0, 13.8, 11.9; ESIHRMS calculated for C19H38N3O3S 
[M+H]+, 388.2634; found, 388.2636. 
9-Oxa-10-azakalkitoxin (109). 
To a stirred solution of 179 (25 mg, 0.07 mmol) in dry CH2Cl2 (2.2 mL) was added 
DAST (17 μL, 0.13 mmol) at –78 oC. The reaction was quenched with saturated aq. 
NaHCO3 after stirring for 10 min and warmed to room temperature followed by extraction 
with CH2Cl2. The organic extract was dried over anhydrous Na2SO4, concentrated under 
reduced pressure, and purified by flash column chromatography on neutral alumina (25 





CHCl3); 1H NMR (600 MHz, CDCl3) , both rotamers, δ 5.92 (ddd, J = 17.1, 10.2, 6.8 Hz, 
1H), 5.27 (d, J = 17.1, 1H), 5.18 – 5.11 (m, 1H), 4.91 (dt, J = 14.5, 7.5 Hz, 1H), 3.69 – 
3.49 (m, 2H), 3.49 – 3.37 (m, 2H), 3.09 – 3.01 (m, 4H, rotamer), 2.93 (s, 3H, rotamer), 
2.87 – 2.71 (m, 2H), 2.70 – 2.62 (m, 1H), 2.62 – 2.51 (m, 4H), 2.40 – 2.31 (m, 1H), 2.20 
– 2.12 (m, 1H), 1.74 – 1.62 (m, 1H), 1.44 – 1.33 (m, 1H), 1.12 – 1.02 (m, 6H), 0.91 (d, J 
= 6.9 Hz, 3H, rotamer), 0.89 (d, J = 6.9 Hz, 3H, rotamer), 0.88 – 0.84 (m, 3H); 13C NMR 
(150 MHz, CDCl3) , both rotamers, δ 176.7, 176.4, 171.2, 170.8, 137.3, 137.2, 116.1, 
116.0, 79.4, 78.6, 78.5, 59.4, 58.1, 47.4, 46.4, 46.1, 45.6, 38.62, 38.61, 37.3, 37.1, 36.8, 
36.7, 36.0, 35.9, 35.8, 34.1, 27.3, 27.0, 17.8, 17.0, 15.5, 15.4, 14.9, 14.8, 12.1, 12.0; 
ESIHRMS calculated for C19H36N3O2S [M+H]+, 370.2528; found, 370.2541. 
Synthesis of 7,8-diazakalkitoxin (110): 
(R,E)-2-Methyl-5-phenylpent-4-en-1-ol (187). 
To a heterogeneous mixture of 159 (7.40 g, 21.18 mmol) and anhydrous diethyl 
ether (200 mL) were added EtOH (1.85 mL, 31.77 mmol) and LiBH4 (0.69 g, 31.77 mmol) 
at 0 oC. After stirring for 2 h at 0 oC and 2 h at room temperature, the reaction was 
quenched by careful slow addition of 1M NaOH (180 mL) at 0 oC followed by stirring for 
15 min at room temperature. The resultant mixture was extracted with ether and the ether 
extract was washed with saturated aq. NH4Cl, water, and brine, dried over anhydrous 
Na2SO4, and concentrated under reduced pressure. Purification was performed by flash 
column chromatography on silica gel to afford 187157 (3.33 g, 89%) as a yellow oil (eluent: 
dichloromethane). [α]20D +5.4 (c 2.5, CH2Cl2); lit157 [α]D +6.1 (c 1.7, CH2Cl2); 1H NMR (400 
MHz, CDCl3) δ 7.42 – 7.16 (m, 5H), 6.42 (d, J = 15.8 Hz, 1H), 6.23 (dt, J = 15.8, 7.3 Hz, 





2.17 – 2.05 (m, 1H), 1.89 – 1.76 (m, 1H), 1.58 (s, 1H), 0.98 (d, J = 6.8 Hz, 3H); 13C NMR 
(100 MHz, CDCl3) δ 137.6, 131.4, 128.7, 128.5, 127.0, 126.0, 68.0, 36.9, 36.1, 16.5.  
(R,E)-2-Methyl-5-phenylpent-4-en-1-al (184). 
To an ice-cold solution of 187 (1g, 5.67 mmol) in dry CH2Cl2 (28 mL) was added 
Dess-Martin periodinane (4.81 g, 11.35 mmol) portion wise, and the reaction was stirred 
for 4 h at room temperature.  The reaction was diluted with ether (30 mL), quenched with 
a mixture of water, saturated aq. Na2S2O3, and saturated aq. NaHCO3 (1:1:1, 50 mL), and 
stirred for 1 h at room temperature. The resultant mixture was extracted with ether, and 
the ether extract was washed with brine, dried over anhydrous Na2SO4, concentrated 
under reduced pressure, and purified by flash column chromatography on silica gel to 
afford the desired aldehyde 184156 (0.74 g, 75%) as a colorless oil (eluent: 5 – 15% ether 
in hexane). This material was immediately forwarded to next reaction. [α]20D –7.12 (c 2.5, 
CH2Cl2); lit157 [α]D –6.07 (c 2.39, CCl4) 1H NMR (400 MHz, CDCl3) δ 9.72 (d, J = 1.4 Hz, 
1H), 7.40 – 7.18 (m, 5H), 6.46 (d, J = 15.8 Hz, 1H), 6.16 (dt, J = 15.8, 7.2 Hz, 1H), 2.71 
– 2.59 (m, 1H), 2.59 – 2.48 (m, 1H), 2.38 – 2.25 (m, 1H), 1.17 (d, J = 7.0 Hz, 3H). 13C 
NMR (100 MHz, CDCl3) δ 204.5, 137.1, 132.5, 128.5, 127.3, 126.6, 126.1, 46.3, 34.0, 
13.2. 
Benzyl N-methyl-N-(methylamino)glycinate (183). 
To a stirred suspension of N,N’-dimethylhydrazine dihydrochloride (1 g,  7.5 mmol) 
and NaHCO3 (1.89 g, 22.50 mmol) in dry DMF-PhMe (1:3, 10 mL) was added benzyl 
bromoacetate158 (1.72 g, 7.5 mmol) dropwise in 1 h at room temperature. The reaction 
mixture was stirred for 1 h at 85 oC and cooled to room temperature. Then the mixture 





Na2SO4, and concentrated under reduced pressure. The residue was purified by flash 
column chromatography on silica gel (50 – 100% EtOAc in hexane) to give the desired 
product 183 (1.04 g, 67%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.43 – 7.23 (m, 
5H), 5.15 (s, 2H), 3.52 (s, 2H), 2.95 (s, 1H), 2.61 (s, 3H), 2.53 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 170.4, 135.6, 128.5, 128.3, 128.3, 66.2, 59.5, 42.3, 35.5; ESIHRMS 
calculated for C11H17N2O2 [M+H]+, 209.1290; found, 209.1289. 
Benzyl (R,E)-N-methyl-N-(methyl(2-methyl-5-phenylpent-4-en-1-yl)amino)glycinate 
(188). 
Hydrazine 183 (800 mg, 3.85 mmol) was treated with aldehyde 184 (737 mg, 4.23 
mmol) in MeOH-CH2Cl2 (1:1, 21 mL) at room temperature. After stirring for 1 h, NaCNBH3 
(724 mg, 11.55 mmol) was added portion wise followed by stirring for 3 h. The reaction 
was quenched with 1:1 mixture of saturated aq. NaHCO3 and brine (50 mL) and extracted 
with CH2Cl2. The resultant organic extract was dried over anhydrous Na2SO4, 
concentrated under reduced pressure, and purified by flash column chromatography on 
silica gel to afford the desired compound 188 (872 mg, 62%) as a colorless oil (eluent: 0 
– 25% EtOAc in hexane). [α]20D +3.0 (c 4.5, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.43 – 
7.25 (m, 9H), 7.23 – 7.15 (m, 1H), 6.37 (d, J = 15.8 Hz, 1H), 6.21 (dt, J = 15.8, 7.2 Hz, 
1H), 5.17 (s, 2H), 3.39 (s, 2H), 2.45 – 2.24 (m, 9H), 2.03 – 1.92 (m, 1H), 1.88 – 1.77 (m, 
1H), 0.90 (d, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 170.6, 137.9, 135.9, 131.0, 
129.5, 128.5, 128.5, 128.3, 128.2, 126.7, 125.9, 66.4, 60.0, 57.3, 38.4, 35.8, 34.3, 31.3, 







Benzyl (R)-N-methyl-N-(methyl(2-methyl-4-oxobutyl)amino)glycinate (189). 
To an ice-cold solution of 188 (470 mg, 1.28 mmol) in acetone-water (3:2, 10 mL) 
was added N-methylmorpholine-N-oxide (451 mg, 3.84 mmol) and OsO4 (12.8 mL, 4 μM 
in PhMe, 0.05 mmol). The reaction flask was rapped with aluminum foil and allowed to 
stir for 16 h at room temperature. Na2SO3 (807 mg, 6.40 mmol) was added and stirred for 
5 min followed by concentration under reduced pressure. The resultant residue was 
dissolved in ethyl acetate, washed with water followed by brine, dried over anhydrous 
Na2SO4, and concentrated under reduced pressure. The so-obtained diol residue was 
treated with NaIO4 (383 mg, 1.80 mmol) in CH2Cl2-water (4:1, 10 mL) at 0 oC for 1.5 h. 
The reaction was diluted with CH2Cl2, washed with water followed by brine, dried over 
anhydrous Na2SO4, and concentrated under reduced pressure. Purification was 
performed by flash column chromatography on silica gel to afford 189 (234 mg, 62%) as 
a yellow oil (eluent: 10 – 40% EtOAc in hexane). [α]20D +9.0 (c 1.25, CH2Cl2); 1H NMR 
(400 MHz, CDCl3) δ 9.64 (s, 1H), 7.44 – 7.19 (m, 5H), 5.14 (s, 2H), 3.34 (s, 2H), 2.48 – 
2.26 (m, 7H), 2.23 (s, 3H), 2.08 (dd, J = 15.7, 4.4 Hz, 1H), 0.90 (d, J = 6.0 Hz, 3H); 13C 
NMR (100 MHz, CDCl3) δ 202.9, 170.5, 135.8, 128.5, 128.4, 128.3, 66.4, 60.6, 56.9, 49.4, 




MeNH2.HCl (11 mg, 0.16 mmol) and MeNH2 (0.13 ml of 2 M in THF, 0.25 mmol) 
were added sequentially to a stirred mixture of 189 (25 mg, 0.08 mmol), anhydrous 





room temperature, the reaction was cooled in an ice-bath and NaCNBH3 (21 mg, 0.33 
mmol) was added. The stirring was continued for 45 min at room temperature and the 
mixture was concentrated under reduced pressure. Purification was performed by flash 
column chromatography on silica gel to afford 190 (18 mg, 72%) as a yellow oil (eluent: 
0 ‒ 30 % MeOH in CH2Cl2). [α]20D +17.1 (c 1.4, CHCl3);  1H NMR (400 MHz, CDCl3) δ 
7.43 – 7.27 (m, 5H), 5.16 (s, 2H), 3.43 – 3.30 (m, 2H), 3.11 – 2.99 (m, 1H), 2.90 (dt, J = 
12.5, 7.2 Hz, 1H), 2.61 (s, 3H), 2.40 – 2.30 (m, 5H), 2.26 (s, 3H), 1.95 – 1.81 (m, 2H), 
1.73 – 1.50 (m, 1H), 0.90 (d, J = 6.5 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.1, 135.5, 
128.6, 128.4, 128.3, 66.8, 60.8, 56.2, 47.8, 34.8, 34.6, 32.8, 31.4, 29.0, 19.4. ESIHRMS 
calculated for C17H30N3O2 [M+H]+, 308.2338; found, 308.2343. 
Benzyl N-(((R)-4-((R)-N,2-dimethylbutanamido)-2-methylbutyl)(methyl)amino)-N-
methylglycinate (191). 
To an ice-cold solution (<5 oC) of amine 190 (170 mg, 0.55 mmol) and (R)-2-
methylbutanoic acid (113 mg, 1.11 mmol) in DMF (3 mL) were added HOBt (187 mg 
wetted with 20 wt.% H2O, 1.11 mmol), EDCI.HCl (213 mg, 1.11 mmol), and DIPEA (193 
μL, 1.11 mmol), and the reaction mixture was stirred for 12 h at room temperature. Then 
the reaction was diluted with EtOAc, washed with water followed by brine, dried over 
anhydrous Na2SO4, concentrated under reduced pressure, and purified by flash column 
chromatography on silica gel to give 191 (145 mg, 67%) as a yellow oil (eluent: 20 – 80% 
ethyl acetate in hexane). [α]20D ‒10.4 (c 6.15, CHCl3); 1H NMR (600 MHz, CDCl3) , both 
rotamers, δ 7.44 – 7.27 (m, 5H), 5.13 (s, 2H), 3.47 – 3.08 (m, 4H), 2.95 (s, 3H, rotamer), 
2.88 (s, 3H, rotamer), 2.61 – 2.48 (m, 1H), 2.40 – 2.15 (m, 7H), 1.87 – 1.49 (m, 4H), 1.43 





(150 MHz, CDCl3) , both rotamers, δ 176.5, 176.1, 170.5, 170.5, 135.9, 135.8, 128.5, 
128.5, 128.22, 128.15, 66.3, 66.2, 61.1, 60.3, 57.0, 56.9, 48.0, 45.9, 37.3, 37.1, 35.9, 
35.3, 35.1, 34.5, 34.4, 34.0, 33.6, 32.2, 32.1, 28.9, 28.8, 27.4, 27.0, 18.2, 18.1, 17.8, 




To a stirred solution of 192160 (7.90 g, 19.02 mmol) in dioxane-water (1:1, 38 mL) 
were added Et3N (6.63 mL, 47.55 mmol) and Boc2O (5.19 g, 23.78 mmol) in 5 min time 
interval at room temperature. After stirring for 30 min at room temperature, volatile 
components were evaporated in a rotary evaporator. The residue was diluted with water 
(50 mL) and the non-polar impurities were washed out with ether and discarded. The 
resultant aqueous phase was cooled in an ice-bath, acidified with half saturated citric acid 
to pH 4, and extracted with CH2Cl2. The CH2Cl2 extract was dried over anhydrous Na2SO4 
and concentrated under reduced pressure. The so-obtained crude acid intermediate was  
Dissolved in dry THF (380 mL) and cooled in an ice-bath. To this ice-cold solution 
were added HOBt (4.48 g wet in 14 wt% water, 28.53 mmol) and EDCI.HCl (5.47 g, 28.53 
mmol). After stirring for 15 min at room temperature, N,O-dimethylhydroxylamine (2.78 g, 
28.53 mmol) and DIPEA (4.97 mL, 28.53 mmol) were added. The stirring was continued 
for 20 h and concentrated under reduced pressure. The residue was dissolved in EtOAc, 
washed with water, saturated aq. NaHCO3, and brine, dried over Na2SO4, concentrated 
under reduced pressure, and purified by flash column chromatography on silica gel (10 – 





[α]20D +63.3 (c 2.3, CHCl3); 1H NMR (400 MHz, CDCl3) δ 6.11 (s, 2H), 5.46 (d, J = 8.1 Hz, 
1H), 4.91 (br s, 1H), 3.84 (d, J = 12.8 Hz, 1H), 3.81 (s, 6H), 3.79 (s, 3H), 3.78 (s, 3H), 
3.71 (d, J = 12.8 Hz, 1H), 3.20 (s, 3H), 2.84 (dd, J = 13.9, 5.9 Hz, 1H), 2.73 (dd, J = 13.9, 
7.4 Hz, 1H), 1.43 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 172.0, 160.3, 158.7, 155.3, 107.7, 
90.6, 79.4, 61.6, 55.7, 55.3, 50.8, 33.7, 32.1, 28.3, 24.6; ESIHRMS calculated for 
C20H32N2O7SNa [M+Na]+, 467.1828; found, 467.1825. 
tert-Butyl (R)-(1-oxo-3-((2,4,5-trimethoxybenzyl)thio)propan-2-yl)carbamate (194).    
To a stirred solution of 193 (5.45 g, 12.26 mmol) in an anhydrous diethyl ether (55 
mL) was added LiAlH4 (0.70 g, 18.39 mmol) portion wise at 0 oC, and the mixture was 
stirred for 40 min. The reaction was diluted with diethyl ether (55 mL) and quenched by 
addition of ice-cold 1 M HCl (100 mL). The organic layer was separated, and the aqueous 
layer was extracted with diethyl ether. The combined organic extract was washed with 1 
M HCl followed by brine, dried over anhydrous Na2SO4, and concentrated under reduced 
pressure. Purification by flash column chromatography on silica gel (10 – 50% EtOAc in 
hexane) afforded the desired product 194 (4.37 g, 92%) as a white solid. M.p. 90 – 93 oC 
[α]20D –16.97 (c 1.65, CHCl3); 1H NMR (400 MHz, CDCl3) δ 9.57 (s, 1H), 6.12 (s, 2H), 5.48 
(br s, 1H), 4.44 – 4.22 (m, 1H), 3.90 – 3.63 (m, 11H), 3.00 – 2.75 (m, 2H), 1.45 (s, 9H); 
13C NMR (100 MHz, CDCl3) δ 199.8, 160.6, 158.8, 155.7, 107.0, 90.6, 80.2, 59.3, 55.7, 
55.3, 31.0, 28.3, 24.4; ESIHRMS calculated for C18H27NO6SNa [M+Na]+, 385.1559; 
found, 385.1565. 
tert-Butyl (R)-(1-((2,4,5-trimethoxybenzyl)thio)but-3-en-2-yl)carbamate (195). 
To a stirred suspension of methyltriphenylphosphonium bromide (8.73 g, 24.43 





slowly, and the mixture was stirred for 1 h at room temperature. The reaction flask was 
cooled to –78 oC, and a solution of 194 (4.28 g, 11.10 mmol) in dry THF (50 mL) was 
added drop wise in 30 min. The cooling bath was removed, and the reaction was stirred 
for 1 h. Then the reaction mixture was diluted with ether (150 mL), washed with half 
saturated aq. sodium potassium tartrate followed by brine, dried over anhydrous Na2SO4, 
and concentrated under reduced pressure. Purification by flash column chromatography 
on silica gel (5 – 25% EtOAc in hexane) afforded the desired product 195 (3.15 g, 74%) 
as a white solid. M.p. 79 –  81 oC; [α]20D +12.7 (c 2, CHCl3); 1H NMR (400 MHz, CDCl3) δ 
6.12 (s, 2H), 5.80 (ddd, J = 17.1, 10.4, 5.3 Hz, 1H), 5.18 (dt, J = 17.1, 1.4 Hz, 1H), 5.10 
(dt, J = 10.4, 1.4 Hz, 1H), 5.00 (br s, 1H), 4.38 (br s, 1H), 3.82 (s, 6H), 3.80 – 3.78 (m, 
4H), 3.74 (d, J = 12.6 Hz, 1H), 2.70 (dd, J = 13.8, 5.4 Hz, 1H), 2.64 (dd, J = 13.8, 6.4 Hz, 
1H), 1.44 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 160.3, 158.8, 155.4, 138.1, 114.9, 107.7, 
90.6, 79.3, 55.7, 55.3, 52.3, 36.8, 28.4, 24.6; ESIHRMS calculated for C19H29NO5SNa 
[M+Na]+, 406.1664; found, 406.1674. 
(R)-1-((2,4,5-Trimethoxybenzyl)thio)but-3-en-2-amine (196). 
To a stirred solution of 195 (1g, 2.61 mmol) in dry CH2Cl2 (24 mL) was added 
trifluoroacetic acid (24 mL) drop wise at 0 oC. After stirring for 30 min, the reaction mixture 
was concentrated under reduced pressure. The residue was dissolved in CH2Cl2 (50 mL) 
and stirred with 1 N NaOH (50 mL) for 15 min at room temperature. The organic layer 
was separated, and the aqueous layer was washed extracted with CH2Cl2. Combined 
organic extracts was washed with brine, dried over anhydrous Na2SO4, and concentrated 
under reduced pressure. The residue was purified by flash column chromatography on 





colorless oil. [α]20D –51.5 (c 3.5, CHCl3); 1H NMR (400 MHz, CDCl3) δ 6.11 (s, 2H), 5.83 
(ddd, J = 17.1, 10.4, 6.1 Hz, 1H), 5.19 (dt, J = 17.1, 1.3 Hz, 1H), 5.06 (dt, J = 10.4, 1.3 
Hz, 1H), 3.84 – 3.74 (m, 10H), 3.71 (d, J = 12.6 Hz, 1H), 3.53 – 3.48 (m, 1H), 2.73 (dd, J 
= 13.6, 4.1 Hz, 1H), 2.38 (dd, J = 13.6, 9.0 Hz, 1H), 1.80 (s, 2H); 13C NMR (100 MHz, 
CDCl3) δ 160.3, 158.7, 141.4, 114.3, 107.9, 90.5, 55.7, 55.3, 53.1, 40.1, 23.8; ESIHRMS 
calculated for C14H23NO3S [M+H]+, 284.1320; found, 284.1311. 
(R)-N-((R)-4-(1,2-Dimethyl-2-(2-oxo-2-(((R)-1-((2,4,5-trimethoxybenzyl)thio)but-3-en-
2-yl)amino)ethyl)hydrazineyl)-3-methylbutyl)-N,2-dimethylbutanamide (197).  
A heterogeneous mixture of 191 (25 mg, 0.06 mmol), palladium (25 mg 10 wt.% 
on carbon) and MeOH (1.5 mL) was stirred under hydrogen environment (1 atm) for 15 
min and filtered through a pad of Celite®. The resultant filtrate was concentrated under 
reduced pressure to afford crude acid intermediate. To a solution of this crude acid 
intermediate and amine 196 (45 mg, 0.16 mmol) in dry CH2Cl2 (0.7 mL) were added HATU 
(49 mg, 0.13 mmol) and DIPEA (22 μL, 0.13 mmol) at room temperature. The reaction 
was stirred for 5 h and concentrated under reduced pressure. Purification of the residue 
by flash column chromatography on silica gel (20 ‒ 70% acetone in CH2Cl2) afforded 197 
(29 mg, 81%) as a yellow oil. [α]20D –22.6 (c 0.5, CHCl3); 1H NMR (600 MHz, CDCl3) , 
both rotamers, δ 7.40 – 7.26 (m, 1H), 6.09 (s, 2H), 5.90 – 5.78 (m, 1H), 5.16 (dd, J = 17.2, 
6.2 Hz, 1H), 5.10 (dd, J = 10.4, 6.2 Hz, 1H), 4.81 – 4.69 (m, 1H), 3.81 – 3.66 (m, 11H), 
3.45 – 3.09 (m, 4H), 2.96 (s, 3H, rotamer), 2.89 (s, 3H, rotamer), 2.79 – 2.70 (m, 1H), 
2.70 – 2.63 (m, 1H), 2.59 – 2.50 (m, 1H), 2.35 – 2.19 (m, 8H), 1.73 – 1.49 (m, 3H), 1.42 
– 1.27 (m, 2H), 1.09 – 1.03 (m, 3H), 0.94 – 0.89 (m, 3H), 0.88 – 0.82(m, 3H). 13C NMR 





158.72, 137.5, 137.4, 115.04, 115.02, 108.0, 107.9, 90.5, 60.3, 59.7, 58.1, 57.6, 55.7, 
55.3, 49.98, 49.89, 47.9, 46.0, 37.4, 37.3, 37.2, 36.9, 36.7, 36.2, 35.5, 35.1, 34.1, 33.6, 
32.2, 29.33, 29.28, 29.24, 29.19, 27.4, 27.0, 24.18, 24.15, 18.2, 18.1, 17.8, 17.1, 12.1, 
12.0; ESIHRMS calculated for C29H51N4O5S [M+H]+, 567.3580; found, 567.3582. 
(R)-N-((R)-4-(2-(2-(((R)-1-Mercaptobut-3-en-2-yl)amino)-2-oxoethyl)-1,2-
dimethylhydrazineyl)-3-methylbutyl)-N,2-dimethylbutanamide (198). 
To an ice-cold solution (<5 oC) of 197 (25 mg, 0.04 mmol) in dry CH2Cl2 (0.5 mL) 
were added trifluoroacetic acid (35 μL, 0.44 mmol) and Et3SiH (35 μL, 0.22 mmol) 
dropwise one after the other. After stirring for 1 h at room temperature, additional 
trifluoroacetic acid (35 μL, 0.44 mmol) and Et3SiH (35 μL, 0.22 mmol) were added 
dropwise and stirring was  continued for additional 1 h. The reaction mixture was 
concentrated under reduced pressure (<25 oC water-bath) and purified by flash column 
chromatography on silica gel (0 ‒ 20% MeOH in CH2Cl2) to give 198 (14 mg, 82%) as a 
colorless oil. [α]20D –15.2 (c 0.25, CHCl3); 1H NMR (600 MHz, CDCl3) , both rotamers, δ 
7.97 (d, J = 8.1 Hz, 1H, rotamer), 7.63 (d, J = 8.4 Hz, 1H, rotamer), 5.99 – 5.59 (m, 1H), 
5.33 – 5.08 (m, 2H), 4.76 – 4.54 (m, 1H), 3.63 (d, J = 15.0 Hz, 1H), 3.55 – 3.23 (m, 3H), 
3.16 – 3.06 (m, 1H), 3.01 (s, 3H, rotamer), 2.90 (s, 3H, rotamer), 2.80 – 2.71 (m, 3H), 
2.69 (s, 3H, rotamer), 2.64 (s, 3H, rotamer), 2.61 – 2.56 (m, 1H), 2.47 (s, 3H, rotamer), 
2.45 (s, 3H, rotamer), 1.87 – 1.57 (m, 3H), 1.49 – 1.32 (m, 3H), 1.09 – 0.96 (m, 6H), 0.88 
– 0.82 (m, 3H); 13C NMR (150 MHz, CDCl3) major rotamer only; δ 177.1, 167.4, 135.5, 
117.2, 59.8, 56.7, 53.1, 45.8, 37.4, 36.2, 35.9, 35.4, 32.0, 28.8, 27.9, 26.9, 18.1, 16.9, 






Benzyl N-(dibenzylamino)-N-methylglycinate (199). 
A mixture of 1,1-dibenzyl-2-methylhydrazine 78 (470 mg, 2.08 mmol), NaHCO3 
(262 mg, 3.12 mmol), benzyl bromoacetate (714 mg, 3.12 mmol), DMF (0.7 mL), and 
toluene (2.1 mL) was stirred for 3 h at 85 oC. The reaction was cooled to room 
temperature, diluted with toluene, washed with water followed by brine, dried over 
anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified 
by flash column chromatography on silica gel (0 ‒ 20% EtOAc in hexane) to give 119 
(650 mg, 83%) as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.51 – 7.09 (m, 15H), 5.04 
(s, 2H), 3.71 (s, 4H), 3.45 (s, 2H), 2.57 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.4, 
139.2, 135.9, 129.1, 128.5, 128.4, 128.2, 128.0, 126.8, 66.3, 58.2, 54.3, 35.8; ESIHRMS 
calculated for C24H27N2O2 [M+H]+, 375.2073; found, 375.2074. 
N-(Dibenzylamino)-N-methylglycine (200). 
To an ice-cold solution of 199 (100 mg, 0.26 mmol) in MeOH (0.4 mL) was added 
KOH solution (0.4 mL, 7 M in water, 2.80 mmol) dropwise. After stirring for 22 h at room 
temperature, the volatile components of the reaction were evaporated under reduced 
pressure. The aqueous residue was diluted with water and non-polar impurities were 
washed out with CH2Cl2 and discarded. The leftover aqueous residue was acidified to pH 
1 by addition of 2 M HCl and then extracted with CH2Cl2. The so-obtained organic extract 
was dried over anhydrous Na2SO4, and concentrated under reduced pressure to afford 
the desired acid 200 (75 mg, 99%) as a yellow oil: 1H NMR (400 MHz, CDCl3) δ 7.45 – 
7.17 (m, 10H), 3.73 (s, 4H), 3.35 (s, 2H), 2.55 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 
170.6, 136.8, 129.2, 128.7, 127.9, 57.5, 54.1, 34.2; ESIHRMS calculated for C17H19N2O2 







To a stirred solution of acid 200  (250 mg, 0.88 mmol) and amino alcohol 112147 
(280 mg, 2.20 mmol) in dry CH2Cl2 (5 mL) were added DIPEA (470 μL, 2.64 mmol), DMAP 
(55 mg, 0.44 mmol), and EDCI.HCl (520 mg, 2.64 mmol) at room temperature. After 
stirring for 12 h, the reaction mixture was concentrated under reduced pressure and the 
residue was purified by flash column chromatography on silica gel to afford 201 (290 mg, 
93%) as a colorless oil (eluent: 50 ‒ 100% EtOAc in hexane). [α]20D +32.8 (c 2.4, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.43 – 7.19 (m, 10H), 6.51 (d, J = 6.9 Hz, 1H), 5.45 (ddd, J 
= 17.0, 10.5, 5.8 Hz, 1H), 5.05 (d, J = 10.5 Hz, 1H), 4.90 (d, J = 17.0 Hz, 1H), 4.29 – 4.09 
(m, 1H), 3.68 (s, 4H), 3.45 (d, J = 16.6 Hz, 1H), 3.41 (dd, J = 11.3, 4.2 Hz, 1H), 3.33 (d, 
J = 16.6 Hz, 1H), 3.28 (dd, J = 11.3, 6.8 Hz, 1H), 2.64 (br s, 1H), 2.48 (s, 3H); 13C NMR 
(100 MHz, CDCl3) δ 171.0, 138.9, 134.2, 128.7, 128.4, 127.2, 116.6, 65.2, 59.2, 54.5, 
53.8, 35.7; ESIHRMS calculated for C21H27N2O3Na [M+Na]+, 376.2001; found, 376.2007. 
(R)-2-((2,2-Dibenzyl-1-methylhydrazineyl)methyl)-4-vinyl-4,5-dihydrooxazole (202). 
DAST (9 μL, 0.08 mmol) was added to a chilled solution of 201 (20 mg, 0.06 mmol) 
in dry CH2Cl2 (1.2 mL) at –78 oC. The reaction was stirred for 10 min at –78 oC and 
quenched by saturated aq. NaHCO3. The resultant mixture was warmed to room 
temperature and extracted with CH2Cl2. The organic extract was dried over anhydrous 
Na2SO4, concentrated under reduced pressure, and purified by flash column 
chromatography on neutral alumina to afford 202 (6 mg, 32%) as a colorless oil (eluent: 
25% EtOAC in hexane): [α]20D +38.0 (c 0.15, CHCl3); 1H NMR (600 MHz, CDCl3) δ 7.40 





J = 10.2 Hz, 1H), 4.61 – 4.49 (m, 1H), 4.14 (dd, J = 9.9, 8.4 Hz, 1H), 3.72 (t, J = 8.4 Hz, 
1H), 3.66 (ABq, J = 13.2 Hz, 4H), 3.47 (ABq, J = 13.8 Hz, 2H), 2.55 (s, 3H); 13C NMR 
(150 MHz, CDCl3) δ 165.8, 139.5, 138.0, 129.2, 127.9, 126.7, 116.3, 72.1, 68.2, 53.6, 
52.5, 35.7; ESIHRMS calculated for C21H26N3O [M+H]+, 336.2076; found, 336.2077. 
(R)-2-(2,2-Dibenzyl-1-methylhydrazineyl)-N-(1-hydroxybut-3-en-2-
yl)ethanethioamide (203). 
DAST (55 μL, 0.42 mmol) was added to a chilled solution of 201 (100 mg, 0.28 
mmol) in dry CH2Cl2 (5.7 mL) at –78 oC. The reaction was stirred for 10 min at –78 oC and 
quenched with saturated aq. NaHCO3. The resultant mixture was warmed to room 
temperature and extracted with CH2Cl2. The organic extract was dried over anhydrous 
Na2SO4 and concentrated under reduced pressure. The resultant residue was stirred with 
MeOH-Et3N (1:1, 5.7 mL, saturated with H2S gas) for 13 h at room temperature. Then the 
reaction was concentrated under reduced pressure and purified by flash column 
chromatography on silica gel to give 203 (63 mg, 66%, 2 steps) as a yellow oil (eluent: 0 
‒ 50% EtOAc in hexane) along with the starting material 201 (25 mg, 25%) as a colorless 
oil (eluent: 50 ‒ 100% EtOAc in hexane). Data for 203: [α]20D +32.1 (c 0.95, CHCl3); 1H 
NMR (600 MHz, CDCl3) δ 8.54 (d, J = 7.5 Hz, 1H), 7.46 – 7.15 (m, 10H), 5.39 (ddd, J = 
16.9, 10.6, 5.8 Hz, 1H), 5.11 (d, J = 10.6 Hz, 1H), 5.07 – 4.99 (m, 1H), 4.95 (d, J = 16.9 
Hz, 1H), 3.95 (d, J = 17.3 Hz, 1H), 3.83 (d, J = 17.3 Hz, 1H), 3.70 (s, 4H), 3.45 (dd, J = 
11.2, 4.7 Hz, 1H), 3.36 (dd, J = 11.2, 6.1 Hz, 1H), 2.45 (s, 3H), 1.61 (br s, 1H); 13C NMR 
(150 MHz, CDCl3) δ 199.1, 138.8, 132.6, 128.6, 128.5, 127.2, 117.8, 67.1, 64.2, 57.5, 







DAST (5 μL, 0.04 mmol) was added to a chilled solution of 203 (10 mg, 0.03 mmol) 
in dry CH2Cl2 (0.5 mL) at –78 oC. The reaction was stirred for 10 min at –78 oC and 
quenched by addition of saturated aq. NaHCO3. The resultant mixture was warmed to 
room temperature and extracted with CH2Cl2. The organic extract was dried over 
anhydrous Na2SO4, concentrated under reduced pressure, and purified by flash column 
chromatography on neutral alumina to afford 204 (7.3 mg, 77%) as a yellow oil (eluent: 0 
‒ 10% EtOAc in hexane): [α]20D +50.0 (c 0.37, CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.40 
– 7.16 (m, 10H), 5.92 (ddd, J = 17.1, 10.3, 6.8 Hz, 1H), 5.27 (dt, J = 17.1, 1.2 Hz, 1H), 
5.16 (dt, J = 10.3, 1.2 Hz, 1H), 4.97 – 4.78 (m, 1H), 3.71 (s, 4H), 3.71 (dd, J = 14.0, 1.2 
Hz, 1H), 3.64 (dd, J = 14.0, 1.2 Hz, 1H), 3.25 (dd, J = 11.0, 8.7 Hz, 1H), 2.89 (dd, J = 
11.0, 8.4 Hz, 1H), 2.45 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 173.3, 139.3, 137.3, 129.0, 
128.0, 126.8, 116.0, 78.3, 57.7, 54.4, 37.2, 36.3; ESIHRMS calculated for C21H26N3S 
[M+H]+, 352.1847; found, 352.1844. 
(R)-N-((R)-4-(2-(2-(((R)-1-Hydroxybut-3-en-2-yl)amino)-2-oxoethyl)-1,2-
dimethylhydrazineyl)-3-methylbutyl)-N,2-dimethylbutanamide (206). 
A heterogeneous mixture of 191 (65 mg, 0.17 mmol), palladium (65 mg, 10 wt.% 
on carbon), and MeOH (4 mL) was stirred under hydrogen environment (1 atm) for 15 
min and filtered through a pad of Celite®. The resultant filtrate was concentrated under 
reduced pressure to give crude acid intermediate 205. To a stirred solution of this crude 
acid 205 and amino alcohol 112147 (51 mg, 0.42 mmol) in dry CH2Cl2 (0.80 mL) were 
added DIPEA (89 μL, 0.50 mmol), DMAP (10 mg, 0.08 mmol), and EDCI.HCl (96 mg, 





concentrated under reduced pressure and the residue was purified by flash column 
chromatography on silica gel to afford 206 (43 mg, 70% 2 steps) as a colorless oil (eluent: 
25 – 75% acetone in hexane). [α]20D +12.2 (c 0.55, CHCl3); 1H NMR (600 MHz, CDCl3) , 
both rotamers, δ 7.54 (d, J = 6.6 Hz, 1H, rotamer), 7.33 (d, J = 8.1 Hz, 1H, rotamer), 5.95 
– 5.77 (m, 1H), 5.30 – 5.10 (m, 2H), 4.53 (br s, 1H), 4.33 (br s, 1H), 3.78 – 3.61 (m, 2H), 
3.60 – 3.49 (m, 1H), 3.38 – 3.07 (m, 3H), 3.00 (s, 3H, rotamer), 2.90 (s, 3H, rotamer), 
2.64 – 2.50 (m, 1H), 2.43 – 2.12 (m, 7H), 1.88 – 1.73 (m, 2H), 1.73 – 1.52 (m, 2H), 1.45 
– 1.30 (m, 1H), 1.30 – 1.15 (m, 1H), 1.13 – 0.99 (m, 3H), 0.99 –  0.65 (m, 6H); 13C NMR 
(150 MHz, CDCl3) , both rotamers, δ 176.6, 170.7, 135.7, 135.1, 116.6, 115.9, 65.1, 64.7, 
60.7, 60.20, 57.9, 57.2, 53.2, 53.0, 47.6, 46.9, 37.4, 37.2, 36.9, 36.6, 36.1, 35.6, 35.4, 
34.0, 33.7, 32.2, 29.6, 28.7, 27.3, 26.9, 18.3, 18.0, 17.8, 17.0, 12.1, 11.9; ESIHRMS 
calculated for C19H39N4O3 [M+H]+, 371.3022; found, 371.3020. 
(R)-N-((R)-4-(1,2-Dimethyl-2-(((R)-4-vinyl-4,5-dihydrooxazol-2-
yl)methyl)hydrazineyl)-3-methylbutyl)-N,2-dimethylbutanamide (207). 
DAST (6 μL, 0.04 mmol) was added to a chilled solution of 206 (11 mg, 0.03 mmol) 
in dry CH2Cl2 (0.9 mL) at –78 oC. The reaction was stirred for 10 min at –78 oC and 
quenched with saturated aq. NaHCO3. The resultant mixture was warmed to room 
temperature and extracted with CH2Cl2. The organic extract was dried over anhydrous 
Na2SO4, concentrated under reduced pressure, and purified by flash column 
chromatography on neutral alumina to afford 207 (3 mg, 30%) as a colorless oil (eluent: 
50% EtOAC in hexane). [α]20D +33.3 (c 0.15, CH2Cl2); 1H NMR (600 MHz, CDCl3) , both 
rotamers, δ 5.79 (ddd, J = 17.2, 10.2, 7.0 Hz, 1H), 5.22 (dd, J = 17.2, 4.5 Hz, 1H), 5.16 – 





(m, 4H), 2.99 (s, 3H, rotamer), 2.90 (s, 3H, rotamer), 2.63 – 2.51 (m, 1H), 2.41 – 2.20 (m, 
8H), 1.78 – 1.52 (m, 3H), 1.44 – 1.32 (m, 1H), 1.32 – 1.18 (m, 1H), 1.10 – 1.04 (m, 3H), 
0.92 – 0.90 (m, 3H), 0.88 – 0.84 (m, 3H); 13C NMR (150 MHz, CDCl3) , both rotamers, δ 
176.5, 176.1, 166.0, 165.9, 137.9, 137.8, 116.5, 116.4, 72.28, 72.25, 68.1, 61.2, 61.0, 
60.0, 51.5, 51.3, 48.0, 46.0, 37.4, 37.1, 35.2, 35.1, 35.0, 34.9, 34.7, 34.0, 33.6, 32.2, 29.0, 
28.9, 27.4, 27.0, 18.18, 18.16, 17.8, 17.1, 12.1, 12.00; ESIHRMS calculated for 
C19H37N4O2 [M+H]+, 353.2917; found, 353.2915. 
(R)-N-((R)-4-(2-(2-(((R)-1-Hydroxybut-3-en-2-yl)amino)-2-thioxoethyl)-1,2-
dimethylhydrazineyl)-3-methylbutyl)-N,2-dimethylbutanamide (208). 
DAST (22 μL, 0.17 mmol) was added to a chilled solution of 206 (42 mg, 0.11 
mmol) in dry CH2Cl2 (2.3 mL) at –78 oC. The reaction was stirred for 10 min at –78 oC and 
quenched with saturated aq. NaHCO3. The resultant mixture was warmed to room 
temperature and extracted with CH2Cl2. The organic extract was dried over anhydrous 
Na2SO4 and concentrated under reduced pressure. The resultant residue was stirred with 
MeOH-Et3N (1:1, 2.3 mL, saturated with H2S gas) for 13 h at room temperature. Then the 
reaction was concentrated under reduced pressure and purified by flash column 
chromatography on silica gel to give 208 (23 mg, 52%, 2 steps) as a yellow oil (eluent: 25 
– 35% acetone in hexane) along with the starting material 206 (17 mg, 40%) as a yellow 
oil (eluent: 35 – 75% acetone in hexane). Data for 208: [α]20D +9.5 (c 0.95, CHCl3); 1H 
NMR (600 MHz, CDCl3) , both rotamers, δ 9.78 – 9.25 (m, 1H), 5.97 – 5.80 (m, 1H), 5.33 
– 5.07 (m, 3H), 4.55 (br s, 1H), 3.91 – 3.75 (m, 2H), 3.76 – 3.51 (m, 3H), 3.40 – 3.25 (m, 
1H, rotamer), 3.13 – 3.02 (m, 1H, rotamer), 2.99 (s, 3H, rotamer), 2.89 (s, 3H, rotamer), 





1H), 1.87 – 1.51 (m, 3H), 1.45 – 1.13 (m, 2H), 1.10 – 1.00 (m, 3H), 0.96 – 0.81 (m, 6H); 
13C NMR (151 MHz, CDCl3), major rotamer only, δ 199.0, 176.7, 134.0, 116.9, 64.7, 63.4, 
61.1, 57.3, 47.0, 37.4, 37.0, 36.4, 35.5, 32.3, 29.8, 26.9, 18.2, 17.0, 11.9; ESIHRMS 
calculated for C19H39N4O2S [M+H]+, 387.2794; found, 387.2789. 
7,8-Diazakalkitoxin (110). 
DAST (5 μL, 0.04 mmol) was added to a chilled solution of 208 (10 mg, 0.03 mmol) 
in dry CH2Cl2 (0.5 mL) at –78 oC. The reaction was stirred for 10 min at –78 oC and 
quenched by addition of saturated aq. NaHCO3. The resultant mixture was warmed to 
room temperature and extracted with CH2Cl2. The organic extract was dried over 
anhydrous Na2SO4, concentrated under reduced pressure, and purified by flash column 
chromatography on neutral alumina to afford 110 (8.5 mg, 89%) as a yellow oil (eluent: 
25 – 50% EtOAc in hexane): [α]20D +42.1 (c 0.28, CH2Cl2); 1H NMR (600 MHz, CDCl3) , 
both rotamers, δ 5.97 – 5.86 (m, 1H), 5.26 (dd, J = 17.1, 4.4 Hz, 1H), 5.16 – 5.11 (m, 1H), 
4.96 – 4.82 (m, 1H), 3.59 – 3.46 (m, 2H), 3.45 – 3.26 (m, 3H), 3.08 – 2.81 (m, 4H), 2.65 
– 2.50(m, 1H), 2.35 – 2.22 (m, 8H), 1.84 – 1.63 (m, 3H), 1.45 – 1.21 (m, 2H), 1.10 – 1.04 
(m, 3H), 0.92 (d, J = 6.5 Hz, 3H), 0.85 (t, J = 7.4 Hz, 3H); 13C NMR (150 MHz, CDCl3) , 
both rotamers, δ 176.5, 176.1, 173.5, 173.2, 137.3, 137.2, 116.1, 116.0, 78.44, 78.39, 
60.9, 60.5, 56.5, 56.4, 48.1, 46.0, 37.4, 37.1, 37.0, 35.9, 35.6, 35.13, 35.09, 34.9, 33.9, 
33.6, 32.2, 28.9, 28.8, 27.4, 27.0, 18.18, 18.17, 17.8, 17.1, 12.1, 12.0.; ESIHRMS 
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Current compound libraries that are used in high-throughput screening (HTS) are 
populated by low molecular weight and relatively planar compounds with high sp2 
character and little stereochemical complexity. Unfortunately, such planar compounds 
cover only a very small corner of chemical space. In order to increase the diversity, 
structurally complex molecules with high fractions of sp3-hybridized atoms should be 
included in compound libraries. However, generating a large number of architecturally 
complex molecules using the current organic synthesis toolbox is considered tedious due 
to the requirement of multi-step synthesis. Recognizing this need, several creative 
strategies, like diversity-oriented synthesis, have been developed with the aim to access 
structurally complex drug-like scaffolds in a minimum number of steps. However, the 
efficiency of these strategies is impeded by the time-consuming process of addressing 
stereogenic complexity. The research presented in this thesis is aimed at providing an 
alternative strategy that not only enriches the Fsp3 in compound collections but also 





Chapter one introduces hydroxylamines and hydrazines as interesting functional 
moieties that are capable of enriching current compound collections by increasing the 
fraction of sp3-hybridized atoms without additional stereochemical complexity. As the 
basis of the research presented in this thesis is the rapid conformational changes of 
hydroxylamine and hydrazine-related molecules at ambient temperature due to their low 
barrier to inversion at nitrogen centers, their conformational properties are highlighted in 
this chapter. Moreover, the present position of hydroxylamines and hydrazines in 
medicinal chemistry, and the synthetic accessibility of hydroxylamine and hydrazine-
related compounds are also discussed. The chapter ends by proposing kalkitoxin, a 
natural anti-cancer agent, as a substrate to test the concept of hydroxylamines and 
hydrazines as convertible mimics of the stereogenic centers. 
Chapter two presents the discovery of an efficient synthetic method for tri-
substituted hydroxylamine synthesis. This method was developed on the basis of 
acylation of N,N-disubstituted hydroxylamines followed by two-step reduction of the 
resulting O-acylhydroxylamines. The first reduction was conducted with DIBAL and was 
followed by treatment with acetic anhydride to give the O-(α-
acetoxyalkyl)hydroxylamines; the second reduction was executed with triethylsilane and 
a Lewis acid. Manipulating the second reduction step, by replacing triethylsilane with a 
carbon nucleophile afforded a new C-C bond formation, and further expanded the scope 
of this method. The efficiency of the method is exemplified by synthesis of several novel 
tri-substituted hydroxylamines. 
Chapter three describes the VT-NMR studies that were conducted to understand 





complex stereomutation of N-alkoxypiperidine systems. Since the VT-NMR phenomena 
were found to be dependent on substituents at the 4-position of the piperidine ring system, 
the ring inversion process is concluded to be the main component of the barrier to 
stereomutation of such systems. 
Chapter four concerns the design and development of hydrazine and 
hydroxylamine analogs of kalkitoxin, with the aim of testing the hypothesis of hydrazines 
and hydroxylamine as convertible mimics of stereogenic centers. The syntheses of 
kalkitoxin and its convertible hydrazine and hydroxylamine mimetics, 9-oxa-10-
azakalkitoxin and 7,8-diazakalkitoxin, are described. Currently, their cytotoxicity studies 
against several human and murine tumor cell lines are under progress. The hydroxalog 
9-oxa-10-azakalkitoxin (IC50 = 2.4 nm) was found to be as potent as kalktoxin (IC50 = 3.2 
nm) against a human liver cell line, so supporting the hydroxylamine analog concept. 
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